WO2009017823A2 - A fold-back diabody diphtheria toxin immunotoxin and methods of use - Google Patents

A fold-back diabody diphtheria toxin immunotoxin and methods of use Download PDF

Info

Publication number
WO2009017823A2
WO2009017823A2 PCT/US2008/009321 US2008009321W WO2009017823A2 WO 2009017823 A2 WO2009017823 A2 WO 2009017823A2 US 2008009321 W US2008009321 W US 2008009321W WO 2009017823 A2 WO2009017823 A2 WO 2009017823A2
Authority
WO
WIPO (PCT)
Prior art keywords
immunotoxin
diabody
cells
toxin
antibody
Prior art date
Application number
PCT/US2008/009321
Other languages
French (fr)
Other versions
WO2009017823A3 (en
Inventor
David Neville
Jung-Hee Woo
Arthur Frankel
Original Assignee
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health filed Critical The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health
Priority to EP08794978A priority Critical patent/EP2187971A2/en
Priority to CA2695382A priority patent/CA2695382A1/en
Priority to US12/671,629 priority patent/US9364557B2/en
Priority to AU2008282729A priority patent/AU2008282729B2/en
Publication of WO2009017823A2 publication Critical patent/WO2009017823A2/en
Publication of WO2009017823A3 publication Critical patent/WO2009017823A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to an immunotoxin.
  • the invention further relates to a method of treating T cell leukemias or lymphomas, graft-versus-host diseases, cancer, and autoimmune diseases by administering an immunotoxin.
  • CD3 and TFR can perform the same routing function as the DT receptor, thus obviating the requirement of a DT receptor interaction for the binding site mutant conjugates anti-CD3-CRM9 and TFR-CRM9 (Intracellular routing of ricin based immunotoxins via the ricin receptor leading to enhanced efficacy has also been reported. Youle et al. (1981) Cell 23:551; Marsh and Neville (1986) Biochem. 25:4461; Youle and Colombatti (1987) J. Biol.Chem. 262:4676).
  • the invention is one aspect relates to an immunotoxin comprising a diphtheria toxin moiety and a diabody targeting moiety. It is a further object of the invention to provide a method of treating cancers such as prostate cancer, breast cancer, and T cell leukemias or lymphomas.
  • Figure 1 shows that the epitopes involved in human serum's inhibition of its toxicity lie in the last 150 amino acids of DT.
  • a schematic diagram of the DT mutants CRM9, CRMl 97 and MSP ⁇ 5 is presented (A). The A- and B-subfragments and their relative size and position are shown. The filled circle represents a point mutation as described in the text.
  • Goat (B) or human (C) serum human serum was a pool from all samples with positive ELISA for anti-DT antibodies
  • UCHT1-CRM9 was added to a final concentration of 1 X 10 "10 M. This mixture was then diluted 10-fold onto Jurkat cells in a protein synthesis inhibition assay as described in the Materials and Methods. Immunotoxin incubated with medium only inhibited protein synthesis to 4% of controls. The results are representative of two independent assays.
  • Figure 2 shows the schematic flow sheet for generation of the single chain antibody scUCHTl gene construct.
  • PCR polymerase chain reaction
  • L linker
  • SP signal peptide.
  • Pl to P6, SPl, and SP2 are primers used in PCR.
  • Figure 3 shows one clone expressing the divalent immunotoxin fusion protein shown in Figure 5.
  • Figure 4 shows another clone expressing a divalent immunotoxin fusion protein shown in Figure 7.
  • Figure 5 is a schematic of a divalent fusion immunotoxin.
  • Figure 6 is a schematic of a divalent fusion immunotoxin.
  • Figure 7 is a schematic of a divalent fusion immunotoxin.
  • Figure 8 shows the cloning scheme used to obtain scUCHTl fusion protein with DTMl and DT 483.
  • Figure 9 shows the cloning scheme used to obtain scUCHTl fusion protein with DT 390.
  • Figure 10 shows the cloning scheme used to obtain scUCHTl fusion protein with DT 370.
  • Figure 11 shows the sizing of the diabody fusion-protein constructs shown in Table 5.
  • the constructs are sized by plotting their elution times versus log MW on a calibrated Superdex 200 size exclusion column.
  • the column has been calibrated with BSA that contains in addition to monomers (68 kDa) dimers, trimers and tetramers (open circles, solid line). Additionally, the column has been calibrated with scFv(M20), 27.5 kDa, and A- dmDT390bisFv(M20), 98.3 kDa, dashed line.
  • the diabody constructs fall on the latter line when given the following molecular weight values: Db(C207), (Table 5, B) solid triangle, 53.7 kDa, calculated MW of [Db(C207)]2 ; A-dmDT390-scfbDb(C207), (Table 5, E) solid square, 97.1 kDa calculated monomer MW; A-dmDT390-Db(C207), (Table 5, F) inverted solid triangle, 141.1 kDa, calculated MW of [A-dmDT390-Db(C207)]2.
  • Figure 12 shows a SDS 12% acrylamide bis-tris non-reducing gel of the fold-back immunotoxin A-dmDT390-scfbDb(C207) (Table 5, G), after the 3-step purification procedure, is shown in third lane from right alongside molecular weight markers in the first lane with marker kDa values printed at the left. (The trace band in the second lane is spillover from lane 3.)
  • Figure 13 shows the % inhibition of tracer FITC-labeled FN 18 binding to HSC-F monkey T cells plotted versus the concentration of binding competitors consisting of scFv(C207), (Table 5, A) biscFv(C207) , the diabody of C207, Db(C207), (Table 5,B) and the single-chain fold-back diabody of C207, scfbDb(C207) (Table 5, C).
  • the relative functional binding affinity for any two competitors can be estimated from the ratio of their concentrations at equal % inhibition values. Estimates are considered to be reliable when comparing parallel curves or parallel curve regions.
  • the rank order of competitor binding from highest to lowest is scfbDb(C207), Db(C207), biscFv(C207) and scFv(C207).
  • FNl 8 competition for FITC-labeled FNl 8 is shown for a comparative standard. In replicate assays the ratio of concentrations at equal displacement for Db(C207)/ scFv(C207) is 7 ⁇ 2 while the ratio for biscFv(C207)/ scFv(C207) is 2.5 ⁇ 0.1 (errors are SD). See Table 5 for structural schematics of these fusion proteins.
  • Figure 14 shows another binding competition assay like Figure. 20 except that the competitors of FITC-labeled FNl 8 binding to HSC-F monkey T cells are now immunotoxin fusion proteins that use a diabody, A-dmDT390-Db(C207) (Table 5, F), a fold-back single- chain diabody, A-dmDT390-scfbDb(C207) (Table 5, G) and biscFv antibody moiety, A- dmDT390-biscFv(C207) (Table 5, E).
  • the diabody immunotoxin is devoid of detectable binding to the T cells.
  • the fold-back single-chain diabody shows 10-fold increase in binding to T cells compared to A-dmDT390-biscFv(C207).
  • the data points for A- dmDT390-biscFv(C207) are for comparative purposes and were previously reported (Wang et al., 2007).
  • Figure 15 shows the % control inhibition of protein synthesis for three immunotoxins on HSC-F monkey T cells is plotted versus the immunotoxin concentrations on the x-axis after a 24 h exposure. Each point is the mean of 6 replicates and 1 SD error bars are shown.
  • Figure 16 shows the loss of resting monkey T cells from the lymphocyte gate by flow cytometry.
  • PBMC peripheral blood mononuclear cells
  • anti-T cell immunotoxins made in various formats.
  • the fold-back diabody immunotoxin, solid squares, is the most potent, exceeding the biscFv immunotoxin, empty circles, by 7 ⁇ 4-fold determined on two replicate assays.
  • the diabody immunotoxin is inactive.
  • Chemically conjugated FN18-CRM9 is provided as a reference.
  • Figure 17 shows the per cent of monkey lymph node CD3 ⁇ + T cells present within the forward scatter/side scatter lymphocyte gate determined by flow cytometry after the administration of the fold-back diabody immunotoxin A-dmDT390-scfbDb(C207) (Table 5,G).
  • CX3X dashed line
  • Monkey 32972 solid line
  • Lymph nodes were surgically removed under anesthesia, macerated and stained prior to flow cytometry.
  • the time 0 point represents a mean monkey lymph node T cell percentage from 11 individual monkeys obtained prior to immunotoxin treatment.
  • Figure 18 shows the depletion of blood CD3 ⁇ + T cells, solid line, in monkey 32972 and changes in the CD20 + B cell population enumerated by flow cytometry and total blood lymphocyte counts following intravenous administration of the fold-back diabody immunotoxin A-dmDT390-scfbDb(C207) (Table 5, G) [see Figure 23 legend].
  • the blood T cell count was 19/mm 3
  • Figure 19 shows the fold back format anti-PSMA immunotoxin was 18-30 fold more potent than the bisFv format immunotoxin.
  • Figure 20 shows the optimized variable chain amino acid and DNA sequences for the J591 variable heavy chain (Vh) (A), and J591 variable light chain (Vl) (B).
  • de J591 is deimmunized J591. Characters highlighted in gray color indicate changes of DNA sequence.
  • Vh de J591, Vh aa-deJ591, Vh-optimized, and Vh optimized J591 are SEQ ID NOs:16-19, respectively.
  • Vl de J591, Vl aa-deJ591, Vl-optimized, and Vl optimized J591 are SEQ ID NOs:20-23, respectively.
  • Ranges can be expressed herein as from “about” one particular value, and/or to "about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about,” it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10" is also disclosed.
  • immunotoxins comprising a mutant diphtheria toxin moiety linked to a targeting moiety, wherein the targeting moiety is a single chain variable region diabody.
  • the immunotoxins disclosed herein in one aspect comprise diabodies.
  • a "diabody” is a single chain antibody fragment comprising two scFv regions wherein one scFv region associates with a second scFv to form a dimer. Where the first scFv and the second scFv share the same antigen specificity, the diabody is referred to as "bivalent" (also called divalent).
  • the diabody is referred to as "bispecific.”
  • the diabodies disclosed herein can be bivalent or bispecific.
  • the disclosed diabodies can act as a targeting moiety for the toxin moiety.
  • the disclosed diabodies can be specific for any antigen provided translocation of the toxin moiety is still possible.
  • the targeting moiety can be specific for the CD3 molecule on T cells and thus T-cell specific.
  • the targeting moiety can be specific for a cancer antigen including but not limited to PSMA or viral antigen such as, for example, GP 120.
  • the diabody comprises the V 1 V H region directed against CD3.
  • the V L V H region is derived from the anti-CD3 antibody UCHTl or C207.
  • the diabody comprises the V L V H region directed against PSMA.
  • the V L V H region is derived from the anti-PSMA antibody J591
  • the immunotoxin can be a fusion protein produced recombinantly. Derivatives of this immunotoxin are designed and constructed as described herein.
  • the toxin moieties of the immunotoxins disclosed herein are mutant diphtheria toxin moieties. It is understood that other toxin moieties such as ricin and pseudomonas exotoxin A (PeA) can be used with the disclosed methods and compositions. It is further understood that the disclosed mutant toxin moieties can comprise substitution mutants. Examples of such substitution mutants include but are not limited to, for example, CRM9. It is also understood that the disclosed mutant toxin moieties can comprise a truncation mutant.
  • the deletion mutants can comprise C-terminal deletions of between 140 and 150 C-terminal amino acids.
  • toxin moieties wherein the truncation mutant comprises a deletion of 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, or 150 C-terminal amino acids of the full length diphtheria toxin. Therefore, disclosed herein are immunotoxins wherein the diphtheria toxin is a deletion mutant with 140-150 C- terminal amino acids deleted. It is understood herein that the disclosed truncation mutants can be referred to either by designating the number of deleted C-terminal acids or by designating the number of remaining amino acids counting from the N-terminus.
  • diphtheria toxin moiety comprising a deletion of 145 amino acids of the complete diphtheria toxin protein (535 amino acids) can be referred to as DT390.
  • DT390 a deletion of 145 amino acids of the complete diphtheria toxin protein
  • DT389 a deletion of 146 amino acids is DT389.
  • Protein toxins of the A-B type have 3 distinct structural and functional domains.
  • an enzymatic domain called the A chain that is highly cytotoxic after transfer or translocation to the cytosol compartment.
  • a translocation domain located within the B chain that facilitates translocation of the a chain into the cytosol; and (3) a receptor binding domain that binds to a cell surface receptor (also in the B chain).
  • the toxin A and B chain is linked by a protease cleavage site spanned by a disulfide bond. This site must be cleaved to achieve translocation into the cytosol compartment and full specific toxicity.
  • Toxin receptors have several special properties. One property is that they are efficiently endocytosed into endosomal vesicles. A second property is that the toxin receptor routes the toxin along an intracellular pathway to its site of efficient translocation to the cytosol compartment. For diphtheria toxin this site is in the late endosomal compartment.
  • Immunotoxins are toxins that have been altered by replacing the toxin receptor binding domain with an alternate receptor binding domain chosen to target the toxin to a specific cell type in order to eliminate that cell type.
  • the new alternate receptor must also route the toxin to its efficient translocation site.
  • the translocation efficiency of diphtheria toxin is 10 to 30- fold greater than that of ricin and pseudomonas exotoxin A, conferring considerable advantage to immunotoxins based on diphtheria toxin.
  • the disclosed immunotoxins can comprise linkers between the toxin moiety and the diabody targeting moiety. It is understood and herein contemplated that any linker known by those of skill in the art can be used to make the disclosed immunotoxins. The choice of which linker to use can be determined by those of skill in the art based on the desired length and flexibility of the linker between each V H and V L domain as well as between the toxin and targeting moieties. Thus, it is understood that the linker can be a chemical linker. It is also understood that the linker (L) can be a Gly-Ser linker. The Gly-Ser linker can be but is not limited to (Gly4Ser)n or (Gly3Ser)n.
  • the linker between the toxin and the diabody can be a chemical linker and the linker between the diabody domains can be a Gly-Ser linker. It is further understood that the for greater flexibility, a longer linker is used; whereas, a shorter linker is used for application where more rigidity is needed.
  • the linker between domains of a diabody will be between 3 and 12 amino acids long. More typically, the diabody linker is between 3 and 5 amino acids long.
  • specifically contemplated are immunotoxins where the linker between the V H and V L domains of the targeting diabody moiety are G4S. It is also understood that more than one of the disclosed linkers can be used in a single chain immunotoxin.
  • immunotoxins wherein the linker between the toxin moiety and a first V L of the targeting diabody is G4S, between the first V L and V H is G4S, between the first V H and second V L is (G4S)3 and between the second V L and V H is G4S.
  • immunotoxins where from left to right the immunotoxin comprises:
  • the disclosed immunotoxins can be placed in a pharmaceutically acceptable carrier for administration to a subject.
  • a chemical linker is used to fuse the toxin and diabody moieties
  • both acid-cleavable and non-cleavable protein cross-linking reagents can be used in the construction of antibody-diphtheria toxin (Neville et al. (1989) J. Biol. Chem. 264:14653-14661); preferred are non-cleavable crosslinkers, such as bismaleimidohexane and m-maleimidobenzoyl-N-hydroxysuccinimide ester.
  • cross-linking reagents react with proteins via heterobifunctional groups (maleimide and N-hydroxysuccinimide ester) or homobifunctional groups (bis- maleimide).
  • the maleimide cross-linking is accomplished by prior protein thiolation with iminothiolane.
  • Cross-linked proteins exhibit first-order dissociation under acid conditions. The ti/ 2 at pH 5.5 varies between 0.1 and 130 h for a series of six different cleavable cross- linkers (Srinivasachar and Neville (1989) Biochemistry 28:2501-2509).
  • the disclosed diabodies can be formed in a "fold-back" formation. Such formation typically occurs through the use of rigid linkers from 3 to 12, more typically from 3 to 5 amino acids long such as the G4S linker.
  • the Toxin-Ll-V L -L2- V H -L3-V L -L4-V H ; wherein Ll, L2, and L4 comprise G4S and L3 comprises (G4S)3 is an example of a fold-back diabody immunotoxin.
  • immunotoxin fusion proteins comprising a diphtheria toxin moiety and a targeting moiety, wherein the targeting moiety is a diabody, wherein the sequence from the amino terminus from left to right is toxin moiety, Li, V L i, L 2 , V m , L 3 , V L2 , L 4 , V H2 , wherein the toxin moiety comprises a truncation mutation, Li, L 2 , and L 4 are (G4S) linkers, and V L and V H are the variable light and heavy domains.
  • immunotoxin fusion proteins comprising a diphtheria toxin moiety and a targeting moiety, wherein the targeting moiety is a diabody, wherein the sequence from the amino terminus from left to right is toxin moiety, Li, Vn, L 2 , V H l , L 3 , V L2 , L 4 , V H2 , wherein the toxin moiety comprises a truncation mutation, Li, L 2 , and L 4 are (G4S) linkers, and V L and V H are the variable light and heavy domains, wherein V L i and V H i can be the same as V L2 and V H2 .
  • fold-back diabodies comprising toxin moieties wherein the truncation mutant comprises a deletion of 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, or 150 C-terminal amino acids of the full length diphtheria toxin.
  • diphtheria toxin immunotoxins comprising a truncation mutant and a fold-back diabody specific for an antigen or cell surface determinant such as CD3 or PSMA.
  • diphtheria toxin immunotoxins comprising a truncation mutant and a fold-back diabody specific for an antigen or cell surface determinant such as CD3 or PSMA, wherein the V L and V H regions of the diabody are the V L and V H regions of an anti-CD3 or anti- PSMA antibody, respectively.
  • diabodies described herein have the V L and V H regions originating from the anti-CD3 antibodies UCHTl and C207, and the anti-PSMA antibody J591, and the resulting immunotoxins are A-dmDT390scfbDb(UCHTl), A- dmDT390scfbDb(C207), and A-dmDT390scfbDb(J591), respectively.
  • A-dmDT390scfbDb(C207) wherein C207 is an anti-CD3 diabody affinity matured mutant of FNl 8 (wherein dm indicates a deletion mutant and scfbDb indicates a single chain fold-back diabody).
  • A- dmDT390scfbDb(C207) immunotoxins wherein the furin site amino acid sequence cleavage site RVRRSV has been replaced with the MMP cleavage site GPLGMLSQ or the PSA cleavage site HSSKLQ.
  • A-dmDT390scfbDb(UCHTl) wherein UCHTl is an anti-CD3 diabody clone.
  • A- dmDT390scfbDb(J591) wherein J591 is an anti-PSMA diabody clone.
  • immunotoxins disclosed herein include but are not limited to A-dmDT395scfbDb(J591); A-dmDT394scfbDb(J591); A-dmDT393scfbDb(J591); A-dmDT392scfbDb(J591); A- dmDT391scfbDb(J591); A-dmDT389scfbDb(J591); A-dmDT388scfbDb(J591); A- dmDT387scfbDb(J591); A-dmDT386scfbDb(J591); A-dmDT385scfbDb(J591); A- dmDT395scfbDb(anti-PSMA); A-dmDT394scfbDb(anti-PSMA); A-dmDT393scfbDb(anti- PSMA); A-d
  • the disclosed immunotoxins can be produced recombinantly as fusion proteins.
  • fold-back diabody immunotoxins formed with A- dmDT390scfbDb(J591) or its derivatives in which the amino acids of the furin protease cleavage RVRRSV that begins at residue 191 from the amino terminus is replaced by a matrix metalloprotease cleavage site GPLGMLSQ (Liu, S et al., Expert Opinion Biol Ther 3,843-853, 2003) or a prostatic specific antigen cleavage site HSSKLQ (Denmeade SR et al., Cancer Research 57, 4924-30, 1997) accomplished by PCR mutagenesis.
  • GPLGMLSQ matrix metalloprotease cleavage site
  • HSSKLQ prostatic specific antigen cleavage site
  • the bivalent immunotoxin production in a EF-2 mutant CHO cell expression system was limited to 5 mg/L and could not be increased by selection for multiple gene insertions. Due to this limitation, with three exceptions (12, 20, 25) all recombinant immunotoxin production for therapeutic uses has been limited to E. coli production necessitating denaturation and refolding from inclusion bodies (6). However, refolding of the multi-domain structure of the bivalent immunotoxin from E. coli was inefficient and full bioactivity was not recovered (25). Also, the multi-domain structure of the bivalent immunotoxin hinders efficient production in Escherichia coli. Therefore, the attempt to develop a robust Pichia pastoris production system for the bivalent or bispecific immunotoxin was driven by the inadequacy of the existing productions systems.
  • Pichia pastoris is a good expression system for the bivalent and bispecific immunotoxins disclosed herein.
  • Pichia was good for the bivalent anti-T cell immunotoxin A-dmDT390-bisFv as it provides optimal protein folding compared to prokaryotic expression systems and provides higher yields compared to mammalian cell expression (CHO cells).
  • Antibody fusion proteins require correct disulfide bridges and the endoplasmic reticulum of yeast provides an oxidizing environment like that of eukaryotic antibody producing cells.
  • the multi-domain structure of the bivalent or bispecific immunotoxin requires a eukaryotic expression system to properly fold this complex protein. Yet most eukaryotes are sensitive to the effects of protein synthesis inhibition upon expression of the immunotoxin.
  • a budding yeast Pichia pastoris has a certain degree of tolerance to DT (Neville et al., 1992; Woo et al., 2002) and yielded the immunotoxin at a level of 40 mg/L in fermentor culture.
  • the immunotoxin was produced by fermentation of genetically engineered Pichia pastoris (JW 102, renamed from pJHW#2 (Woo et al., 2002)) via the secretory route.
  • JW 102 genetically engineered Pichia pastoris
  • the present method provides a yield of 120 mg/1 after a 163 h induction period and the purified yield is 90.8 mg/L.
  • Pichia pastoris was sensitive to the toxic effects of cytosolic expressed diphtheria toxin A chain which ADP ribosylates elongation factor 2 (EF-2) leading to cessation of protein synthesis. Toxicity to expression of A-dmDT390-bisFv by the secretory route was indicated by a continuous fall in methanol consumption after induction. A mixed feed of glycerol and methanol was provided to the cells. Expression of the catalytic domain (A chain) of DT in the cytosol is lethal to Pichia pastoris.
  • EF-2 ADP ribosylates elongation factor 2
  • EF-2 elongation factor 2
  • the sensitivity of the eukaryotic EF-2 to ADP-ribosylation by these toxins lies in the structure of protein.
  • EF-2 is a single polypeptide chain of about 850 amino acids and is composed of two domains.
  • the N-terminal G domain is responsible for binding and hydrolysis of GTP that promotes translation, and the C-terminal R (or diphthamide) domain is thought to interact with the ribosome (Kohno et al., 1986; Perentesis et al., 1992).
  • the diphthamide domain contains a histidine residue in a region of 22 residues that are well conserved in the EF-2 of all eukaryotes. This conserved histidine is specifically modified post-translationally to the derivative, diphthamide, which is the unique target for ADP-ribosylation by DT (Van Ness et al., 1880). In S.
  • the conserved histidine can be mutated and substitutions with some other 2 amino acids yielded functional EF-2s that were resistant to ADP-ribosylation (Phan et al., 1993; Kimata and Kohno 1994). However, cells with EF-2 mutated at diphthamide grew more slowly than those expressing wild-type EF-2.
  • the expression level of the immuntoxins disclosed herein including for example the diphtheria toxin diabody immunotoxins and diphterhia toxin bivalent antibody immunotoxins disclosed herein such as A-dmDT390-scfbDb and A- dmDT390-bisFv could be further increased by rendering Pichia pastoris insensitive to toxin, the EF-2 gene of Pichia pastoris has been mutated so that the GIy at position 701 was changed to Arg, which has been shown to prevent ADP-ribosylation of EF-2 in other organisms.
  • the EF-2 mutagenesis required cloning of the gene, introduction of the in vitro mutated sequence with a selection marker, URA3, to the genome and PCR identification of mutated clones.
  • the entire EF-2 gene of Pichia pastoris has been cloned and sequenced.
  • the coding sequence of Pichia pastoris EF-2 is 2526 nucleotides coding for 842 amino acids.
  • the Pichia pastoris EF-2 is the same as the EF-2 of S. cerevisiae and S. pombe in length and shares 88% and 78% of identity in amino acid sequence with these two, respectively. In contrast to these two yeasts, Pichia pastoris has only one copy of the EF-2 gene that contains a short intron.
  • a pBLURA- ⁇ 5'mutEF-2 was constructed that targets the Pichia pastoris EF-2 gene and introduces a mutation of GIy 701 to Arg in the gene by homologous recombination.
  • the construct contains the 3' end 1028 nucleotides of EF-2 that has been mutagenized in vitro to contain the amino acid substitution and the auxotrophic marker URA3.
  • a PCR detection method was also developed for fast and accurate identification of mutant clones after uracil selection.
  • the targeted mutation strategy with construct pBLURA- ⁇ 5'mutEF-2 allowed mutation of the EF-2 gene of Pichia pastoris with about 40% of uracil positive clones being found to contain the introduced mutations.
  • EF-2 mutants were developed with different auxotrophic markers, (specifically mutEF2JC308 (adel arg4 his4), mutEF2JC303 (arg4 his4) and mutEF2JC307 (his4)) and demonstrated that the GIy 701 to Arg mutation in EF-2 confers resistance to the cytosolic expression of DT A chain.
  • A-dmDT390-bisFv was not toxic to the mutant strain.
  • the EF-2 mutants allowed expression of A-dmDT390-bisFv under the control of the constitutive GAP promoter (P GAP )- In shake-flask culture, the production of A-dmDT390-bisFv under P GAP was about 30% higher than that under P AOXI - The increase in production under PQ AP may be more significant in fermentation cultures since fermentation allows cells to grow to very high density.
  • the expression level of an exemplary bivalent or bispecific immunotoxin was improved by 4-fold in bioreactor culture compared to shake flask culture by optimizing the fermentation conditions in Pichia pastoris as follows: (1) use of Soytone Peptone and yeast extract based complex medium, (2) use of methanol/glycerol mixed feed (4:1) to supplement the energy source during methanol induction, (3) continuous feeding of PMSF and yeast extract during induction, and (4) lowering temperature to 15 0 C during methanol induction. The lowered temperature resulted in a 2-fold increase in secretion relative to using 23 0 C during methanol induction.
  • AOXl alcohol oxidase
  • Bivalent immunotoxin expression was increased at low induction temperatures, reaching a maximum at 17.5 0 C, and secretion of bioactive immunotoxin reached a maximum at 15 0 C, in spite of the fact that methanol consumption rate at 15 0 C fell to 75% of its 23 0 C value. Because continuous feeding of PMSF and yeast extract during induction effectively inhibited protease activity in supernatants, it appears unlikely that a reduction in protease activity with lower induction temperature accounts for the nearly 2-fold increase in bivalent immunotoxin secretion seen at 15 0 C. The limitation in Pichia pastoris secretion of bivalent immunotoxin previously described may actually represent an overexpression at 23 0 C that is reduced at 15 0 C achieving a better balance of input and output within the secretory compartment.
  • the immunotoxin was produced in Pichia pastoris (JW 102) via the secretory route under control of the AOXl promoter in the fermentor using methanol as a carbon source.
  • the toxicity towards Pichia pastoris resulted in a decrease in the metabolic rate of methanol consumption, a cell growth rate reduction and very low productivity in a defined medium during methanol induction.
  • the method can comprise methods of enhancing codon preference that are known and exemplified.
  • any of the disclosed immunotoxins are useful for the treatment of various conditions or diseases. Therefore, disclosed herein in one aspect are methods of treating a cancer in a subject comprising administering to the subject an immunotoxin or a derivative thereof, under conditions such that the cancer is treated. Further disclosed herein are methods of treating a cancer in a subject comprising administering to the subject an immunotoxin that is a truncation mutant, wherein the truncation mutant comprises a deletion of 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, or 150 C-terminal amino acids of the full length diphtheria toxin.
  • the diabody is an anti-PSMA diabody such as, for example, a diabody wherein the diabody comprises the V L V H regions of J591.
  • PSMA or prostate specific membrane antigen is a transmembrane antigen expressed on prostate cells and highly over-expressed in prostate tumors. It is weakly expressed on some other tissues and is considered highly tissue specific and thus is considered a prime target for immunotoxin mediated therapy of prostatic cancer (Fracasso, G et al, The Prostate 53, 9-23, 2002 and Huang , X. et al, The Prostate 61,1-11, 2005).
  • PSMA is over-expressed on the neovasculature that feeds a variety of human primary cancers and their metastatic counterparts such as breast, lung and kidney (Milowsy, MI et al.J. Clin Oncol 25,540-47,2007).
  • PSMA is a homodimer with a 2-fold axis of symmetry.
  • a divalent anti- PSMA diabody immunotoxin with binding sites oriented 180 degrees apart is ideally suited to complex PSMA.
  • PSMA is a functional glutamate carboxylase metalloprotease.
  • toxin moiety can be a truncation mutant such as, for example, DT395, DT394, DT393, DT392, DT391, DT390, DT389, DT388, DT387, DT386, and DT385.
  • the immunotoxin that is administered to the subject is A- dmDT390scfbDb(J591); A-dmDT389scfbDb(J591); A-dmDT380scfbDb(J591); A- dmDT395scfbDb(J591), or any other DT truncation mutant J591 fold-back diabody combination.
  • the disclosed methods of treating a cancer have utility for treating any cancer where PSMA is expressed on cancerous tissue, such as, for example, prostate cancer or in a cancer where PSMA is expressed in the neovasculature, breast cancer, lung cancer, and renal cancer.
  • any cancer with a targetable antigen can be treated with the disclosed methods providing that the targeted epitope routes DT to its efficient translocation site.
  • the cancer can comprise a T-cell leukemia.
  • methods of treating T cell leukemias or lymphomas in an animal comprising administering to the animal one of the disclosed diphtheria toxin diabody immunotoxins, or derivatives thereof, under conditions such that the T cell leukemias or lymphomas are treated.
  • the immunotoxin for treating a T cell leukemia can comprise a diabody wherein the diabody is an anti-CD3 diabody. It is further understood that any anti-CD3 diabody can be used in the disclosed methods.
  • the diabody can comprise the VLVH regions of UCHTl.
  • any of the disclosed anti-CD3 diabodies can be used with any of the disclosed toxin moieties including, for example, DT390, DT389, DT395, DT394, DT393, DT392, DT391, DT388, DT387, DT386, and DT385.
  • the immunotoxin can comprise A- dmDT390scfbDb(UCHTl) or A-dmDT390scfbDb(C207).
  • Treatment means a method of reducing the effects of a disease or condition.
  • Treatment can also refer to a method of reducing the disease or condition itself rather than just the symptoms.
  • the treatment can be any reduction from native levels and can be, but is not limited to, the complete ablation of the disease, condition, or the symptoms of the disease or condition. Therefore, in the disclosed methods, treatment” can refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of an established disease or the disease progression.
  • a disclosed method for reducing the effects of prostate cancer is considered to be a treatment if there is a 10% reduction in one or more symptoms of the disease in a subject with the disease when compared to native levels in the same subject or control subjects.
  • the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels. It is understood and herein contemplated that "treatment” does not necessarily refer to a cure of the disease or condition, but an improvement in the outlook of a disease or condition.
  • compositions and immunotoxins disclosed herein are useful in transplantation related conditions and disease such as graft versus host disease, graft rejection, and the induction of immune tolerance.
  • T cells The role of T cells in the aforementioned transplantation related diseases and conditions makes the CD3 molecule (i.e., the T cell receptor), which is only present on T cells, a viable target for the action of the disclosed immunotoxins. Therefore, disclosed herein are methods of treating graft- versus-host disease in an animal, comprising administering to the animal an immunotoxin disclosed herein, or derivatives thereof under conditions such that the graft- versus-host disease is treated.
  • the immunotoxin is an anti-CD3 diphtheria toxin immunotoxin.
  • any anti-CD3 antibody derived diabody such as a diabody derived from UCHTl, C207, or FNl 8 can be used in the methods disclosed herein.
  • any of the disclosed anti-CD3 diabodies can be used with any of the disclosed toxin moieties including, for example, DT390, DT389, DT395, DT394, DT393, DT392, DT391, DT388, DT387, DT386; and DT385.
  • the immunotoxin can comprise A-dmDT390scfbDb(UCHTl) or A-dmDT390scfbDb(C207).
  • Also disclosed are methods of inducing immune tolerance to a graft in a recipient comprising: a)administering to the recipient an anti-CD3 immunotoxin disclosed herein, thereby reducing the recipient's T-cell population; and b) administering to the recipient an agent that inhibits dendritic cell maturation.
  • any anti-CD3 antibody derived diabody such as a diabody derived from UCHTl, C207, or FNl 8 can be used in the methods disclosed herein.
  • any of the disclosed anti-CD3 diabodies can be used with any of the disclosed toxin moieties including, for example, DT390, DT389, DT395, DT394, DT393, DT392, DT391, DT388, DT387, DT386; and DT385.
  • the immunotoxin can comprise A-dmDT390scfbDb(UCHTl) or A-dmDT390scfbDb(C207).
  • Also disclosed herein are methods of inhibiting a rejection response in a primate recipient to a foreign mammalian graft comprising the steps of: a) administering to the recipient an anti-CD3-DT immunotoxin, wherein the immunotoxin comprises scfbDb-DT, so as to reduce the recipient's T-cell lymphocyte population by at least 80%, as compared to the recipient's T-cell lymphocyte population prior to administration of the immunotoxin; and b) transplanting the graft into the recipient, such that a rejection response by the recipient to the graft is inhibited.
  • any anti-CD3 antibody derived diabody such as a diabody derived from UCHTl, C207, or FNl 8 can be used in the methods disclosed herein. It is further contemplated that any of the disclosed anti-CD3 diabodies can be used with any of the disclosed toxin moieties including, for example, DT390, DT389, DT395, DT394, DT393, DT392, DT391, DT388, DT387, DT386; and DT385.
  • the immunotoxin can comprise A-dmDT390scfbDb(UCHTl) or A-dmDT390scfbDb(C207).
  • “Inhibit,” “inhibiting,” and “inhibition” mean to decrease an activity, response, condition, disease, or other biological parameter. This can include but is not limited to the complete ablation of the activity, response, condition, or disease. This may also include, for example, a 10% reduction in the activity, response, condition, or disease as compared to the native or control level. Thus, the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels.
  • the disclosed methods of treating graft- versus-host disease, inducing immune tolerance to a graft, and inhibiting a rejection response can be complemented by the use of an immunosuppressive agent in addition to the methods already disclosed.
  • the immunotoxin for treating graft- versus-host disease can comprise a diabody wherein the diabody is an anti-CD3 diabody. It is further understood that any anti-CD3 diabody can be used in the disclosed methods.
  • the diabody can comprise the VLVH regions of UCHTl.
  • any of the disclosed anti-CD3 diabodies can be used with any of the disclosed toxin moieties including, for example, DT390, DT389, DT395, DT394, DT393, DT392, DT391, DT388, DT387, DT386, and DT385.
  • the immunotoxin can comprise A-dmDT390scfbDb(UCHTl) or A-dmDT390scfbDb(C207). Therefore, disclosed herein are methods of treating graft- versus-host disease, inducing immune tolerance to a graft, and inhibiting a rejection response, further comprising administering an immunosuppressive agent.
  • suitable immunosuppressive agents include but are not limited to cyclosporine, rapamycin, and mycophenolate mofetil and the anti-B cell antibody (anti-CD20) rituximab. It is further contemplated that the disclosed immunosuppressive agent can be an agent that inhibits dendritic cell maturation. Such action can occur, for example through the inhibition of nuclear translocation, such as, inhibition of nuclear translocation of NFKB.
  • immunosuppressive agents that are inhibitors of dendritic cell maturation that are inhibitors of nuclear translocation of NFK B such as, for example, deoxyspergualin and analogs or derivatives of deoxyspergualin including, for example, methyl-deoxyspergualin or a deoxyspergualin analog lacking a chiral center (e.g., LF 08-0299) (Andoins et al., 1996, which is incorporated herein by reference).
  • Other derivatives or analogs of deoxyspergualin can be used that include, for example, those identified in U.S. Pat. No. 4,518,532; U.S. Pat. No. 4,518,532; U.S. Pat. No.
  • immunosuppressive agents that inhibit dendritic cell maturation wherein the agent that inhibits dendritic cell maturation activates one or more NF-AT dependent Th2 cytokines. Also disclosed are methods wherein the immunosuppressive agents that inhibit dendritic cell maturation wherein the agent that inhibits dendritic cell maturation inhibits one or more NFKB dependent ThI cytokines. It is further contemplated that the disclosed immunosuppressive agent that is an inhibitor of dendritic cell maturation can function through other means.
  • the inhibitor of dendritic cell maturation is a soluble IL- 17 receptor Fc fusion protein; a glucocorticoid; blocker of tumor necrosis factor alpha binding; blocker of granulocyte macrophage colony stimulating factor binding; blocker of IL-12p70 binding; blocker of EL- I ⁇ binding; and/or an anti-CD 154 ligand.
  • the graft used in the methods disclosed herein can comprises donor cells, tissue or organ. It is further contemplated that the donor cells, tissue, or organ is selected from the group consisting of kidney, liver, heart, pancreas, lung, skin, and isolated cell transplants of pancreatic islets, hepatocytes, stem cell, and differentiated precursors cells. It is understood and herein contemplated that the donor graft (tissue, cell, or organ) can be from an allogeneic, syngeneic, or xenogeneic donor. It is further contemplated that the donor source can be a cadaver.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a diabody-DT mutant in an amount effective to treat T cell leukemias or lymphomas, which carry the CD3 epitope, graft- versus-host disease or autoimmune diseases, or treat a cancer such as prostate cancer or breast cancer which carries PSMA and a pharmaceutically acceptable diluent, carrier, or excipient.
  • T cell leukemias or lymphomas which carry the CD3 epitope, graft- versus-host disease or autoimmune diseases, or treat a cancer such as prostate cancer or breast cancer which carries PSMA and a pharmaceutically acceptable diluent, carrier, or excipient.
  • one embodiment of the invention provides a method of treating an autoimmune disease in an animal comprising administering to the animal an imrnunotoxin comprising a mutant diphtheria toxin moiety and an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the autoimmune disease is treated.
  • an imrnunotoxin comprising a mutant diphtheria toxin moiety and an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the autoimmune disease is treated.
  • the immunotoxin for treating an autoimmune disease can comprise a diabody wherein the diabody is an anti-CD3 diabody. It is further understood that any anti-CD3 diabody can be used in the disclosed methods. Thus, for example, the diabody can comprise the VLVH regions of UCHTl. It is further contemplated that any of the disclosed anti-CD3 diabodies can be used with any of the disclosed toxin moieties including, for example, DT390, DT389, DT395, DT394, DT393, DT392, DT391, DT388, DT387, DT386, and DT385. Thus, for example, the immunotoxin can comprise A- dmDT390scfbDb(UCHTl) or A-dmDT390scfbDb(C207).
  • Also disclosed are methods for treating acquired immunodeficiency syndrome in an animal comprising administering to the animal an immunotoxin comprising a diphtheria toxin binding mutant moiety and an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof under conditions such that the acquired immunodeficiency syndrome is treated.
  • a method of treating acquired immunodeficiency syndrome in an animal comprising administering to the animal a non-toxic mutant of diphtheria toxin followed by an antibody-diphtheria toxin immunotoxin which routes by the anti-CD3 pathway or derivatives thereof under conditions such that the acquired immunodeficiency syndrome is treated is provided.
  • any anti-CD3 antibody derived diabody such as a diabody derived from UCHTl, C207, or FNl 8 can be used in the methods disclosed herein. It is further contemplated that any of the disclosed anti-CD3 diabodies can be used with any of the disclosed toxin moieties including, for example, DT390, DT389, DT395, DT394, DT393, DT392, DT391, DT388, DT387, and DT386.
  • the immunotoxin can comprise A-dmDT390scfbDb(UCHTl) or A- dmDT390scfbDb(C207).
  • Conjugation of anti-V/3 and anti-V ⁇ lgG monoclonal antibodies to CRM9 is performed by the same methods used to conjugate anti-CD3 to CRM9 using a non-cleavable linker such as bismaleimidohexane and previously described in detail (Neville et al. (1988) J. Biol. Chem. 264:14653-61).
  • the monoclonal antibody FNl 8 is the monkey equivalent of the human anti-CD3 (UCHTl) and is known to bind the same CD3 receptor epitopes (e and ⁇ ) as bound by the human CD3 antibody and is the same isotype as the human CD3 antibody.
  • the present CD3-CRM9 conjugate and FN18-CRM9 are expected to have the same activity.
  • Conjugates can be administered as an LV. bolus in a carrier consisting of 0.1M Na 2 SO 4 + 0.01M phosphate buffer, pH 7.4 plus 1 part in 50 of serum previously obtained from the subject.
  • the dose schedule is every other or third day for 3 to 6 days.
  • the total dose is preferably from 25 to 200 micrograms of toxin per kg of body weight.
  • the actual dose of FN18-CRM9 used was equal to 0.167 of the minimum lethal dose (MLD) in guinea pigs. Since the estimation of the MLD was performed in an animal lacking an immunotoxin target cell population (guinea pigs), the true MLD of FN18-CRM9 and anti-CD3-CRM9 is expected to be higher in monkeys and humans than in guinea pigs.
  • MLD minimum lethal dose
  • FN18-CRM9 The specificity of FN18-CRM9 toward T cells can be seen by comparing the total white blood cell (WBC) count in the same two monkeys. WBCs fell, but only to 45% of baseline value on day 2 compared to 6% of baseline values for the CD4+ T cell subset. Most of the fall in WBC values can be accounted for by the T cell component of the WBC population ( «40%). However, B cells are initially depleted after FN18-CRM9 although these cells recover more quickly. FNl 8 is an IgG, isotype and as such is known to bind to Fc 11 receptors present on B cells and macrophages with low affinity. The FN18-CRM9 depletion of B cells indicates that significant interactions between the Fc portion of the FNl 8 antibody and B cells is taking place.
  • WBC white blood cell
  • peripheral T cell depletion induced by unconjugated FNl 8 at a dose known to produce immunosuppression 0.2mg/kg/day was compared to the immunotoxin FN18-CRM9 administered at l/9th the FN 18 dose.
  • Peripheral CD4+ T cell depletion is more pronounced and more long-lasting with the conjugate.
  • the demonstration that FN18-CRM9 reduces the peripheral helper T cell subset (CD4+) to levels less than or equal to 200 cell/mm 3 for a period as long as 21 days demonstrates that this immunotoxin and its anti-human analogs are effective immunosuppressive reagents.
  • FN18-CRM9 is a potent agent for inducing T cell depletion in non-human primates demonstrates that an anti-human homolog of FN18-CRM9, UCHT1-CRM9 (Oxoid USA, Charlotte, NC) for example, is a potent agent for inducing T cell depletion in humans.
  • the Fc binding region of anti-TCR/CD3 monoclonals may or may not be needed to induce T cell depletion when the anti-TCR/CD3 monoclonals are conjugated to CRM9.
  • the Fen binding regions can be removed, for example, by forming the conjugates with F(ab') 2 derivatives as is indicated in the literature (Thorpe et al. (1985) J. Nat'l. Cancer Inst. 75:151-159).
  • anti-TCR/CD3 IgA switch variants such as monoclonal antibody T3.A may be used (Ponticelli et al. (1990) Transplantation 50:889-892). These avoid rapid vascular clearance characteristic of F(ab')2 immunotoxins.
  • F(ab') 2 and IgA switch variants of anti-TCR/CD3-CRM9 immunotoxins are therefore derivative anti-TCR/CD3 immunotoxins. These derivatives will avoid the B cell interaction noted and can increase specificity. However, IgG 23 switch variants will maximize T cell activation through the Fci, receptor and may be useful in certain situations where T cell activation aids immunotoxin induced toxicity.
  • antibody can mean the entire antibody or any portion of the antibody sufficient for specific antigen or receptor binding.
  • TCR/CD3 Since receptor recycling is a requirement for effective CRM9 based immunotoxins and since TCR/CD3 recycles as a unit, antibodies directed at other epitopes on TCR/CD3 will constitute effective derivatives, in particular antibodies directed at the approximately 50 VjS subset families or the approximately equal number of Va subsets can be used to conjugate CRM9 and ablate specific V/3 or Va subsets in vivo. In addition, in some cases it will be desireable to develop specific monoclonal antibodies reacting with unique rearrangements of either the Va or VjS subset families.
  • the target cells deplete the effective dose and this depletion decreases as target burden decreases. Since the log kill is exponential in effective dose, much higher increases in log kill than 50-fold on changing the target from T cells to a VjS subset can occur. The expected increase in log kill will only occur if the immunotoxin is specific for the defined target. Extraneous interactions with other cell types via the antibody Fc piece is preferably eliminated.
  • V ⁇ n HIV has been shown to preferentially infect one (V ⁇ n) or a few of the 20 V/3 subset families providing a small T cell reservoir of HIV replication, and because HIV infection apparently involves an unknown superantigen
  • CRM9 based immunotoxins directed at these specific Vj3 subsets such as anti-VjSi 2 -CRM9 can reduce the HIV virus load.
  • total ablation of a VjS subset in the presence of an endogenous superantigen can lead to long-term ablation of the subset since maturing T cells are negatively selected in the presence of endogenous superantigens. Since the specific VjS subset responding to the superantigen is eliminated, infection cannot take place.
  • the two strategies that can be utilized for using anti-V/3i 2 -CRM9 immunotoxins to treat HIV infections are (1) treatment depleting the susceptible VjS subset to an extent where continued infection cannot be maintained and (2) treatment to the extent that all or nearly all of the VjS 12 subset is eradicated.
  • Anti-human VjS monoclonal antibodies such as S5-11 are available (T Cell Sciences, Cambridge, MA) and can be conjugated to CRM9 by standard methodologies. Briefly, as in Example 5, conjugation of anti-V/3 and anti-V ⁇ lgG monoclonal antibodies to CRM9 is performed by the same methods used to conjugate anti-CD3 to CRM9 using a non-cleavable linker such as bismaleimidohexase and previously described in detail (Neville et al. (1988) J. of Biol. Chem. 264:14653-61).
  • a non-cleavable linker such as bismaleimidohexase
  • Conjugates can be administered as an LV. bolus in a carrier consisting of 0.1M Na 2 SO 4 + 0.01M phosphate buffer, pH 7.4 plus 1 part in 50 of serum previously obtained from the patient.
  • the dose schedule is every other or third day for 3 to 6 days.
  • the total dose is preferably from 25 to 200 micrograms of toxin per kg of body weight, but may be increased if anti-diphtheria toxin antibodies are present in the patient's sera in significant amounts.
  • V ⁇ or Va subsets which may be found to be associated with HIV infection can be treated in the same manner described herein by conjugating the CRM9 to the antibody specifically reactive with the appropriate V/3 or Va subset.
  • CRM9 is a diphtheria toxin (DT) binding site mutant and forms the basis of the anti- T cell immunotoxin anti-CD3-CRM9.
  • This immunotoxin has been constructed against human and rhesus T cells and has shown above to kill 3 logs of human T cells in a nude mouse xenograft system.
  • the present example demonstrates a 2 log kill of T cells in rhesus monkey lymph nodes that is also shown to produce prolongation of skin allograft rejection in monkeys.
  • ELISA ELISA assays were performed in order to determine the levels of anti-DT titers existing in 9 individuals in a population ages 27 to 55. There were 3 individuals with titers of 1 : 100 (low) and 6 with titers of 1 : 1000 (moderate).
  • Rhesus monkeys were screened by the same assay and a 1 : 1000 titered monkey was selected.
  • Monkeys were treated by LV. route 5 min prior to the immunotoxin dose with a 100 fold excess of CRM 197 over the CRM9 content of the immunotoxin to be administered.
  • a Hl histamine blocking agent such as Benadryl or Tagevil was given LV. to minimize any possibility of an anaphylactic reaction (for Benadryl 4 mg/kg). No histaminic reaction was detected.
  • Anti-CD3-CRM9 was given at a total dose between 0.1 and 0.2 mg/kg (toxin weight) in 3 equally divided doses (approximately 0.033 mg/kg) on 3 consecutive days. In these monkeys, the total dose of immunotoxin was 0.1 mg/kg.
  • a comparison of the efficacy of anti-CD3-CRM9 in monkeys was conducted by comparing the decrease in the lymph node T/B cell ratio (a measure of lymph node T cell depletion) and the immunosuppressive effect of the immunotoxin as judged by prolongation of mismatched skin graft survival. Effects on the survival of skin grafts is a clear indicator of the general effect a given treatment has on the subject's immune system.
  • the monkey with the preexisting anti-DT titer that was pretreated with CRM 197 shows the same level of T/B cell inversion as in the negative titered monkey.
  • Skin graft survival was significantly prolonged over the titered monkey treated without CRMl 97.
  • the failure to achieve a prolongation of graft survival equal to the negatively titered monkey is likely due to the lower weight of this monkey which causes T cells to repopulate faster, in this case 3-4 days faster, due to the larger thymic T cell precursor pool in younger animals.
  • Age related effects such as these can be compensated for by modification of dosage levels and timing of administration.
  • Immunotoxin UCHT1-CRM9 for the Treatment of Steroid Resistant Graft- Versus- Host Disease Treatment protocols for this type of disease can be expected to last a year, with Patients being followed for at least 5 years.
  • UCHT1-CRM9 is a covalent 1 :1 conjugate of anti-human CD3 IgGl monoclonal antibody and CRM9.
  • the conjugate is synthesized, purified, sterile filtered and assayed for concentration, biological efficacy toward target cells and non-target cell toxicity by standardized culture assays.
  • the method of synthesis, purification assay are identical to that used for FNI8-CRM9 which was used in the pre-clinical monkey studies described in Examples 5 - 7.
  • the patient population consists of individuals suffering from steroid resistant GVHD whose prognosis is poor. Patients are assayed for anti-CRM9 (anti-DT) titers and antibodies to murine immunoglobulin. Patients having anti-CRM9 titers of 1 : 1000 and below are treated according to the present protocol. Patients who have a history of receiving murine immunoglobulins or who exhibit positive anti-Ig titers may require special consideration.
  • anti-CRM9 anti-DT
  • UCHT1-CRM9 is administered at a dose which is 1/10 or less of the estimated minimum lethal dose (MLD) in a T lymphopenic patient.
  • MLD estimated minimum lethal dose
  • the MLD is expected to be at least 0.15 mg/kg (CRM9 content) based on the MLD of 0.15 mg/kg of IgGl-CRM9 in guinea pigs which lack a target cell population for the IgGl.
  • the optimal dose schedule has been found in monkeys to be administration on 3 consecutive days in 3 equally divided doses, and this schedule can be used throughout the treatment period.
  • a second dosage group can include patients selected for antitoxin titers of 1 :330 or less to whom CRM197 will be given at 1.0 mg/kg.
  • a third dosage group can include patients with 1:1000 antitoxin titers or less will be given CRM197 at 3.3 mg/kg, a dose expected to be tolerable in humans, because it is easily tolerated by monkeys (see Example 7).
  • the monkey MLD data should be very similar to humans on a per weight basis. However, GVHD patients are expected to be more like guinea pigs, because they have a smaller target cell population compared to non-GVHD patients.
  • Dose escalation can be tested by increasing the dose by a factor of 1.5.
  • Table 1 exemplifies such a dose escalation test. For example three patients are used in each dosage group. There is a 3 to 4 week delay between each patient so that any late toxicity is detected before a dosage group is completed:
  • the first dosage group will consume 2.6 mg of the CRM9 immunotoxin, and will be supplied as a pool of two 2 mg batches.
  • the second group will consume 3.9 mg and will also be supplied as 2 pooled batches.
  • the third group will require 5.9 mg and will be supplied as three pooled batches.
  • the fourth group will require 8.9 mg and will be supplied as three pooled batches and an additional two pooled batches.
  • a Hl histamine blocking agent such as Benadryl or Tagevil is given LV. to minimize any possibility of an anaphylactic reaction (for Benadryl 4 mg/kg).
  • the CRMl 97 is administered LV. in a 5 mg/ml sterile filtered solution in phosphate buffered saline pH 7.4 (PBS) over a 5 min time period.
  • PBS phosphate buffered saline pH 7.4
  • the immunotoxin is then given LV. at 0.2 mg/ml over 2 min time period in a sterile filtered solution of 0.9OmM sodium sulfate and 1OmM sodium phosphate pH 7.4.
  • E Immune function assays ELIS A assays of serum to monitor antibody responses to UCHTl (primary response) and CRM9 (secondary response). ELISA assays to monitor antibody responses to polio and DPT reimmunizations done at 1 year following bone marrow transplantation.
  • An anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood
  • the present Example examines the effect of human serum with pre-existing anti-DT antibodies on the toxicity of UCHTl -CRM9, an immunotoxin directed against CD3 molecules on T-lymphocytes. Sera with detectable anti-DT antibodies at 1 : 100 or greater dilutions inhibited the immunotoxin toxicity.
  • Experiments with radiolabeled-UCHTl-CRM9 indicate that anti-DT antibodies partially block its binding to the cell surface as well as inhibit the translocation from the endosome to the cytosol.
  • the inhibitory effect could be adsorbed using a full-length DT mutant or B-subfragment. A C-terminal truncation mutant could not adsorb the inhibitory effect, suggesting that the last 150 amino acids contain the epitope(s) recognized by the inhibitory antibodies.
  • an anti-CD3 single-chain immunotoxin sFv-DT390
  • the IC 50 of sFv-DT390 was 4.8 X 10 "n M, 1/16 the potency of the divalent UCHTl -CRM9. More importantly, sFv-DT390 toxicity was only slightly affected by the anti-DT antibodies in human sera. "sFv” and “scUCHTl” both are singe chain antibodies containing the variable region.
  • DT diphtheria toxin
  • FN18-CRM9 A rhesus monkey analog of UCHTl -CRM9, FN18-CRM9 was capable of not only depleting circulating T-cells but also depleting resident T-cells in the lymph nodes 1. This immunotoxin also delayed skin allograft rejection as compared to antibody treatment and non-treatment controls. FN18-CRM9 has also been used as an adjunct in inducing tolerance to mismatched kidney transplants (24).
  • a DT point-mutant, a truncation mutant and DT-subfragments were used in an attempt to neutralize the anti-DT effect in human sera. Based on the neutralization data, a single-chain immunotoxin was constructed with a C-terminal deletion mutant of DT which is expected to bypass the inhibitory effect of the pre-existing anti-DT antibodies.
  • Jurkat cells (ATCC) were maintained in RPMI 1640 supplemented with 10% fetal calf serum, 25 mM sodium bicarbonate and 50 ⁇ g/ml of gentamycin sulfate.
  • Serum and adsorbing molecules Serum and adsorbing molecules.
  • variable light (V L ) and variable heavy (V H ) chain regions of the UCHTl antibody were amplified by a two step protocol of RT-PCR using primers based on the published sequence (13).
  • the 5' V L primer added a unique Ncol restriction enzyme site while the 3' V H primer added a termination codon at the J to constant region junction and an EcoRI site.
  • the V L region was joined to the V H region by single-stranded overlap extension and the two regions are separated by a (Gly 3 Ser) 4 linker that should allow for proper folding of the individual variable domains to form a function antibody binding site (14).
  • genomic DNA was isolated from a strain of C. diphtheriae producing the DT mutant CRM9 (07[JS*' 0* - 20 "*- 911' ]) as described (15). This DNA was used for PCR.
  • the 5' primer was specific for the toxin gene beginning at the signal sequence and added a unique Ndel restriction site.
  • the 3' primer was specific for the DT sequence terminating at amino acid 390 and added an Ncol site in frame with the coding sequence.
  • the PCR products were digested with the appropriate restriction enzymes and cloned into the E. coli expression plasmid pET-17b (Novagen, Inc., Madison, WI, USA) which had been linearized with Ndel and EcoRI.
  • the resulting plasmid was used to transformed E. coli BL21/DE3 cells.
  • Cells were grown to an OD 590 of 0.5, induced with 0.5 M IPTG (Invitrogen, San Diego, CA, USA) and incubated for an additional 3 hours.
  • the sFv-DT390 protein was isolated in the soluble fraction after cells were broken with a French Press and the lysate subjected to centrifugation at 35,000 X g.
  • Immunotoxins were incubated for 30 minutes with the indicated serum sample or leucine 1 free medium at room temperature prior to addition to cells. In some experiments the serum was pre-incubated for 30 minutes with an adsorbing molecule at the given concentrations to bind the antibodies.
  • the immunotoxin/serum mixture was incubated with Jurkat cells (5 x 10 4 cells/well in 96 well plate) for 20 hours. A 1 hour pulse of [ 3 H]-leucine (4.5 ⁇ Ci/ml) was given before cells were collected onto filters with a Skatron harvester. Samples were counted in a Beckman scintillation counter. Each experiment was performed in 4 replicates.
  • Results were calculated into a mean value, and recorded as a percentage of control cells.
  • Anti-DT antibodies were detected in human serum by ELISA.
  • CRM9 (10 ⁇ g/ml) was adsorbed to Costar 96-well EIA/RIA flat bottom plates (Costar, Cambridge, MA, USA) for 2 hours and then washed in phosphate buffered saline (PBS) containing 0.1% Tween 20. Each well was then incubated with PBS containing 3% gelatin to prevent non-specific binding of antibodies to the plastic. Serum samples were diluted in PBS containing 0.1% Tween 20 and 0.3% gelatin prior to addition to the plate.
  • PBS phosphate buffered saline
  • UCHT1-CRM9 was iodinated using the Bolton-Hunter reagent (NEN Dupont, Wilmington, DE, USA) as described (16).
  • Jurkat cells were washed twice with binding medium (RPMI 1640 supplemented with 0.2% bovine serum albumin, 10 mM Hepes (pH 7.4) and without sodium bicarbonate).
  • Cells (1.5 x 10 6 ) were incubated for 2 hours on ice with 125 I-UCHTl -CRM9 (1 x 10 "9 M) that had been pre-incubated with serum or binding medium. Unbound antibody was removed by washing the cells twice in PBS (pH 7.4) with centrifugation and resuspension.
  • Serum with anti-DT antibodies inhibits UCHT1-CRM9 toxicity.
  • aELISA was performed in triplicate for each serum sample as described under "Materials and Methods.” The O.D. values were derived from 1:100 dilutions and presented as a mean value ⁇ SD. The background value was 0.060 ⁇ 0.02. titers are recorded as the highest serum dilution that showed a positive reaction in ELISA.
  • bUCHTl-CRM9 (2 x 10 '10 ) was incubated with different dilutions of serum for 30 min. The mixture was then added to cells as described under "Materials and Methods.” Four replicates were performed for each sample. Data are presented as a mean value ⁇ S. C. in percentage of the control counts.
  • UCHTl -CRM9 inhibited protein synthesis to 2.0% of controls.
  • the goat anti-DT serum could be diluted to 1 : 10,000 and still completely inhibited the toxicity of UCHTl -CRM9. 0ND, not done
  • Sera do not inhibit endocytosis of UCHT1-CRM9.
  • the inhibitory effect of serum on UCHT1-CRM9 toxicity could be due to prevention of the immunotoxin binding to the cell surface or the endocytosis of UCHTl -CRM9 into the cell.
  • Endocytosis assays were conducted using ' 25 I-UCHT 1-CRM9 to determine if either of these processes were affected by anti-DT antibodies present in sera.
  • the results indicate that the presence of serum (goat anti-DT or human) reduces as much as 80% of the immunotoxin counts binding to the cell surface (Table 3). While this is a significant reduction in binding, limiting 90% of input immunotoxin (one log less UCHT1-CRM9) in toxicity assays reduces protein synthesis to ⁇ 25% of controls (see Figure 1).
  • [ 12 1]-UCHTl -CRM9 (2 x 10-9M) was incubated with medium or anti-DT serum (1 :4 dilution of human sample 10010 or a 1 : 1 ,000 dilution of goat serum; Table 2) for 30 minutes at room temperature. This mixture was added to Jurkat cells (1.5 X 106) for 2 hours on ice (final concentration of [ 125 I]-UCHT1-CRM9 was 1 x 10-10). The cells were then washed and endocytosis assays performed as described in Materials and Methods. The % Bound value represents the cell associated counts divided by the cell associated counts divided by the cell associated counts without serum. Non- labeled UCHT1-CRM9 was incubated with the above dilutions of sera and the resulting mixture was used in protein synthesis inhibition assays. The results shown are representative of two independent assays.
  • the inhibitory effect of anti-DT antibodies can be removed by adsorption.
  • CRMl 97 the full length DT-like construct, was capable of completely adsorbing the protective antibodies from both goat ( Figure IB) and pooled human serum ( Figure 1C).
  • the B-subfragment of DT is also capable of complete adsorption, however —100 fold more is required.
  • the A-subfragment of DT had little or no effect on either serum, although the serum samples were demonstrated to contain antibodies reactive to both the A- and the B-subfragments by Western Blot analysis. Of interest were the results seen with MSP ⁇ 5, the truncation mutant. Adsorption of goat serum with MSP ⁇ 5 gave a dose dependent removal of the serum's protecting effect (Figure IB). However, this adsorption could not bring toxicity down to levels obtained when CRMl 97 or the B-subfragment was used.
  • sFv-DT390 is not inhibited by anti-DT antibodies present in human sera.
  • the predicted molecular weight for the fusion protein is 71,000 Daltons and has been confirmed by Western Blot analysis of both in vitro transcribed and translated protein as well as protein isolated from E. coli using goat anti-DT antibodies.
  • the IC 50 (concentration required to inhibit protein synthesis to 50% of controls) of sFv-DT390 was 4.8 X 10 "11 M compared to 2.9 X 10 ⁇ 12 M for UCHT1-CRM9, a 16-fold difference (i.e., 16-fold less toxic).
  • UCHT1-CRM9 toxicity was completely inhibited with a 1:10 dilution of the human sera but at a 1 :100 dilution toxicity was equivalent to controls without serum.
  • the sFv-DT390 immunotoxin is only partially inhibited with the 1:10 dilution of the human, sera and the 1 : 100 dilution no effect on the toxicity. Both immunotoxins are completely inhibited by goat anti-DT serum (1 : 1,000 dilution).
  • the goat anti-DT serum which gave the highest ELISA value could be diluted 10,000 times and still completely inhibited UCHT1-CRM9 toxicity. Since this correlation exists, there is no indication that any other component of the serum inhibits the toxicity of UCHT1-CRM9. Furthermore, the data show that a titer of 1 : 1 OO dilution is necessary for an inhibition of the immuno toxin toxicity.
  • Intoxication of cells by immunotoxins can be subdivided into four general stages: 1) specific binding to the cell surface, 2) endocytosis into the cell, 3) translocation of enzymatic domain of the toxin out of the endosome and 4) enzymatic inactivation of the target molecule.
  • the results presented indicate that, while the amount of immunotoxin reaching the cell surface is lower in the presence of serum, the same percentage of bound immunotoxin is endocytosed. Taking into account the reduced amount of immunotoxin bound to the cell, the amount of endocytosed immunotoxin should intoxicate the cells to below 25% of controls. However, the immunotoxin had no effect on protein synthesis in the presence of serum containing anti-DT antibodies.
  • the anti-DT antibodies probably affect the translocation of the A-subfragment into the cytosol.
  • CRMl 97, B-subfragment, and MSP ⁇ 5 could adsorb the protecting anti-DT antibodies from the goat and rhesus monkey sera.
  • MSP ⁇ 5 could not prevent the UCHTl -CRM9 toxicity in the presence of the human sera, showing a difference in the anti-DT antibody repertoire among humans, goat and rhesus monkeys. This difference does not seem to be due to immunization routes, because monkeys used in the present study were not immunized for DT and presumably acquire the antibodies after a natural infection with toxigenic strains of C. diphtheriae.
  • rhesus monkeys and humans shared a similar antibody repertoire (21), but the present results suggest that the effect of antibodies from the host for whom immunotoxin treatment is intended should be useful.
  • sFv-DT390 The IC 50 of sFv-DT390 is 4.8 x 10 "11 M, 1/16 as potent as UCHT1-CRM9. Like many other single-chain constructs, sFv-DT390 is monovalent as compared to immunotoxins generated with full length, bivalent antibodies. The reduced toxicity in sFv-DT390 could be explained primarily on this affinity difference. Immunotoxins generated with purified F(ab)' fragments of antibodies also show an in vitro loss in toxicity (generally a 1.5 log difference) when compared to their counterparts generated with full length antibodies (22). The toxicity of sFv-DT390 is comparable to that reported for DAB486IL-2 (23). From the present data some advantages of sFv-DT390 are expected.
  • sFv-DT390 is only 1/3 of the molecular weight of UCHT1-CRM9.
  • the molar concentration of sFv-DT390 will be 3 times higher than that of UCHTl -CRM9 if the same amount is given (for example, 0.2 mg/kg). Therefore, their difference in potency could be reduced to approximately 5 times.
  • sFv-DT390 contains only the variable region of UCHTl, and is expected to have less immunogenicity in human anti-mouse antibody (HAMA) responses than the native murine antibody UCHTl.
  • HAMA human anti-mouse antibody
  • sFv-DT390 or others with similar properties, are expected to be useful in the treatment of T-cell mediated diseases in humans, especially in anti-DT positive individuals and in patients who need repeated treatments. To obtain evidence supporting this assumption, it is only necessary to construct a rhesus monkey analog of sFv-DT390, and test it in monkey models as described in previous examples. Table 4: Anti-DT antibodies present in human sera have reduced effect on sFv-DT390 toxicity.
  • UCHT1CRM9 or sFv-DT390 (2 x 10 '9 M) was incubated with the indicated dilutions of serum for 30 mm. The mixture was then added to cells as desc ⁇ bed under "Materials and Methods.” The final concentration of lmmunotoxin on cells was 1 x 10 "10 M. Four replicates were performed for each sample. Data are presented as a mean value ⁇ S.D. in percentage of the control counts. UCHT1-CRM9 inhibited protein synthesis to 5% of controls while the sFv-DT390 inhibited protein synthesis to 18% of controls. The ELISA value was determined using a 1:100 dilution of serum. The results are representative of two independent expe ⁇ ments.
  • Murine anti-CD3 monoclonal antibodies are used in clinical practice for immunosuppression.
  • mAbs are used in clinical practice for immunosuppression.
  • a chimeric anti-human CD3 single chain antibody scUCHTl was generated. It is an IgM variant of the UCHTl described in Example 9.
  • scUCHTl consists of the light and heavy variable chain binding domains of UCHTl and a human IgM Fc region (CH 2 to CH 4 ). The method used was reported by Shu et al. [37] and is further described below. The following data show that the engineered chimeric anti-CD3 single chain antibody (scUCHTl) will be useful in clinical immunosuppressive treatment.
  • Oligonucleotide primers and DNA amplification Oligonucleotide primers and DNA amplification.
  • scUCHTl The procedures of cloning scUCHTl is schematically depicted in Fig. 2.
  • mRNA isolated from UCHTl hybridoma cells (provided by Dr. P. C. Beverley, Imperial Cancer Research Fund,London was reverse transcribed into cDNA.
  • the V L and V H regions of UCHTl were amplified with polymerase chain reaction (PCR) from the cDNA using primer pairs Pl, P2 and P3, P4 respectively.
  • Primers P2 and P3 have a 25 bp complementary overlap and each encoded a part of a linker peptide (Gly 4 Ser) 3 .
  • V L - linker- V H The single chain variable fragment (V L - linker- V H ) was created by recombinant amplification of V L and V H using primers Pl and P4.
  • a mouse kappa chain signal sequence was added at the V L 5'-end by PCR, first with primers SP2 and P4, and then with primers SPl and P4.
  • the human IgM Fc region (CH 2 to CH 4 ) was amplified from the plasmid pBlue-hulgM (kindly provided by Dr. S. V. S. Kashmiri, National Cancer Institute, Bethesda. This gene fragment was about 1.8 kb.
  • the V L -linker-v H -CH2 region which is important for antigen recognition was confirmed by sequence analysis.
  • the single chain variable fragment and the human IgM Fc region were cloned into plasmid pBK/CMV (Stratagene, La Jolla, CA, USA).
  • pBK/scUCHTl plasmid as template, an in vitro transcription-translation assay yielded a product of 75 kDa, the expected size. Expression in COS-7 and SP2/0 cells.
  • the gene fragment encoding scUCHTl was then cloned into an expression vector pLNCX [36].
  • the scUCHTl gene construct was introduced into COS-7 cells with a calcium-phosphate method [32], and introduced into SP2/0 myeloma cells by electroporation [33].
  • Cells transfected were selected with 500 ⁇ g/ml G418 (GIBCO/BRL, Gaithersburg, MD, USA) in DMEM medium.
  • the drug resistant transfectants were screened for scUCHTl secretion by an anti-human IgM ELISA technique. Transfectants secreting scUCHTl were cloned by limiting dilution.
  • COS-4C10 and SP2/0-7C8 Two stable clones, COS-4C10 and SP2/0-7C8, which could produce about 0.5 mg/ml scUCHTl in culture medium, were selected for further evaluation.
  • the culture supernatant of COS-4C10 and SP2/0-7C8 cells was analyzed by immunoblotting using anti-human IgM antibody. Human IgM antibody was included as a control in the analysis.
  • scUCHTl produced by COS-7 and SP2/0 cells had a similar electrophoretic mobility to that of the control human IgM heavy chain (75 kDa).
  • scUCHTl from COS-7 cells appeared as a single band of approximately 150 kDa, which was thought to be a homodimer of the single chain antibody.
  • SP2/0 cells mainly produced a protein of similar size with some higher molecular weight products.
  • scUCHTl was efficiently produced by both COS-7 and SP2/0 cells. Hollow fiber culture should increase its production.
  • scUCHTl the IgM-like molecule, has a secretory tailpiece with a penultimate cysteine (Cys 575) which is involved in polymerization and also provides retention and degradation of IgM monomers [41-43]. Replacing the Cys 575 with serine might also greatly improve the yield.
  • scUCHTl secreted from COS-7 cells was shown to be a divalent form by immunoblotting, suggesting a disulfide bond linkage of two monovalent molecules.
  • the disulfide bond is likely situated between the CH2 and CH3 regions, where the Cys 337-Cys 337 disulfide bond is thought to exist.
  • Cys 337 is believed to be sufficient for assembly of IgM monomers, and was neither sufficient nor necessary for formation of polymers.
  • Cys 575 was necessary for assembly of IgM polymers, and Cys 414 was not required for formation of IgM monomers or polymers [44]. This divalent form of the single chain antibody should increase its binding affinity.
  • scUCHTl Western blotting analysis of scUCHTl.
  • scUCHTl was precipitated from the culture supernatant using goat anti-human IgM-Agarose (Sigma, St. Louis, MO, USA), and separated on 4-20% SDS-PAGE gradient gel under reducing and non-reducing conditions. The separated proteins were transferred to ProBlottTM membrane (Applied Biosystems, Foster City, CA, USA) by electroblotting at 50 volts for 1 hour. The membrane was blocked and incubated with alkaline phosphatase labeled goat anti-human IgM antibody (PIERCE, Rockford, IL, USA) following the manufacturer's instruction. Color development was carried out with substrate NBT/BCIP (PIERCE).
  • Culture supernatant was mixed with anti-human IgM-Agarose, and incubated at 4°C with shaking overnight, and then the mixture was transferred to a column.
  • the column was washed with washing buffer (0.01 M Na-phosphate, pH 7.2, 0.5 M NaCl) until the OD280 of flow-through was ⁇ 0.01.
  • scUCHTl was eluted with elution buffer (0.1 M glycine, pH 2.4, and 0.15 M NaCl). The fractions were neutralized with 1 M Na-phosphate (pH 8.0) immediately, and then concentrated and dialyzed against PBS.
  • the parental antibody UCHTl was iodinated using Bolton-Hunter Reagent (NEN, Wilmington, DE, USA) as described previously [34].
  • the 125 I-labeled UCHTl was used as tracer and diluted with DMEM medium to 0.3-0.6 nM.
  • UCHTl and the purified scUCHTl from COS-7 and SP2/0 transfectant cells were used as competitors.
  • Human CD3 expressing Jurkat cells were suspended in DMEM medium (2 x 10 7 /ml). 50 ⁇ l of such cell suspension (1 x 10 6 ) was incubated with 50 ⁇ l diluted tracer and 50 ml diluted competitors on ice for 2 hours.
  • results were expressed as a percentage of the 125 I-UCHTl bound to cells in the absence of competitors.
  • scUCHTl from both COS-7 and SP2/0 cells could specifically inhibit the binding of 125 I-UCHTl to Jurkat cells in a dose dependent way.
  • concentration of the competitors (UCHTl, scUCHTl from COS-7 and SP2/0 cells) increased from 1 to 100 nM
  • the tracer 125 I iodinated UCHTl bound to Jurkat cells decreased from 80% to nearly 0%. No significant difference was observed among the affinity curves of UCHTl and scUCHTl from COS-7 and SP2/0 cells.
  • scUCHTl has nearly the same affinity as UCHTl .
  • scUCHTl contains human IgM constant region, and is expected be less immunogenic than UCHTl.
  • the degree of its immunogenicity might vary due to the murine variable region of scUCHTl .
  • Humanized variable regions by CDR-grafting or human variable regions can be used to further reduce its immunogenicity [31].
  • PBMCs Human peripheral blood mononuclear cells
  • FCS Ficoll-Hypaque gradient
  • the parental antibody UCHTl started to induce proliferation at 0.1 ng/ml, and peaked at 100 ng/ml. A small drop in CPM was observed as the concentration increased to 1,000 ng/ml.
  • [ 3 H]thymidine incorporation in PBMCs incubated with scUCHTl was only slightly increased in the range of 0.1 - 10 ng/ml, and when the concentration was higher than 10 ng/ml, the incorporated counts decreased and were close to 0 counts at 1,000 ng/ml. Thus showing that scUCHTl did not induce a human T cell proliferation response.
  • TNF- ⁇ and IFN- ⁇ productions of human PBMCs induced by UCHTl and scUCHTl were measured with ELISA.
  • 4 x 10 5 PBMCs were cultured with serial dilutions of anti-CD3 antibodies (UCHTl, scUCHTl) in 96-well flat-bottom plates in RPMI 1640 supplemented with 10% FCS. Supernatant was collected at 36 hours for TNF- ⁇ and 72 hours for IFN- ⁇ after the start of the culture [35].
  • TNF- ⁇ and IFN- ⁇ were measured with ELISA kits (Endogen Inc. Cambridge, MA, USA) following the manufacturer's instruction.
  • the native antibody UCHTl induced production of both TNF- ⁇ and IFN- ⁇ in a dose dependent way. Higher concentration of UCHTl induced higher production of TNF- ⁇ and IFN- ⁇ . On the contrary, scUCHTl did not induce secretion of TNF- ⁇ at any concentration, and inhibited IFN- ⁇ production when its concentration was higher than 0.1 ng/ml.
  • the PBMCs cultured with UCHTl and scUCHTl were also checked with trypan blue exclusion test. Cells were shown to be alive in both situations. In TNF- ⁇ and IFN- ⁇ ELISA assays, an unrelated human IgM was included and it did not affect the TNF-a and IFN-g production.
  • Anti-CD3 mAbs can induce T cell activation and proliferation both in in vitro and in vivo situations [45]. Crossing-linking of anti-CD3 antibody between T cells and FcR expressing cells is an essential step in this process [46]. T cell activation therefore reflects an efficient interaction of the mAb with a human FcR. Previous data of in vitro study indicated that T cell activation resulted in increased production of TNF- ⁇ , IFN- ⁇ , and IL-2 [24].
  • Human IgG Fc receptors Fc ⁇ R I, Fc ⁇ R ⁇ , Fc ⁇ R HT are distributed on human monocytes, T, B lymphocytes, and NK cells [47].
  • Fc ⁇ R I and Fc ⁇ R II can recognize both mouse and human IgG.
  • UCHTl was potent in induction of T cell proliferation and TNF- ⁇ and IFN- ⁇ release.
  • Human IgM Fc receptor (Fc ⁇ R) was reported to be present mainly on a small fraction of B lymphocytes, NK cells, and possibly a helper subset of T lymphocytes [47, 48]. Pentamer form of IgM and an intact CH 3 domain are required for optimal binding to Fc ⁇ R. Monomelic or dimeric subunits of IgM are less efficient in binding to Fc ⁇ R [49, 50].
  • scUCHTl can cross-link human B and T cells, and possibly T and T cells.
  • scUCHTl from both COS-7 and SP2/0 cells had little effect in the T cell proliferation assay at low concentrations (below 10 ng/ml), and became inhibitory as the concentration increased. In accordance with these results, scUCHTl did not induce TNF- ⁇ production and even inhibited the basal yield of IFN- ⁇ .
  • the present chimeric anti-CD3 single chain antibody scUCHTl possesses high human CD3 binding specificity and affinity, and does not induce T cell proliferation and cytokine release. Moreover, it has a human IgM Fc fragment, which should decrease the possibility of inducing human anti-mouse antibody response. Thus, scUCHTl can be used for clinical immunosuppressive treatment.
  • Corynebacteriophage beta (C.diphtheriae) tox 228 gene sequence was from genebank. (Science 221, 885-858, 1983). The sequence is 2220 bp. There are 300 bp of 5' untranslated region (1 to 300) including the promoter sequence around (-180 to -10), 1682 of coding region (301- 1983) including signal peptide (301 to 376), A chain (377 to 955) and B chain (956 to 1983), and 3' untranslated region (1984 to 2220).
  • the full-length DT was amplified in two fragments.
  • the pelB leader sequence ( ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTGCGCT GCC CAA CCA GCG ATG GCC 3') SEQ ID NO:1) was added to the 5' end of the DT coding sequenc to all the constructs during polymerase chain reaction by primer EcosignalDT-1 and EcosignalDT-2.
  • a mutant residue was introduced at position 52.
  • the glycine (GGG) at position 52 wild type DT was substituted by glutamic acid (GAG).
  • the two primers p546R and p514S carried the mutant codon (GGG to GAG).
  • the PCR products of these two primers contained the substituted codon (GAG) instead of codon GGG.
  • the jointed double stranded DNA of the two fragments (1683bp) were cloned into pET 17b by restriction site Ndel and BamHI.
  • IgM immunoglobulin M
  • B cells or macrophages contain IgM Fc receptors.
  • IgM Fc receptors Binding of imrnuno toxin to cells other than T cells reduces the specificity of the anti-T cell immunotoxin and this situation is purposefully avoided.
  • using a bacterial expression system no carbohydrate is attached to the antibody which also eliminates Fc receptor binding.
  • substituting other human IgG constant domains would be a routine modification and should be claimed.
  • divalent fusion protein immunotoxins are provided. These have been expressed in E. coli, and Western blots of reduced and non-reduced SDS gels confirm that most of the immunotoxin is secreted as the dimeric (divalent) species.
  • the position of the toxin has been varied in an attempt to minimize stearic hindrance of the divalent antibody site, yet provide the best interactions with the CD3 receptor to facilitate toxin translocation across the membrane.
  • PCR amplification was conducted using BamHI and Ndel restriction sites and the pET17b vector.
  • Figs. 3 and 4 show two different clones expressing divalent immunotoxin fusion proteins cartooned in Figs. 5 and 6, respectively. Another variation is shown in Fig. 7.
  • the clone producing this consists of a clone constructed by using the single chain antibody followed by a stop codon and the single chain immunotoxin, all under one promoter (Better et al. Proc. Natl. Acad. Sci. 90:457-461, January 1993).
  • 3 species are present: sc divalent antibody, divalent fusion immunotoxin, and a divalent sc antibody containing only one toxin.
  • This species is isolated by size separation and is the species cartooned in Fig. 7.
  • the advantage of this species is that stearic hindrance to the divalent antibody domains is limited by the presence of only one toxin domain.
  • Other variations are routine to construct given the methods described herin and in the art. Those diagramed are considered to be the most likely to exhibit divalent character. Numerous orientations of toxin relative to antibody domains can be made and many are expected to be effective.
  • the other mutation S to F at 508 has been added because of previous restrictions on cloning mutant DT that can revert to wild type toxin with a minimum lethal dose of 0.1 microgram/kg by means of a single base pair reversion.
  • Other mutations can be routinely made in the C terminus to perform this function (Shen et al. J. Biol. Chem. 269(46):29077- 29084, 1994). They are: F530A; K526A; N524A; V523A; K516A Y514A.
  • a clone having a single point mutation in DT reducing toxicity by 10-100 fold can be made providing that the clone contains an antibody fragment fusion protein, because chemical conjugation of antibody to DT has been shown to reduce systemic wild type toxin toxicity by 100 fold (Neville et al. J. Biol. Chem. 264(25): 14653-14661, 1989). Therefore, the present invention provides a full length mutant DT sequence with the 525 S to F mutation alone as well as those listed above. These same mutations are also contemplated for the B chain mutant site in DTM2 and can be made similarly. Previous data with chemical conjugation has shown that the longer the C-terminus the better the translocation function (Colombatti et al. J. Biol. Chem.
  • the present invention provides an improvement on CRM 197 (a non- toxic toxin mutant described in U.S. Serial No. 08/034,509, filed September 19, 1994) referred to herein as DTM2.
  • DTM2 has the same mutation as CRM 197 plus two mutations in the C- terminus which block binding (see sheet). This is expected to reduce the likelihood of immune complex disease which could result when CRMl 97 becomes bound to cells and then is further bound by circulating antitoxin. Kidneys are particularly susceptible. DTM2 can not bind to cells thereby lessening the possibility of tissue damage.
  • DTM2 is made for high level production by including the pelB secretory signal for production in E.
  • DTM2 a iron independent mutated promoter DT sequence cloned from CRM9 DNA for production in C. diptheriae.
  • the essential feature of DTM2 is the S to F mutation at 525 and the G to E mutation at 52, and a construct containing these two mutations is provided.
  • a fold-back single-chain diabody format enhances the bioactivity of an anti-CD3 recombinant diphtheria toxin based immunotoxin.
  • Anti-CD3 immunotoxins induce profound but transient T cell depletion in vivo by inhibiting eukaryotic protein synthesis, and they have utility in non-human primate models of transplantation tolerance and autoimmune disease therapy (Neville et al, 1992; Hu et al, 1997; Fechner et al, 1997, Thomas et al, 1997 and Contreras et al, 2003).
  • the conjugated immunotoxins were formed by chemically cross-linking the antibody or antibody fragment to a diphtheria toxin binding site mutant, CRM9. In this way the binding site of the immunotoxin was dictated by the antibody moiety (Neville et al, 1996).
  • the beneficial effect of the second scFv was ascribed to the divalent character of the biscFv binding, which in the case of the anti-human CD3 antibody UCHTl was increased 5 -fold for the biscFv binding over the scFv binding toward human T cells.
  • Anti-monkey CD3 immunotoxins are important tools in organ transplantation research where the primary goal is to achieve tolerance to allografted organ transplants. Rodents are easily tolerized and are not a good model for human transplantation tolerance protocols compared to monkeys (Fechner et al., 1997, Thomas et al., 1997 and Contreras et ah, 2003).
  • the FN18 scFv appeared more sensitive than anti-human UCHTl to positional loss of affinity when placed distal to the DT390 toxin domains compared to the UCHTl scFv.
  • the divalent character of the C207 biscFv was judged to be suboptimal as determined by the relatively low increase in binding to monkey T cells of the biscFv relative to the scFv which was only 1.7 ⁇ 0.4 fold, compared to 5-fold for the UCHTl biscFv/scFv binding ratio.
  • Diabodies are recombinant non-covalent dimeric molecules with cross-over pairing of the VL and VH domains achieved by linking the VL and VH domains with a peptide linker that is too short to allow the interchain assembly of a functional Fv fragment (Holliger et al., 1993).
  • the diabody will be bivalent. If the linked VL and VH domains are derived from two different Fv structures the diabody will be bispecific (Le Gall et al., 2004).
  • Single-chain monomelic diabodies have also been generated by linking two diabodies through a longer linker that allows the diabody subunits to fold back head to tail (Kontermann and Muller, 1999).
  • Plasmid pPICZ ⁇ was purchased from Invitrogen.
  • the hybridoma secreting FN 18 was kindly provided by Dr. Margreet Jonker, Biomedical Primate Research Center Rijswijk, and was produced and purified by the National Cell Culture Center, Minneapolis, MN.
  • Chemically conjugated anti-monkey CD3 immunotoxin, FN18-CRM9 was prepared as previously described (Neville et al., 1989).
  • the Herpes Saimiri virus transformed cynomolgous cell T cell line HSC-F (Akari et al., 1996) was supplied by the Centralized Facility for ADDS Reagents supported by EU Programme EVA and the UK Medical Research Council. This cell line exhibits the moderate binding FNl 8 phenotype (Liu et al., 2007).
  • FN18-FITC conjugate was purchased from Biosource and added to 250,000 HSC-F cells at 5 x 10 "9 M in the presence of varying concentrations of scFv and immunotoxin binding competitors at 4 0 C for 30 min.
  • the displacement of FN18-FITC was measured by FACS on a Beckman-Coulter Cytomics FC 500 instrument after washing the cells two times at 400 x g at 4 0 C and resuspending in 0.5 mL of 1 X PBS containing 2.5 ⁇ g of propidium iodide to exclude dead cells from further analysis.
  • MCI Mean channel fluorescent values, MCI, were corrected (MCF') by subtracting an appropriate FITC-isotope control from both the FN18-FITC tracer, and FN18-FITC tracer plus competitor MCF values.
  • the % inhibition was determined as [(MCF'FNIS-F ⁇ C - MCF ⁇ 18- F 1 TC + COMPETITOR) / MCF'FNIS-F ⁇ C] X 100.
  • Relative binding affinity between any two competitors was determined by dividing their respective concentrations at equal % inhibition obtained from plots of % inhibition versus concentration as previously described (Thompson et al., 2001).
  • T cells from normal monkeys were isolated from blood by two centrifugations through Lymphocyte Separation Medium from BioWhittaker following the manufacturer's directions. About 400,000 cells were washed and incubated in RPMI 1640 medium containing 25 mM HEPES (Gibco) with 10% fetal calf serum + 2 g/L NaHCO3, adjusted to pH 7.4, + 0.1 mM nonessential amino acids + 1.0 mM sodium pyruvate + 50 ⁇ g/L of gentamicin sulfate with and without varying concentrations of immunotoxins for 72 h at 5% CO 2 , 37 0 C.
  • HEPES Gibco
  • nonessential amino acids + 1.0 mM sodium pyruvate + 50 ⁇ g/L of gentamicin sulfate with and without varying concentrations of immunotoxins for 72 h at 5% CO 2 , 37 0 C.
  • Cells were washed and then stained for 30 min at 4 0 C with anti-CD3 (SP34-2- PE BD Pharmingen), anti-CD4-FITC (BD Pharmingen), anti-CD20-PE Cy7 (BD Biosciences), and the vital dye 7- ADD (BD Pharmingen) and analyzed on a Beckman- Coulter Cytomics FC 500 instrument counting 10 4 events. Cells were analyzed for uptake of the vital dye, the per cent of cells within the lymphocyte forward scatter/ side scatter gate, and the per cent of cells within the lymphocyte gate within the quadrant displaying the CD3 + and CD4 + epitopes by 2-color FACS.
  • the % of cells within the lymphocyte gate at each immunotoxin concentration was divided by % of cells within the lymphocyte gate for the 72 h no-treatment control (Gl).
  • the % of cells within the CD3 + CD4 + quadrant at each immunotoxin concentration was divided by % of cells within the CD3 + CD4 + quadrant for the 72 h no-treatment control (Ql).
  • the % loss of CD3 + CD4 + cells was calculated as Gl x Ql x 100.
  • C207 is an affinity matured anti-rhesus CD3 mutant antibody selected from a library of FN 18 sFvs randomly mutagenized with nucleotide analogs, displayed on yeast and selected by sorting flow cytometry using dye-labeled monkey CD3 ⁇ ectodomain heterodimer (Wang et al., 2007). Construction of biscFv(C207) and its production in P. pastoris has been described as has the construction of the diphtheria toxin based immunotoxin utilizing biscFv(C207) (Wang et al., 2007) shown in Table 5 schematic E.
  • diabody (C207) the Db(C207) gene was PCR-amplified from the plasmid pGK1903 using the primers GP-102 and WP-052. These vectors were sequenced using two primers located in the pPICZ ⁇ , 5'-AOXl primer and 3'-AOXl primer (Invitrogen). Expression and purification of diabody (C207) and fold- back diabody (C207) was performed using a protein L affinity resin as described previously (Wang et al., 2007).
  • the Db(C207) gene was PCR amplified from plasmid pGK1903 using two primer sets; the first amplification used primers GP-94 & WP-053 and second used primers GP-90 & WP-052.
  • the first PCR product was digested with Ncol and BamHl and the second PCR product was digested with BamHl and EcoRI. Then the two scFv parts in the vector pGK2006 (A-dmDT390-biscFv(C207) in pwPICZ ⁇ ) were sequentially replaced with C207- Db counterparts using Ncol and BamHl for the first scFv and BamHl and EcoRI for the second scFv (see Table 5, G). The resulting plasmid (pGK2019) was transformed into Pichia pastoris JW 107 and the transformants were selected on YPD plates containing zeocin (100 ⁇ g/ml).
  • A-dmDT390-scfbDb(C207) (Table 5, G) was administered as an intravenous bolus in two dosing schedules;(A) doses given on day 0 and 2 doses at a total dose of 0.15 mg/kg (monkey CX3X) and (B) 8 divided doses given over 4 days, 6 hours apart for a total dose of 0.2 mg/kg (monkey 32972). Lymphocyte phenotype levels were monitored in blood and also in lymph nodes following maceration by flow cytometry on a Beckman-Coulter Cytomics FC 500 instrument counting 10 4 events.
  • Staining reagents were: CD3 + (CD3 sp34 FITC, Pharmingen, Catalog # 556611, clone SP34), CD4 + (CD4 PerCP-Cy5.5, Pharmingen, Catalog # 552838, clone L200), CD8b + (CD8beta ECD, Coulter, Catalog # 6607123, clone 2st8.5h7), CD20 + (CD20 PeCy7, BD/Pharmingen, Catalog # 335793).
  • IgG isotype controls (isotype for sp34: IgG3 FITC, Southern Biotech, Catalog # 0105-02, clone BlO and isotype for fhl8: IgGl FITC, Coulter, Catalog # IM0639U, clone 679.1Mc7) were subtracted from mean fluorescent values. Blood T and B cell values were calculated by multiplying the total lymphocyte count per mm 3 by the % of T cells or B cells enumerated by flow cytometry. When the total lymphocyte count was not performed on a cytometry day, the count obtained on the previous day was used.
  • the size of the diabody (Table 5, B) and the diabody immunotoxin (Table 5, F) corresponds to a dimeric protein mediated through molecular associations between the VH and VL domains on neighboring molecules since intermolecular self-associations were prevented by the short G4S linker separating these domains. This is shown to be the case in Fig. 11 where the Superdex 200 size exclusion column elution times of these constructs are plotted versus log MW. The column was calibrated using BSA monomers and oligomers (solid line) and with scFv(M20) and A-dmDT390bisFv(M20), dashed line.
  • the relative binding of these constructs to the monkey T cell line HSC-F is estimated from the inhibition of the anti-monkey anti-T cell antibody FNl 8 labeled with FITC by the constructs in a competition assay.
  • the ratio of the construct concentrations at equal levels of inhibition reflects the relative avidity of the constructs and is shown in Fig. 13.
  • the rank order of competitor binding from highest to lowest is scfbDb(C207) (Table 5, C), Db(C207) (Table 5, B), biscFv(C207) (Table 5, D) and scFv(C207) (Table 5, A).
  • FNl 8 competition for FITC-labeled FNl 8 is shown for a comparative standard.
  • Anti-T cell activity of immunotoxin made in the fold-back diabody format.
  • the anti-T cell activity of immunotoxin made in the fold-back diabody format was judged by two in vitro assays and by its effects in vivo.
  • Fig. 15 the % control inhibition of protein synthesis for three immunotoxins on the transformed HSC-F monkey T line is shown.
  • Fig. 17 the loss of lymph node T cells over time enumerated by flow cytometry following bolus intravenous administration of the fold-back diabody immunotoxin is shown for two monkeys.
  • Monkey 32972 received the immunotoxin twice daily, 6 h apart, over 4 days, for a total dose of 0.2 mg/kg.
  • Monkey CX3X received two intravenous bolus doses of immunotoxin, one on day 0 and one on day 2 for a total dose of 0.15 mg/kg.
  • a third monkey AH44 received another biscFv immunotoxin, A- dmDT390biscFv(M20) in the same dose and schedule as monkey CX3X.
  • This immunotoxin was described previously (Wang et al., 2007) and is 13.5-fold less active against resting T cells compared to A-dmDT390-biscFv(C207). Lymph nodes were not noticeably deleted of T cells 4 days after the initial immunotoxin dose. The profound loss of T cells in the blood for monkey 32972 is shown in Fig. 18. B cells are only moderately affected.
  • T cells were present in the blood one month later but the per cent of SP34 + T cells in the lymphocyte gate was reduced from the pre-treatment value of 66% to 18.7% while the % of CD20 + B cells rose from 19.2 to 35.3 as did the percentage of CD2 + SP34 ' cells (probable NK cells).
  • RNAase based immunotoxin targeted at B cells using the CD22 epitope.
  • the results showed that the dimeric diabody format was inactive using the larger DT390 based toxin moiety, probably due to steric hindrance. Therefore a fold-back diabody format was tried. In this format two identical diabodies are linked through a longer linker that allows the diabody subunits to fold back head to tail.
  • the fraction of multivalent binding never approaches the high values seen in some low molecular weight systems such as tris-vancomycin binding a trivalent D- AIa-D- Ala ligand (Rao et al., 1998).
  • the trivalent KD (4 x 10 ⁇ 17 M) was approximately equal to the third power of the monovalent KD (1.6 x 10 "6 M).
  • the fold-back divalent diabody shares the divalent diabody features of enhanced rigidity and a close to 180 degree angle between the two antigen sites and these features contribute to enhanced improvements over the biscFv format.
  • the simultaneous and concerted interaction of all 4 domains undoubtedly stabilizes the structure and provides extra thermal stability compared to the biscFv format where only 2 concerted domain interactions occur for each part of the biscFv.
  • the rigid 180 degree angle between the two antigen sites permits divalent interactions between monovalently bound diabody- immunotoxin on neighboring cells in closely packed tissue such as lymph nodes, thus expanding the fraction of divalent binding sites beyond that limited on a single cell surface. This decreases the overall kinetic off rate and enhances signaling facilitating endocytosis of immunotoxin.
  • Prostate cancer is the most common non-skin neoplasm in men in the United States with 250,000 cases per year and is the second leading cause of cancer mortality in men with 30,000 deaths per year.
  • One in six men will develop prostate cancer at some point in their lives.
  • the disease is more common in older men and those of African- American ancestry and those with first-degree relatives with prostate cancer.
  • Environmental factors including a high animal fat diet and low selenium and vitamin D may contribute to the high rate of disease in the United States.
  • prostate carcinogenesis The molecular mechanisms leading to prostate carcinogenesis appear to be multiple and diverse. Disorders in cell renewal (sonic hedgehog, Notch and Wnt pathways), cell survival (PTEN and Ras signaling) and cell proliferation (MAPK pathways) may all been shown to contribute to prostate cancer formation and progression. Thus, there are multiple targets for new therapeutics, but the role of particular molecules in individual prostate cancer patients is unknown and unlikely to be solitary.
  • New therapeutics agents for prostate cancer may nevertheless take advantage of the persistence of several prostate differentiation antigens in most metastatic tumor deposits.
  • the cell surface membrane 100 kilodalton glycoprotein prostate specific membrane antigen (PSMA) is expressed on epithelial prostate cells on both the prostate and all stages of androgen-insensitive or metastatic disease.
  • the antigen is an enzyme and forms a homodimer on the cell surface and undergoes rapid endocytosis on antibody binding.
  • the protein is absent from non-prostate tissues.
  • Emara M Sanfilippo F (1992) Cell Immunol; 144:143-54.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Provided are methods and compositions related to diphtheria toxin diabody immunotoxins.

Description

A FOLD-BACK DIABODY DIPHTHERIA TOXIN IMMUNOTOXIN AND
METHODS OF USE
This application claims priority to United States Provisional Application 60/953,416 filed on August 1, 2007; this application is incorporated herein in its entirety by reference.
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
The present invention relates to an immunotoxin. The invention further relates to a method of treating T cell leukemias or lymphomas, graft-versus-host diseases, cancer, and autoimmune diseases by administering an immunotoxin.
BACKGROUND
Irnmunotoxins are toxins with altered receptor specificities. The alteration is achieved by coupling a monoclonal antibody (mAb) or growth factor to the toxin or toxin fragment. Plant and bacterial protein toxins intoxicate cells by a multi-step process whereby different toxin domains sequentially interact with cellular components. The intoxication pathway at a minimum consists of surface receptor binding, toxin processing, intracellular routing of toxin A chains to the cytosol, and enzymatic inactivation of protein synthesis (Neville and Hudson (1986) Ann. Rev. Biochem. 55:195). The goal of immunotoxin research has been to achieve targeted cell killing comparable to the enormous but indiscriminate cell killing power of the native toxins. An equally important goal has been to maintain the low non-target cell toxicity of toxin A chains, which lack cell receptor binding and membrane translocation functions (Youle and Neville (1982) J. Clin. Biol. 257:1598; Neville (1986) in CRC Crit. Rev., Therap. Drug Carrier Syst., CRC Press Inc., 2:329; Immunotoxins, Frankel ed.(1988) Kluwer Academic Publishers). Because of this latter consideration most in vivo clinical studies have focused on A chain immunotoxins or immunotoxins with truncated B chains lacking the receptor binding domain. While some clinical results have been encouraging, the reproducible achievement of both goals is at present uncertain (Program and Abstracts 2nd Int. Symposium on Immunotoxins, June 1990, Lake Buena Vista, Florida). Recently, Youle and co-workers have introduced highly efficacious holo- immunotoxins based on diphtheria toxin (DT) binding mutants (Greenfield et al. (1987) Science 238:536; Johnson et al. (1988) J. Biol. Chem. 263:1295; Johnson et al. (1989) J. Neurosurg. 70:240). These DT binding site mutants were equal to the wild-type immunotoxins in potency when directed at the human transferrin receptor (TFR) or human CD3, a component of the T cell receptor complex. Since the binding of the mutants was only 1/100-1/1000 of native DT, the toxin receptor appeared to be not needed along the intoxication pathway. This conclusion is limited to immunotoxins which route through CD3 and TFR, because similar immunotoxins directed at CD5 and the high-molecular weight-melanoma-associated antigen are relatively non-toxic (Neville et al. (1989) J. Biol. Chem. 264:14653). On the basis of data obtained with acid-cleavable conjugates which released free DT or the DT binding site mutant CRM9 in acidified endosomes, it was concluded that the DT receptor participates in the optimal intracellular routing of DT and many DT conjugates (Neville et al. (1989) J. Biol. Chem. 264:14653). It was also concluded that CD3 and TFR can perform the same routing function as the DT receptor, thus obviating the requirement of a DT receptor interaction for the binding site mutant conjugates anti-CD3-CRM9 and TFR-CRM9 (Intracellular routing of ricin based immunotoxins via the ricin receptor leading to enhanced efficacy has also been reported. Youle et al. (1981) Cell 23:551; Marsh and Neville (1986) Biochem. 25:4461; Youle and Colombatti (1987) J. Biol.Chem. 262:4676). The disadvantages of these chemically conjugated immunotoxins are linkage heterogeneity, Fc receptor interactions and a mutated toxin-binding domain in which binding to DT receptors is reduced but not eliminated. These disadvantages were overcome by developing recombinant immunotoxins based on diphtheria toxin truncated at residue 390 which provided optimal translocation of the toxin A chain into the cytosol while eliminating the toxin binding domain (Williams et al., 1990 and Thompson et al., 2001). These DT based immunotoxins were restricted to having the antibody moiety placed C-terminal to the truncated toxin because antibody domains fused to the N-terminal of the toxin interfered with translocation of biologically active A chain (Madshus et al, 1992 and Hexam et al, 2001).
SUMMARY OF THE INVENTION
The invention is one aspect relates to an immunotoxin comprising a diphtheria toxin moiety and a diabody targeting moiety. It is a further object of the invention to provide a method of treating cancers such as prostate cancer, breast cancer, and T cell leukemias or lymphomas.
It is a further object of the invention to provide a method of treating autoimmune diseases.
It is a further object of the invention to provide a method of inhibiting graft rejection, inhibiting graft-versus-host disease, and inducing immune tolerance.
Further objects and advantages of the present invention will be clear from the description that follows.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows that the epitopes involved in human serum's inhibition of its toxicity lie in the last 150 amino acids of DT. A schematic diagram of the DT mutants CRM9, CRMl 97 and MSPΔ5 is presented (A). The A- and B-subfragments and their relative size and position are shown. The filled circle represents a point mutation as described in the text. Goat (B) or human (C) serum (human serum was a pool from all samples with positive ELISA for anti-DT antibodies) was incubated with increasing molar concentrations of CRM197 (-O-), MSPΔ5 (-X-) or the B-subfragment (-Δ-) of DT for 30 minutes at room temperature. To this reaction, UCHT1-CRM9 was added to a final concentration of 1 X 10"10 M. This mixture was then diluted 10-fold onto Jurkat cells in a protein synthesis inhibition assay as described in the Materials and Methods. Immunotoxin incubated with medium only inhibited protein synthesis to 4% of controls. The results are representative of two independent assays.
Figure 2 shows the schematic flow sheet for generation of the single chain antibody scUCHTl gene construct. PCR: polymerase chain reaction; L: linker; SP: signal peptide. Pl to P6, SPl, and SP2 are primers used in PCR.
Figure 3 shows one clone expressing the divalent immunotoxin fusion protein shown in Figure 5.
Figure 4 shows another clone expressing a divalent immunotoxin fusion protein shown in Figure 7.
Figure 5 is a schematic of a divalent fusion immunotoxin.
Figure 6 is a schematic of a divalent fusion immunotoxin.
Figure 7 is a schematic of a divalent fusion immunotoxin. Figure 8 shows the cloning scheme used to obtain scUCHTl fusion protein with DTMl and DT 483.
Figure 9 shows the cloning scheme used to obtain scUCHTl fusion protein with DT 390.
Figure 10 shows the cloning scheme used to obtain scUCHTl fusion protein with DT 370.
Figure 11 shows the sizing of the diabody fusion-protein constructs shown in Table 5. The constructs are sized by plotting their elution times versus log MW on a calibrated Superdex 200 size exclusion column. The column has been calibrated with BSA that contains in addition to monomers (68 kDa) dimers, trimers and tetramers (open circles, solid line). Additionally, the column has been calibrated with scFv(M20), 27.5 kDa, and A- dmDT390bisFv(M20), 98.3 kDa, dashed line. The diabody constructs fall on the latter line when given the following molecular weight values: Db(C207), (Table 5, B) solid triangle, 53.7 kDa, calculated MW of [Db(C207)]2 ; A-dmDT390-scfbDb(C207), (Table 5, E) solid square, 97.1 kDa calculated monomer MW; A-dmDT390-Db(C207), (Table 5, F) inverted solid triangle, 141.1 kDa, calculated MW of [A-dmDT390-Db(C207)]2. The single-chain fold-back diabody, scfbDb(C207), (Table 5, C) solid diamond, having a monomelic MW of 54.6 kDa, elutes slightly above the dashed line indicating a more compact hydrodynamic structure than the corresponding dimeric diabody.
Figure 12 shows a SDS 12% acrylamide bis-tris non-reducing gel of the fold-back immunotoxin A-dmDT390-scfbDb(C207) (Table 5, G), after the 3-step purification procedure, is shown in third lane from right alongside molecular weight markers in the first lane with marker kDa values printed at the left. (The trace band in the second lane is spillover from lane 3.)
Figure 13 shows the % inhibition of tracer FITC-labeled FN 18 binding to HSC-F monkey T cells plotted versus the concentration of binding competitors consisting of scFv(C207), (Table 5, A) biscFv(C207) , the diabody of C207, Db(C207), (Table 5,B) and the single-chain fold-back diabody of C207, scfbDb(C207) (Table 5, C). The relative functional binding affinity for any two competitors can be estimated from the ratio of their concentrations at equal % inhibition values. Estimates are considered to be reliable when comparing parallel curves or parallel curve regions. The rank order of competitor binding from highest to lowest is scfbDb(C207), Db(C207), biscFv(C207) and scFv(C207). FNl 8 competition for FITC-labeled FNl 8 is shown for a comparative standard. In replicate assays the ratio of concentrations at equal displacement for Db(C207)/ scFv(C207) is 7±2 while the ratio for biscFv(C207)/ scFv(C207) is 2.5±0.1 (errors are SD). See Table 5 for structural schematics of these fusion proteins.
Figure 14 shows another binding competition assay like Figure. 20 except that the competitors of FITC-labeled FNl 8 binding to HSC-F monkey T cells are now immunotoxin fusion proteins that use a diabody, A-dmDT390-Db(C207) (Table 5, F), a fold-back single- chain diabody, A-dmDT390-scfbDb(C207) (Table 5, G) and biscFv antibody moiety, A- dmDT390-biscFv(C207) (Table 5, E). The diabody immunotoxin is devoid of detectable binding to the T cells. The fold-back single-chain diabody shows 10-fold increase in binding to T cells compared to A-dmDT390-biscFv(C207). The data points for A- dmDT390-biscFv(C207) are for comparative purposes and were previously reported (Wang et al., 2007).
Figure 15 shows the % control inhibition of protein synthesis for three immunotoxins on HSC-F monkey T cells is plotted versus the immunotoxin concentrations on the x-axis after a 24 h exposure. Each point is the mean of 6 replicates and 1 SD error bars are shown. The single-chain fold-back diabody recombinant immunotoxin, A- dmDT390-scfbDb(C207) (Table 5, G), solid diamonds, is the most potent immunotoxin, exceeding the immunotoxin constructed with the biscFv antibody moiety, A-dmDT390- biscFv(C207) (Table 5, E) by 5-fold (empty squares). Only single sided error bars are shown for these two immunotoxins.
Figure 16 shows the loss of resting monkey T cells from the lymphocyte gate by flow cytometry. PBMC were isolated from blood by gradient centrifugation and incubated for 72 h with anti-T cell immunotoxins made in various formats. The fold-back diabody immunotoxin, solid squares, is the most potent, exceeding the biscFv immunotoxin, empty circles, by 7±4-fold determined on two replicate assays. The diabody immunotoxin is inactive. Chemically conjugated FN18-CRM9 is provided as a reference.
Figure 17 shows the per cent of monkey lymph node CD3ε+ T cells present within the forward scatter/side scatter lymphocyte gate determined by flow cytometry after the administration of the fold-back diabody immunotoxin A-dmDT390-scfbDb(C207) (Table 5,G). One monkey, CX3X, dashed line, received an IV bolus of immunotoxin on days 0 and 2 of 75 μg/kg each (arrows). Monkey 32972, solid line, received immunotoxin as an intravenous bolus twice daily, 6 hours apart for 4 days at 25 μg/kg each. Lymph nodes were surgically removed under anesthesia, macerated and stained prior to flow cytometry. The time 0 point represents a mean monkey lymph node T cell percentage from 11 individual monkeys obtained prior to immunotoxin treatment.
Figure 18 shows the depletion of blood CD3ε+ T cells, solid line, in monkey 32972 and changes in the CD20+ B cell population enumerated by flow cytometry and total blood lymphocyte counts following intravenous administration of the fold-back diabody immunotoxin A-dmDT390-scfbDb(C207) (Table 5, G) [see Figure 23 legend]. At day 5, after 4 days of immunotoxin administration, the blood T cell count was 19/mm3
Figure 19 shows the fold back format anti-PSMA immunotoxin was 18-30 fold more potent than the bisFv format immunotoxin.
Figure 20 shows the optimized variable chain amino acid and DNA sequences for the J591 variable heavy chain (Vh) (A), and J591 variable light chain (Vl) (B). de J591 is deimmunized J591. Characters highlighted in gray color indicate changes of DNA sequence. Vh de J591, Vh aa-deJ591, Vh-optimized, and Vh optimized J591 are SEQ ID NOs:16-19, respectively. Vl de J591, Vl aa-deJ591, Vl-optimized, and Vl optimized J591 are SEQ ID NOs:20-23, respectively.
DETAILED DESCRIPTION OF THE INVENTION
As used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a pharmaceutical carrier" includes mixtures of two or more such carriers, and the like.
Ranges can be expressed herein as from "about" one particular value, and/or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as "about" that particular value in addition to the value itself. For example, if the value "10" is disclosed, then "about 10" is also disclosed. It is also understood that when a value is disclosed that "less than or equal to" the value, "greater than or equal to the value" and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value "10" is disclosed, then the "less than or equal to 10," as well as "greater than or equal to 10" is also disclosed. It is also understood that throughout the application, data are provided in a number of different formats, and that these data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point "10" and a particular data point "15" are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed, as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
Disclosed herein in one aspect are immunotoxins, comprising a mutant diphtheria toxin moiety linked to a targeting moiety, wherein the targeting moiety is a single chain variable region diabody. The immunotoxins disclosed herein in one aspect comprise diabodies. Herein, a "diabody" is a single chain antibody fragment comprising two scFv regions wherein one scFv region associates with a second scFv to form a dimer. Where the first scFv and the second scFv share the same antigen specificity, the diabody is referred to as "bivalent" (also called divalent). Where the first scFv and the second scFv are of different antigen specificities, the diabody is referred to as "bispecific." Thus it is understood and herein contemplated that the diabodies disclosed herein can be bivalent or bispecific.
It is understood and herein contemplated that the disclosed diabodies can act as a targeting moiety for the toxin moiety. Thus, it is disclosed herein that the disclosed diabodies can be specific for any antigen provided translocation of the toxin moiety is still possible. For example, the targeting moiety can be specific for the CD3 molecule on T cells and thus T-cell specific. Also, for example, the targeting moiety can be specific for a cancer antigen including but not limited to PSMA or viral antigen such as, for example, GP 120. Thus, disclosed herein are diabodies wherein the diabody comprises the V1VH region directed against CD3. Also disclosed are diabodies wherein the VLVH region is derived from the anti-CD3 antibody UCHTl or C207. Further disclosed herein are diabodies wherein the diabody comprises the VL VH region directed against PSMA. Also disclosed are diabodies wherein the VLVH region is derived from the anti-PSMA antibody J591
The immunotoxin can be a fusion protein produced recombinantly. Derivatives of this immunotoxin are designed and constructed as described herein. As disclosed above, the toxin moieties of the immunotoxins disclosed herein are mutant diphtheria toxin moieties. It is understood that other toxin moieties such as ricin and pseudomonas exotoxin A (PeA) can be used with the disclosed methods and compositions. It is further understood that the disclosed mutant toxin moieties can comprise substitution mutants. Examples of such substitution mutants include but are not limited to, for example, CRM9. It is also understood that the disclosed mutant toxin moieties can comprise a truncation mutant. The deletion mutants can comprise C-terminal deletions of between 140 and 150 C-terminal amino acids. Thus, disclosed herein are toxin moieties wherein the truncation mutant comprises a deletion of 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, or 150 C-terminal amino acids of the full length diphtheria toxin. Therefore, disclosed herein are immunotoxins wherein the diphtheria toxin is a deletion mutant with 140-150 C- terminal amino acids deleted. It is understood herein that the disclosed truncation mutants can be referred to either by designating the number of deleted C-terminal acids or by designating the number of remaining amino acids counting from the N-terminus. Thus, for example, a diphtheria toxin moiety comprising a deletion of 145 amino acids of the complete diphtheria toxin protein (535 amino acids) can be referred to as DT390. Likewise a deletion of 146 amino acids is DT389. Further examples of alternate naming of truncation mutants are as follows:
140 C-terminal truncation mutant = DT395
141 C-terminal truncation mutant = DT394
142 C-terminal truncation mutant = DT393
143 C-terminal truncation mutant = DT392
144 C-terminal truncation mutant = DT391
147 C-terminal truncation mutant = DT388
148 C-terminal truncation mutant = DT387
149 C-terminal truncation mutant = DT386
150 C-terminal truncation mutant = DT385 The C-terminally truncated toxin moiety retains its toxin function, and membrane translocation function to the cytosol in full amounts. The loss in binding function located in the C terminus of the protein diminishes systemic toxicity by reducing binding to non-target cells. The routing function normally supplied by the toxin binding function is supplied by the receptor bound by the targeting diabody component (e.g., an anti-CD3 diabody). The essential routing pathway is (1) localization to coated pits for endocytosis, (2) escape from lysosomal routing, and (3) return to the plasma membrane. Any receptor bound antibody which can route in this manner will be effective as a diabody for use with the toxin moiety, irrespective of the antigen or epitope to which the antibody is directed. Thus, a wide variety of cell types can in principle be targeted. In practical terms very few receptors fulfill these criteria. When antibodies dissociate from their receptors due to changes in receptor configuration induced in certain receptors as a consequence of endosomal acidification, they enter the lysosomal pathway. This can be prevented or minimized by directing the antibody towards an ecto-domain epitope on the same receptor which is closer to the plasma membranes (Ruud, et al. (1989) Scand. J. Immunol. 29:299; Herz et al. (1990) J. Biol. Chem. 265:21355). Other DT binding site mutants can be used to form derivatives by changing amino acids in the C- terminus which can reduce the binding function as long as the translocation function is maintained. Specific examples are described in the Examples.
Protein toxins of the A-B type have 3 distinct structural and functional domains. (1) an enzymatic domain called the A chain that is highly cytotoxic after transfer or translocation to the cytosol compartment. (2) a translocation domain located within the B chain that facilitates translocation of the a chain into the cytosol; and (3) a receptor binding domain that binds to a cell surface receptor (also in the B chain). The toxin A and B chain is linked by a protease cleavage site spanned by a disulfide bond. This site must be cleaved to achieve translocation into the cytosol compartment and full specific toxicity. Thus an added level of specificity can be built into fusion immunotoxins by replacing cleavage sites that most cells can cleave with cleavage sites that are unique to cancer cells or cancer neovasculature (Liu, S et al., Expert Opinion Biol Ther 3,843-853, 2003). Toxin receptors have several special properties. One property is that they are efficiently endocytosed into endosomal vesicles. A second property is that the toxin receptor routes the toxin along an intracellular pathway to its site of efficient translocation to the cytosol compartment. For diphtheria toxin this site is in the late endosomal compartment. For ricin and pseudomonas exotoxin A this site is along the endoplasmic reticulum/Golgi apparatus. Immunotoxins are toxins that have been altered by replacing the toxin receptor binding domain with an alternate receptor binding domain chosen to target the toxin to a specific cell type in order to eliminate that cell type. However, in order for the immunotoxin to function efficiently, the new alternate receptor must also route the toxin to its efficient translocation site. The translocation efficiency of diphtheria toxin is 10 to 30- fold greater than that of ricin and pseudomonas exotoxin A, conferring considerable advantage to immunotoxins based on diphtheria toxin. However, the number of receptor types that route diphtheria toxin to the site efficient translocation are very limited, and until recently only 2 examples were known, the CD3ε chain of the T cell receptor complex expressed only on T cells and the transferrin receptor, expressed on all cells but up- regulated with increasing mitotic activity. With the finding herein that a DT-based immunotoxin directed at the prostate specific membrane antigen (PSMA) receptor is highly toxic, a third example has been found.
It is understood that the disclosed immunotoxins can comprise linkers between the toxin moiety and the diabody targeting moiety. It is understood and herein contemplated that any linker known by those of skill in the art can be used to make the disclosed immunotoxins. The choice of which linker to use can be determined by those of skill in the art based on the desired length and flexibility of the linker between each VH and VL domain as well as between the toxin and targeting moieties. Thus, it is understood that the linker can be a chemical linker. It is also understood that the linker (L) can be a Gly-Ser linker. The Gly-Ser linker can be but is not limited to (Gly4Ser)n or (Gly3Ser)n. Thus, for example, the linker can be G4S, (G4S)2, (G4S)3, (G4S)4, (G4S)5, (G4S)6, (G4S)7, (G4S)8, (G4S)9, (G4S)10, G3S, (G3S)2, (G3S)3, (G3S)4, (G3S)5, (G3S)6, (G3S)7, (G3S)8, (G3S)9, (G3S)10. It is further understood that the linkers used can be a combination of chemical and gly-ser linkers. For example, the linker between the toxin and the diabody can be a chemical linker and the linker between the diabody domains can be a Gly-Ser linker. It is further understood that the for greater flexibility, a longer linker is used; whereas, a shorter linker is used for application where more rigidity is needed. Typically, the linker between domains of a diabody will be between 3 and 12 amino acids long. More typically, the diabody linker is between 3 and 5 amino acids long. Thus, for example, specifically contemplated are immunotoxins where the linker between the VH and VL domains of the targeting diabody moiety are G4S. It is also understood that more than one of the disclosed linkers can be used in a single chain immunotoxin. Thus, for example, specifically contemplated herein are immunotoxins wherein the linker between the toxin moiety and a first VL of the targeting diabody is G4S, between the first VL and VH is G4S, between the first VH and second VL is (G4S)3 and between the second VL and VH is G4S. Alternatively stated, disclosed herein are immunotoxins where from left to right the immunotoxin comprises:
Toxin-Ll-VL-L2-VH-L3-VL-L4-VH; wherein Ll, L2, and L4 comprise G4S and L3 comprises (G4S)3.
It is understood and herein contemplated that the disclosed immunotoxins (including fusion proteins and immunoconjugates) can be placed in a pharmaceutically acceptable carrier for administration to a subject. Furthermore, where a chemical linker is used to fuse the toxin and diabody moieties, both acid-cleavable and non-cleavable protein cross-linking reagents can be used in the construction of antibody-diphtheria toxin (Neville et al. (1989) J. Biol. Chem. 264:14653-14661); preferred are non-cleavable crosslinkers, such as bismaleimidohexane and m-maleimidobenzoyl-N-hydroxysuccinimide ester. The synthesis of acid-cleavable protein cross-linking reagents based on orthoester, acetal, and ketal functionalities has been described (Srinivasachar and Neville (1989) Biochemistry 28:2501- 2509). The unique feature of these functionalities is that their observed hydrolytic rate constants increase 10-fold for each drop in pH, a consequence of specific H3O+ catalysis leading to a carbonium ion intermediate (Cordes and Bull (1974) Chem. Rev. 74:581-603). Moreover, these functionalities are resistant to base catalysis permitting manipulation and storage at alkaline pH. The cross-linking reagents react with proteins via heterobifunctional groups (maleimide and N-hydroxysuccinimide ester) or homobifunctional groups (bis- maleimide). The maleimide cross-linking is accomplished by prior protein thiolation with iminothiolane. Cross-linked proteins exhibit first-order dissociation under acid conditions. The ti/2 at pH 5.5 varies between 0.1 and 130 h for a series of six different cleavable cross- linkers (Srinivasachar and Neville (1989) Biochemistry 28:2501-2509).
Also disclosed herein, the disclosed diabodies can be formed in a "fold-back" formation. Such formation typically occurs through the use of rigid linkers from 3 to 12, more typically from 3 to 5 amino acids long such as the G4S linker. The Toxin-Ll-VL-L2- VH-L3-VL-L4-VH; wherein Ll, L2, and L4 comprise G4S and L3 comprises (G4S)3 is an example of a fold-back diabody immunotoxin. Therefore, disclosed herein are immunotoxin fusion proteins comprising a diphtheria toxin moiety and a targeting moiety, wherein the targeting moiety is a diabody, wherein the sequence from the amino terminus from left to right is toxin moiety, Li, VLi, L2, Vm, L3, VL2, L4, VH2, wherein the toxin moiety comprises a truncation mutation, Li, L2, and L4 are (G4S) linkers, and VL and VH are the variable light and heavy domains. Also disclosed herein are immunotoxin fusion proteins comprising a diphtheria toxin moiety and a targeting moiety, wherein the targeting moiety is a diabody, wherein the sequence from the amino terminus from left to right is toxin moiety, Li, Vn, L2, VH l, L3, VL2, L4, VH2, wherein the toxin moiety comprises a truncation mutation, Li, L2, and L4 are (G4S) linkers, and VL and VH are the variable light and heavy domains, wherein VLi and VH i can be the same as VL2 and VH2.
Also disclosed herein are fold-back diabodies comprising toxin moieties wherein the truncation mutant comprises a deletion of 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, or 150 C-terminal amino acids of the full length diphtheria toxin. Also disclosed herein are diphtheria toxin immunotoxins comprising a truncation mutant and a fold-back diabody specific for an antigen or cell surface determinant such as CD3 or PSMA. Also disclosed herein are diphtheria toxin immunotoxins comprising a truncation mutant and a fold-back diabody specific for an antigen or cell surface determinant such as CD3 or PSMA, wherein the VL and VH regions of the diabody are the VL and VH regions of an anti-CD3 or anti- PSMA antibody, respectively. For example, diabodies described herein have the VL and VH regions originating from the anti-CD3 antibodies UCHTl and C207, and the anti-PSMA antibody J591, and the resulting immunotoxins are A-dmDT390scfbDb(UCHTl), A- dmDT390scfbDb(C207), and A-dmDT390scfbDb(J591), respectively. Thus, for example disclosed herein is A-dmDT390scfbDb(C207) wherein C207 is an anti-CD3 diabody affinity matured mutant of FNl 8 (wherein dm indicates a deletion mutant and scfbDb indicates a single chain fold-back diabody). Also disclosed herein are A- dmDT390scfbDb(C207) immunotoxins wherein the furin site amino acid sequence cleavage site RVRRSV has been replaced with the MMP cleavage site GPLGMLSQ or the PSA cleavage site HSSKLQ. Also disclosed herein, for example, is A-dmDT390scfbDb(UCHTl) wherein UCHTl is an anti-CD3 diabody clone. Also disclosed herein, for example, is A- dmDT390scfbDb(J591) wherein J591 is an anti-PSMA diabody clone. Additional examples of immunotoxins disclosed herein include but are not limited to A-dmDT395scfbDb(J591); A-dmDT394scfbDb(J591); A-dmDT393scfbDb(J591); A-dmDT392scfbDb(J591); A- dmDT391scfbDb(J591); A-dmDT389scfbDb(J591); A-dmDT388scfbDb(J591); A- dmDT387scfbDb(J591); A-dmDT386scfbDb(J591); A-dmDT385scfbDb(J591); A- dmDT395scfbDb(anti-PSMA); A-dmDT394scfbDb(anti-PSMA); A-dmDT393scfbDb(anti- PSMA); A-dmDT392scfbDb(anti-PSMA); A-dmDT391scfbDb(anti-PSMA); A- dmDT389scfbDb(anti-PSMA); A-dmDT388scfbDb(anti-PSMA); A-dmDT387scfbDb(anti- PSMA); A-dmDT386scfbDb(anti-PSMA); A-dmDT385scfbDb(anti-PSMA); A- dmDT395scfbDb(UCHTl); A-dmDT394scfbDb(UCHTl); A-dmDT393scfbDb(UCHTl); A-dmDT392scfbDb(UCHTl); A-dmDT391scfbDb(UCHTl); A- dmDT389scfbDb(UCHTl); A-dmDT388scfbDb(UCHTl); A-dmDT387scfbDb(UCHTl); A-dmDT386scfbDb(UCHTl); A-dmDT385scfbDb(UCHTl); A-dmDT395scfbDb(C207); A-dmDT394scfbDb(C207); A-dmDT393scfbDb(C207); A-dmDT392scfbDb(C207); A- dmDT391scfbDb(C207); A-dmDT389scfbDb(C207); A-dmDT388scfbDb(C207); A- dmDT387scfbDb(C207); A-dmDT386scfbDb(C207); A-dmDT385scfbDb(C207); A- dmDT395scfbDb(anti-CD3); A-dmDT394scfbDb(anti-CD3); A-dmDT393scfbDb(anti- CD3); A-dmDT392scfbDb(anti-CD3); A-dmDT391scfbDb(anti-CD3); A- dmDT389scfbDb(anti-CD3); A-dmDT388scfbDb(anti-CD3); A-dmDT387scfbDb(anti- CD3); A-dmDT386scfbDb(anti-CD3); A-dmDT385scfbDb(anti-CD3).
It is herein contemplated that the disclosed immunotoxins can be produced recombinantly as fusion proteins.
Also are disclosed herein fold-back diabody immunotoxins formed with A- dmDT390scfbDb(J591) or its derivatives in which the amino acids of the furin protease cleavage RVRRSV that begins at residue 191 from the amino terminus is replaced by a matrix metalloprotease cleavage site GPLGMLSQ (Liu, S et al., Expert Opinion Biol Ther 3,843-853, 2003) or a prostatic specific antigen cleavage site HSSKLQ (Denmeade SR et al., Cancer Research 57, 4924-30, 1997) accomplished by PCR mutagenesis. These fold- back immunotoxins have higher specificity towards cancers permitting higher doses in vivo.
Although many workers express immunotoxins in E. coli and refold these immunotoxins from solubilized solid E. coli granules, this technology is only applicable to simple antibody domains such as single chain scFv. In order to express biscFv domains and fold-back diabody domains the refolding machinery present in eukaryote endoplasmic reticulum is needed. The yeast, P. pastoris, has this machinery. The use of toxin-resistant eukaryotic cells can overcome the immunotoxin toxicity. However, selection and characterization of toxin-resistant eukaryotic cells are tedious, labor intensive and time- consuming work. Furthermore, the bivalent immunotoxin production in a EF-2 mutant CHO cell expression system was limited to 5 mg/L and could not be increased by selection for multiple gene insertions. Due to this limitation, with three exceptions (12, 20, 25) all recombinant immunotoxin production for therapeutic uses has been limited to E. coli production necessitating denaturation and refolding from inclusion bodies (6). However, refolding of the multi-domain structure of the bivalent immunotoxin from E. coli was inefficient and full bioactivity was not recovered (25). Also, the multi-domain structure of the bivalent immunotoxin hinders efficient production in Escherichia coli. Therefore, the attempt to develop a robust Pichia pastoris production system for the bivalent or bispecific immunotoxin was driven by the inadequacy of the existing productions systems.
Pichia pastoris is a good expression system for the bivalent and bispecific immunotoxins disclosed herein. For example, Pichia was good for the bivalent anti-T cell immunotoxin A-dmDT390-bisFv as it provides optimal protein folding compared to prokaryotic expression systems and provides higher yields compared to mammalian cell expression (CHO cells). Antibody fusion proteins require correct disulfide bridges and the endoplasmic reticulum of yeast provides an oxidizing environment like that of eukaryotic antibody producing cells. The multi-domain structure of the bivalent or bispecific immunotoxin requires a eukaryotic expression system to properly fold this complex protein. Yet most eukaryotes are sensitive to the effects of protein synthesis inhibition upon expression of the immunotoxin. However, a budding yeast, Pichia pastoris has a certain degree of tolerance to DT (Neville et al., 1992; Woo et al., 2002) and yielded the immunotoxin at a level of 40 mg/L in fermentor culture. The immunotoxin was produced by fermentation of genetically engineered Pichia pastoris (JW 102, renamed from pJHW#2 (Woo et al., 2002)) via the secretory route. As shown in Example 41, the present method provides a yield of 120 mg/1 after a 163 h induction period and the purified yield is 90.8 mg/L.
After gene optimization to reduce the AT content of the DNA sequence, secreted expression levels under the AOXl promoter of 25- 30 mg/L can be obtained in bioreactors after 24-44 hours of induction. Pichia pastoris was sensitive to the toxic effects of cytosolic expressed diphtheria toxin A chain which ADP ribosylates elongation factor 2 (EF-2) leading to cessation of protein synthesis. Toxicity to expression of A-dmDT390-bisFv by the secretory route was indicated by a continuous fall in methanol consumption after induction. A mixed feed of glycerol and methanol was provided to the cells. Expression of the catalytic domain (A chain) of DT in the cytosol is lethal to Pichia pastoris. When cells bearing the construct A-dmDT390-BisFv (UCHTl) were induced by methanol to express the immunotoxin, nearly 50% were killed after 24 hours (Woo et al., 2002). In contrast, when the same immunotoxin was expressed in CHO cells that had been mutated to DT resistance, no toxic effect was observed (Liu, et al., 2000; Thompson, et al., 2001). In the cytosol of eukaryotes, the catalytic domain of DT catalyzes ADP ribosylation of elongation factor 2 (EF-2), leading to inhibition of protein synthesis and cell death (by protein starvation and or apoptosis, Van Ness et al., 1980; Houchins, 2000). The sensitivity of the eukaryotic EF-2 to ADP-ribosylation by these toxins lies in the structure of protein. EF-2 is a single polypeptide chain of about 850 amino acids and is composed of two domains. The N-terminal G domain is responsible for binding and hydrolysis of GTP that promotes translation, and the C-terminal R (or diphthamide) domain is thought to interact with the ribosome (Kohno et al., 1986; Perentesis et al., 1992). The diphthamide domain contains a histidine residue in a region of 22 residues that are well conserved in the EF-2 of all eukaryotes. This conserved histidine is specifically modified post-translationally to the derivative, diphthamide, which is the unique target for ADP-ribosylation by DT (Van Ness et al., 1880). In S. cerevisiae, the conserved histidine can be mutated and substitutions with some other 2 amino acids yielded functional EF-2s that were resistant to ADP-ribosylation (Phan et al., 1993; Kimata and Kohno 1994). However, cells with EF-2 mutated at diphthamide grew more slowly than those expressing wild-type EF-2. In CHO cells, a single substitution of arginine for glycine, which is another well conserved residue located at the 3rd position to the C-terminal side of the diphthamide, also prevented the formation of diphthamide (Kohno & Uchida, 1987; Foley et al., 1992) and resulted in non-ADP- ribosylatable EF-2. This mutation had the same effect on EF-2 of S. cerevisiae (Kimata et al., 1993). In contrast to the mutation at diphthamide, the GIy to Arg mutation in EF-2 did not affect cell growth of CHO and S. cerevisiae (Foley et al., 1992; Kimata and Kohno 1994; Kimata et al., 1993).
In order to determine if the expression level of the immuntoxins disclosed herein including for example the diphtheria toxin diabody immunotoxins and diphterhia toxin bivalent antibody immunotoxins disclosed herein such as A-dmDT390-scfbDb and A- dmDT390-bisFv could be further increased by rendering Pichia pastoris insensitive to toxin, the EF-2 gene of Pichia pastoris has been mutated so that the GIy at position 701 was changed to Arg, which has been shown to prevent ADP-ribosylation of EF-2 in other organisms. The EF-2 mutagenesis required cloning of the gene, introduction of the in vitro mutated sequence with a selection marker, URA3, to the genome and PCR identification of mutated clones. The entire EF-2 gene of Pichia pastoris has been cloned and sequenced. The coding sequence of Pichia pastoris EF-2 is 2526 nucleotides coding for 842 amino acids. The Pichia pastoris EF-2 is the same as the EF-2 of S. cerevisiae and S. pombe in length and shares 88% and 78% of identity in amino acid sequence with these two, respectively. In contrast to these two yeasts, Pichia pastoris has only one copy of the EF-2 gene that contains a short intron. Before the complete sequence of EF-2 was known, different approaches were used to mutate Pichia pastoris to obtain DT resistant strains. All these efforts were unsuccessful due to the lack of robust selection. Based on the EF-2 sequence obtained, a pBLURA-Δ5'mutEF-2 was constructed that targets the Pichia pastoris EF-2 gene and introduces a mutation of GIy 701 to Arg in the gene by homologous recombination. The construct contains the 3' end 1028 nucleotides of EF-2 that has been mutagenized in vitro to contain the amino acid substitution and the auxotrophic marker URA3. A PCR detection method was also developed for fast and accurate identification of mutant clones after uracil selection. The targeted mutation strategy with construct pBLURA-Δ5'mutEF-2 allowed mutation of the EF-2 gene of Pichia pastoris with about 40% of uracil positive clones being found to contain the introduced mutations. EF-2 mutants were developed with different auxotrophic markers, (specifically mutEF2JC308 (adel arg4 his4), mutEF2JC303 (arg4 his4) and mutEF2JC307 (his4)) and demonstrated that the GIy 701 to Arg mutation in EF-2 confers resistance to the cytosolic expression of DT A chain.
When EF-2 mutants were used to express A-dmDT390-bisFv under the control of AOXl promoter, they did not show the advantage over the non-mutated expressing strain JWl 02 in the production of the protein in shake-flask. However, in large-scale fermentation culture under conditions adopted from those optimal for JW 102, the production of the mutant strain YYL#8-2 [mutEF2JC307-8(2)], increased continuously for 96 hours and reached a level 1.46-fold greater than the non-mutated JW 102 strain. Cell growth and methanol consumption rates of the mutant strain expressing A-dmDT390-bisFv were the same as that of the non-expressing wild type strain. Therefore it appeared that expression of A-dmDT390-bisFv was not toxic to the mutant strain. The EF-2 mutants allowed expression of A-dmDT390-bisFv under the control of the constitutive GAP promoter (PGAP)- In shake-flask culture, the production of A-dmDT390-bisFv under PGAP was about 30% higher than that under PAOXI- The increase in production under PQAP may be more significant in fermentation cultures since fermentation allows cells to grow to very high density. In the Pichia pastoris expression system, most heterologous proteins such as botulinum neurotoxin fragments for vaccine use (Potter et al., 2000), hepatitis B surface antigen (Hardy et al., 2000), gelatin (Werten et al., 1999), collagen (Nokelainen et al., 2001), and insulin (Wang et al., 2001) were successfully expressed and/or secreted by using a simple defined medium. The cytosolic expression of the catalytic domain of DT causes protein synthesis inhibition, leading to complete cell death in the defined medium, but not in complex media (Liu et al., 2003). This finding indicates that complex media play a role in attenuation of protein synthesis inhibition that is caused by ADP-ribosylation of EF-2. A very low production of the bivalent immunotoxin was observed in the defined medium but not in a complex medium in shake flask culture. Fermentation of Pichia pastoris for expression of heterologous proteins had been developed on the basis of a defined medium but use of complex media for expression of the bivalent immunotoxin in a secreted form provides a higher level of production.
In the present large scale production of bivalent or bispecific immunotoxins in Pichia pastoris, lowering the induction temperature to 15 0C substantially improved the secretion of bioactive immunotoxin, and thereby compensated for the limitation in Pichia pastoris secretory capacity. In addition, the use of complex medium containing yeast extract further enhanced immunotoxin secretion, apparently by attenuating the toxic effects of the immunotoxin on the Pichia pastoris host.
The expression level of an exemplary bivalent or bispecific immunotoxin was improved by 4-fold in bioreactor culture compared to shake flask culture by optimizing the fermentation conditions in Pichia pastoris as follows: (1) use of Soytone Peptone and yeast extract based complex medium, (2) use of methanol/glycerol mixed feed (4:1) to supplement the energy source during methanol induction, (3) continuous feeding of PMSF and yeast extract during induction, and (4) lowering temperature to 15 0C during methanol induction. The lowered temperature resulted in a 2-fold increase in secretion relative to using 23 0C during methanol induction.
As noted above, a major problem in production of the bivalent immunotoxin was reduction of methanol utilization during the methanol induction phase. The reduction of methanol utilization results from a reduction in the activity of the rate limiting enzyme, alcohol oxidase (AOXl). This could be secondary to protein synthesis inhibition by the bivalent immunotoxin reaching the cytosol compartment through leakage from the secretory compartment or by proton dependent translocation from the mildly acidic secretory compartment (Arata et al., 2002). The fact that methanol utilization is not affected by immunotoxin production in a Pichia pastoris strain mutated to toxin resistance in the EF-2 gene (Liu et al., 2003) indicates that toxin induced ADP-ribosylation is the cause of the decreased AOXl activity in strain JW102. However, control of AOXl level is balanced by both synthesis as well as degradation, and degradative mechanisms could be augmented in response to toxin mediated ADP-ribosylation. For reasons unknown, yeast extract increased methanol utilization, though not to wild type levels, hi addition, low methanol utilization negatively affected Pichia pastoris cell growth. This was corrected in the present method by adding another carbon source, glycerol, and continuous feeding of yeast extract during methanol induction. These two corrections raised the methanol consumption to 80 % of the non-expressing strain.
To further compensate for Pichia pastoris protein synthesis inhibition by the expressed immunotoxin, the fermentation conditions were manipulated for full activation of alcohol oxidase I (AOXl), the rate limiting enzyme for methanol metabolism (Veenhuis et al., 1983). Since the immunotoxin gene was under the control of the same strong promoter as the AOXl gene, the immunotoxin should be highly expressed. However, it has previously been observed in the secretion of heterologous proteins that each protein appears to have an optimal secretion level. Expression beyond the optimal level (overexpression) of secreted heterologous proteins can cause a reduction in secreted protein yields in mammalian, insects and yeast cells (Bannister and Wittrup, 2000; Liebman et al., 1999; Liu et al., 2003; Pendse et al., 1992). In order to determine whether the bivalent immunotoxin was being overexpressed in Pichia pastoris, the induction temperature was lowered during methanol induction. Since most cellular activities including protein synthesis are decreased at low temperature, lowering induction temperature should decrease the synthetic rate of the bivalent immunotoxin. Any resulting change in secretion rate was judged. Bivalent immunotoxin expression was increased at low induction temperatures, reaching a maximum at 17.5 0C, and secretion of bioactive immunotoxin reached a maximum at 15 0C, in spite of the fact that methanol consumption rate at 15 0C fell to 75% of its 23 0C value. Because continuous feeding of PMSF and yeast extract during induction effectively inhibited protease activity in supernatants, it appears unlikely that a reduction in protease activity with lower induction temperature accounts for the nearly 2-fold increase in bivalent immunotoxin secretion seen at 15 0C. The limitation in Pichia pastoris secretion of bivalent immunotoxin previously described may actually represent an overexpression at 23 0C that is reduced at 15 0C achieving a better balance of input and output within the secretory compartment.
In short, the immunotoxin was produced in Pichia pastoris (JW 102) via the secretory route under control of the AOXl promoter in the fermentor using methanol as a carbon source. There were two major impediments to efficient immunotoxin production, the toxicity of the immunotoxin towards Pichia pastoris and the limited secretory capacity of Pichia pastoris for the immunotoxin. The toxicity towards Pichia pastoris resulted in a decrease in the metabolic rate of methanol consumption, a cell growth rate reduction and very low productivity in a defined medium during methanol induction. These problems were overcome by (1) using an enzymatic digest of soy protein (e.g., Soytone peptone) and yeast extract based complex medium, (2) using methanol/glycerol mixed feed (4:1) to supplement energy source during methanol induction, and (3) continuously feeding PMSF and yeast extract during methanol induction. Lowering the induction temperature to 15 0C improved secreted immunotoxin yield by almost 2-fold, up to 40 mg/L (at 67 hours induction) compared to secretion at a induction temperature of 23 0C, even though methanol consumption was reduced. In addition, with the use of the present method, the fraction of immunotoxin present as biologically inactive oligomeric forms was decreased. In addition further improvements in fold-back diabody immunotoxins are possible by engineering extra copies of proteins into Pichia pastoris (JW 102) that are involved in overcoming degradation of heterologous proteins by the manifestations of the unfolded protein response.
In a method of producing immunotoxin, the method can comprise methods of enhancing codon preference that are known and exemplified.
It is understood that any of the disclosed immunotoxins are useful for the treatment of various conditions or diseases. Therefore, disclosed herein in one aspect are methods of treating a cancer in a subject comprising administering to the subject an immunotoxin or a derivative thereof, under conditions such that the cancer is treated. Further disclosed herein are methods of treating a cancer in a subject comprising administering to the subject an immunotoxin that is a truncation mutant, wherein the truncation mutant comprises a deletion of 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, or 150 C-terminal amino acids of the full length diphtheria toxin. Also disclosed are methods wherein the diabody is an anti-PSMA diabody such as, for example, a diabody wherein the diabody comprises the VLVH regions of J591. PSMA or prostate specific membrane antigen is a transmembrane antigen expressed on prostate cells and highly over-expressed in prostate tumors. It is weakly expressed on some other tissues and is considered highly tissue specific and thus is considered a prime target for immunotoxin mediated therapy of prostatic cancer (Fracasso, G et al, The Prostate 53, 9-23, 2002 and Huang , X. et al, The Prostate 61,1-11, 2005). In addition, PSMA is over-expressed on the neovasculature that feeds a variety of human primary cancers and their metastatic counterparts such as breast, lung and kidney (Milowsy, MI et al.J. Clin Oncol 25,540-47,2007). PSMA is a homodimer with a 2-fold axis of symmetry. Thus a divalent anti- PSMA diabody immunotoxin with binding sites oriented 180 degrees apart is ideally suited to complex PSMA. PSMA is a functional glutamate carboxylase metalloprotease. It is an analog of the transferrin receptor (Davis, MI et al., PNAS WZ 5981-86, 2005) that has been previously shown to route DT-based immunotoxins to the site of efficient translocation to the cytosol compartment. As disclosed herein, it is understood that the toxin moiety can be a truncation mutant such as, for example, DT395, DT394, DT393, DT392, DT391, DT390, DT389, DT388, DT387, DT386, and DT385. Thus, for example disclosed herein are methods of treating a cancer in a subject wherein the immunotoxin that is administered to the subject is A- dmDT390scfbDb(J591); A-dmDT389scfbDb(J591); A-dmDT380scfbDb(J591); A- dmDT395scfbDb(J591), or any other DT truncation mutant J591 fold-back diabody combination. It is understood that the disclosed methods of treating a cancer have utility for treating any cancer where PSMA is expressed on cancerous tissue, such as, for example, prostate cancer or in a cancer where PSMA is expressed in the neovasculature, breast cancer, lung cancer, and renal cancer.
It is further contemplated that any cancer with a targetable antigen can be treated with the disclosed methods providing that the targeted epitope routes DT to its efficient translocation site. For example, the cancer can comprise a T-cell leukemia. Thus disclosed herein are methods of treating T cell leukemias or lymphomas in an animal comprising administering to the animal one of the disclosed diphtheria toxin diabody immunotoxins, or derivatives thereof, under conditions such that the T cell leukemias or lymphomas are treated. It is understood and herein contemplated that the immunotoxin for treating a T cell leukemia can comprise a diabody wherein the diabody is an anti-CD3 diabody. It is further understood that any anti-CD3 diabody can be used in the disclosed methods. Thus, for example, the diabody can comprise the VLVH regions of UCHTl. It is further contemplated that any of the disclosed anti-CD3 diabodies can be used with any of the disclosed toxin moieties including, for example, DT390, DT389, DT395, DT394, DT393, DT392, DT391, DT388, DT387, DT386, and DT385. Thus, for example, the immunotoxin can comprise A- dmDT390scfbDb(UCHTl) or A-dmDT390scfbDb(C207).
"Treatment," "treat," or "treating" mean a method of reducing the effects of a disease or condition. Treatment can also refer to a method of reducing the disease or condition itself rather than just the symptoms. The treatment can be any reduction from native levels and can be, but is not limited to, the complete ablation of the disease, condition, or the symptoms of the disease or condition. Therefore, in the disclosed methods, treatment" can refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of an established disease or the disease progression. For example, a disclosed method for reducing the effects of prostate cancer is considered to be a treatment if there is a 10% reduction in one or more symptoms of the disease in a subject with the disease when compared to native levels in the same subject or control subjects. Thus, the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels. It is understood and herein contemplated that "treatment" does not necessarily refer to a cure of the disease or condition, but an improvement in the outlook of a disease or condition.
The compositions and immunotoxins disclosed herein are useful in transplantation related conditions and disease such as graft versus host disease, graft rejection, and the induction of immune tolerance. The role of T cells in the aforementioned transplantation related diseases and conditions makes the CD3 molecule (i.e., the T cell receptor), which is only present on T cells, a viable target for the action of the disclosed immunotoxins. Therefore, disclosed herein are methods of treating graft- versus-host disease in an animal, comprising administering to the animal an immunotoxin disclosed herein, or derivatives thereof under conditions such that the graft- versus-host disease is treated. In particular disclosed herein are methods of treating graft versus host disease wherein the immunotoxin is an anti-CD3 diphtheria toxin immunotoxin. It is understood that any anti-CD3 antibody derived diabody such as a diabody derived from UCHTl, C207, or FNl 8 can be used in the methods disclosed herein. It is further contemplated that any of the disclosed anti-CD3 diabodies can be used with any of the disclosed toxin moieties including, for example, DT390, DT389, DT395, DT394, DT393, DT392, DT391, DT388, DT387, DT386; and DT385. Thus, for example, the immunotoxin can comprise A-dmDT390scfbDb(UCHTl) or A-dmDT390scfbDb(C207).
Also disclosed are methods of inducing immune tolerance to a graft in a recipient, comprising: a)administering to the recipient an anti-CD3 immunotoxin disclosed herein, thereby reducing the recipient's T-cell population; and b) administering to the recipient an agent that inhibits dendritic cell maturation. It is understood that any anti-CD3 antibody derived diabody such as a diabody derived from UCHTl, C207, or FNl 8 can be used in the methods disclosed herein. It is further contemplated that any of the disclosed anti-CD3 diabodies can be used with any of the disclosed toxin moieties including, for example, DT390, DT389, DT395, DT394, DT393, DT392, DT391, DT388, DT387, DT386; and DT385. Thus, for example, the immunotoxin can comprise A-dmDT390scfbDb(UCHTl) or A-dmDT390scfbDb(C207).
Also disclosed herein are methods of inhibiting a rejection response in a primate recipient to a foreign mammalian graft comprising the steps of: a) administering to the recipient an anti-CD3-DT immunotoxin, wherein the immunotoxin comprises scfbDb-DT, so as to reduce the recipient's T-cell lymphocyte population by at least 80%, as compared to the recipient's T-cell lymphocyte population prior to administration of the immunotoxin; and b) transplanting the graft into the recipient, such that a rejection response by the recipient to the graft is inhibited. It is understood that any anti-CD3 antibody derived diabody such as a diabody derived from UCHTl, C207, or FNl 8 can be used in the methods disclosed herein. It is further contemplated that any of the disclosed anti-CD3 diabodies can be used with any of the disclosed toxin moieties including, for example, DT390, DT389, DT395, DT394, DT393, DT392, DT391, DT388, DT387, DT386; and DT385. Thus, for example, the immunotoxin can comprise A-dmDT390scfbDb(UCHTl) or A-dmDT390scfbDb(C207).
"Inhibit," "inhibiting," and "inhibition" mean to decrease an activity, response, condition, disease, or other biological parameter. This can include but is not limited to the complete ablation of the activity, response, condition, or disease. This may also include, for example, a 10% reduction in the activity, response, condition, or disease as compared to the native or control level. Thus, the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels.
It is contemplated herein that the disclosed methods of treating graft- versus-host disease, inducing immune tolerance to a graft, and inhibiting a rejection response can be complemented by the use of an immunosuppressive agent in addition to the methods already disclosed. It is understood and herein contemplated that the immunotoxin for treating graft- versus-host disease can comprise a diabody wherein the diabody is an anti-CD3 diabody. It is further understood that any anti-CD3 diabody can be used in the disclosed methods. Thus, for example, the diabody can comprise the VLVH regions of UCHTl. It is further contemplated that any of the disclosed anti-CD3 diabodies can be used with any of the disclosed toxin moieties including, for example, DT390, DT389, DT395, DT394, DT393, DT392, DT391, DT388, DT387, DT386, and DT385. Thus, for example, the immunotoxin can comprise A-dmDT390scfbDb(UCHTl) or A-dmDT390scfbDb(C207). Therefore, disclosed herein are methods of treating graft- versus-host disease, inducing immune tolerance to a graft, and inhibiting a rejection response, further comprising administering an immunosuppressive agent. Examples of suitable immunosuppressive agents include but are not limited to cyclosporine, rapamycin, and mycophenolate mofetil and the anti-B cell antibody (anti-CD20) rituximab. It is further contemplated that the disclosed immunosuppressive agent can be an agent that inhibits dendritic cell maturation. Such action can occur, for example through the inhibition of nuclear translocation, such as, inhibition of nuclear translocation of NFKB. Thus, for example disclosed herein are methods of treating graft-versus-host disease, inducing immune tolerance to a graft, and inhibiting a rejection response further comprising an immunosuppressive agent wherein the immunosuppressive agent is an agent that inhibits dendritic cell maturation is an inhibitor of nuclear translocation of NFKB. Specifically contemplated herein are immunosuppressive agents that are inhibitors of dendritic cell maturation that are inhibitors of nuclear translocation of NFK B such as, for example, deoxyspergualin and analogs or derivatives of deoxyspergualin including, for example, methyl-deoxyspergualin or a deoxyspergualin analog lacking a chiral center (e.g., LF 08-0299) (Andoins et al., 1996, which is incorporated herein by reference). Other derivatives or analogs of deoxyspergualin can be used that include, for example, those identified in U.S. Pat. No. 4,518,532; U.S. Pat. No. 4,518,532; U.S. Pat. No. 4,525,299; U.S. Pat. No. 4,956,504; U.S. Pat. No. 5,162,581; U.S. Pat. No. 5, 476,870; U.S. Pat. No. 5,637,613; W.O. 96/24579; EP 600762; EP 669316; EP 7433000; EP 765866; and EP 755380, which are incorporated herein by reference. Also disclosed are inhibitors of dendritic cell maturation that are inhibitor of nuclear translocation of NFKB such as the proteosome inhibitor bortezomib. Also disclosed are methods wherein immunosuppressive agents that inhibit dendritic cell maturation wherein the agent that inhibits dendritic cell maturation activates one or more NF-AT dependent Th2 cytokines. Also disclosed are methods wherein the immunosuppressive agents that inhibit dendritic cell maturation wherein the agent that inhibits dendritic cell maturation inhibits one or more NFKB dependent ThI cytokines. It is further contemplated that the disclosed immunosuppressive agent that is an inhibitor of dendritic cell maturation can function through other means. Therefore, disclosed herein are methods of treating graft- versus-host disease, inducing immune tolerance to a graft, and inhibiting a rejection response wherein the inhibitor of dendritic cell maturation is a soluble IL- 17 receptor Fc fusion protein; a glucocorticoid; blocker of tumor necrosis factor alpha binding; blocker of granulocyte macrophage colony stimulating factor binding; blocker of IL-12p70 binding; blocker of EL- Iβ binding; and/or an anti-CD 154 ligand.
It is understood that one of skill in the art will be able to determine the optimal time to administer the immunosuppressive agent. Such administration can occur 24 hours before transplantation. In particular, administration can occur 0 to 12 hours before transplantation. Further contemplated are methods wherein the immunosuppressant is administered beginning from about 0 to 6 hours before the transplantation. The immunosuppressive agent can be administered to the recipient as well as the donor. Specifically contemplated herein are methods wherein the agent that inhibits dendritic cell maturation is administered to the recipient at least once. Also disclosed herein are methods comprising administering to a transplant donor, prior to harvesting the transplant, an agent that inhibits dendritic cell maturation.
It is understood herein that the graft used in the methods disclosed herein can comprises donor cells, tissue or organ. It is further contemplated that the donor cells, tissue, or organ is selected from the group consisting of kidney, liver, heart, pancreas, lung, skin, and isolated cell transplants of pancreatic islets, hepatocytes, stem cell, and differentiated precursors cells. It is understood and herein contemplated that the donor graft (tissue, cell, or organ) can be from an allogeneic, syngeneic, or xenogeneic donor. It is further contemplated that the donor source can be a cadaver.
In another embodiment, the present invention relates to a pharmaceutical composition comprising a diabody-DT mutant in an amount effective to treat T cell leukemias or lymphomas, which carry the CD3 epitope, graft- versus-host disease or autoimmune diseases, or treat a cancer such as prostate cancer or breast cancer which carries PSMA and a pharmaceutically acceptable diluent, carrier, or excipient. One skilled in the art will appreciate that the amounts to be administered for any particular treatment protocol can readily be determined. Suitable amounts might be expected to fall within the range of 0.1 to 0.25 mg (toxin content) per kg of body weight.
Thus, one embodiment of the invention provides a method of treating an autoimmune disease in an animal comprising administering to the animal an imrnunotoxin comprising a mutant diphtheria toxin moiety and an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the autoimmune disease is treated. It is understood and herein contemplated that in a T cell mediated autoimmune disease, because the immune response is T cell mediated, eliminating or inducing tolerance in the autoreactive T cells will treat the autoimmune disease. Stated another way, by reducing the number of or inducing tolerance in the T cells responsible for the autoimmune disease through the use of the immunotoxins disclosed herein, the autoimmune disease will be treated. Any of the immunotoxins described herein can be used. It is understood and herein contemplated that the immunotoxin for treating an autoimmune disease can comprise a diabody wherein the diabody is an anti-CD3 diabody. It is further understood that any anti-CD3 diabody can be used in the disclosed methods. Thus, for example, the diabody can comprise the VLVH regions of UCHTl. It is further contemplated that any of the disclosed anti-CD3 diabodies can be used with any of the disclosed toxin moieties including, for example, DT390, DT389, DT395, DT394, DT393, DT392, DT391, DT388, DT387, DT386, and DT385. Thus, for example, the immunotoxin can comprise A- dmDT390scfbDb(UCHTl) or A-dmDT390scfbDb(C207).
Also disclosed are methods for treating acquired immunodeficiency syndrome in an animal, comprising administering to the animal an immunotoxin comprising a diphtheria toxin binding mutant moiety and an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof under conditions such that the acquired immunodeficiency syndrome is treated. Alternatively, a method of treating acquired immunodeficiency syndrome in an animal, comprising administering to the animal a non-toxic mutant of diphtheria toxin followed by an antibody-diphtheria toxin immunotoxin which routes by the anti-CD3 pathway or derivatives thereof under conditions such that the acquired immunodeficiency syndrome is treated is provided. It is understood that any anti-CD3 antibody derived diabody such as a diabody derived from UCHTl, C207, or FNl 8 can be used in the methods disclosed herein. It is further contemplated that any of the disclosed anti-CD3 diabodies can be used with any of the disclosed toxin moieties including, for example, DT390, DT389, DT395, DT394, DT393, DT392, DT391, DT388, DT387, and DT386. Thus, for example, the immunotoxin can comprise A-dmDT390scfbDb(UCHTl) or A- dmDT390scfbDb(C207).
The present invention will be illustrated in further detail in the following non- limiting examples.
EXAMPLE 1 Cell Depletion in Rhesus Monkeys Induced by FN18-CRM9
FN18-CRM9 conjugate
Conjugation of anti-V/3 and anti-VαlgG monoclonal antibodies to CRM9 is performed by the same methods used to conjugate anti-CD3 to CRM9 using a non-cleavable linker such as bismaleimidohexane and previously described in detail (Neville et al. (1988) J. Biol. Chem. 264:14653-61). The monoclonal antibody FNl 8 is the monkey equivalent of the human anti-CD3 (UCHTl) and is known to bind the same CD3 receptor epitopes (e and γ) as bound by the human CD3 antibody and is the same isotype as the human CD3 antibody. Thus, in terms of the parameters relevant for predicting successful T cell depletion, the present CD3-CRM9 conjugate and FN18-CRM9 are expected to have the same activity.
Administration
Conjugates can be administered as an LV. bolus in a carrier consisting of 0.1M Na2SO4 + 0.01M phosphate buffer, pH 7.4 plus 1 part in 50 of serum previously obtained from the subject. The dose schedule is every other or third day for 3 to 6 days. The total dose is preferably from 25 to 200 micrograms of toxin per kg of body weight.
The actual dose of FN18-CRM9 used was equal to 0.167 of the minimum lethal dose (MLD) in guinea pigs. Since the estimation of the MLD was performed in an animal lacking an immunotoxin target cell population (guinea pigs), the true MLD of FN18-CRM9 and anti-CD3-CRM9 is expected to be higher in monkeys and humans than in guinea pigs.
T Cell Kill
Helper T cell (CD4+ cells) numbers in peripheral blood fell dramatically after the initial administration of FN18-CRM9 in two rhesus monkeys. T cell counts began to rise by day 4 (sampled just prior to the second dose of FN18-CRM9). On day 5 in monkey 8629, CD4+ cells were depressed below the limit of detection (<50 cells/mm3). Cells remained below or equal to 200/mm3 out to day 21. This low level of CD4+ cells is associated with profound immunodeficiency in humans and in monkeys (Nooij and Jonker (1987) Eur. J. Immunol. 17:1089-1093). The remarkable feature of this study is the long duration of helper T cell depletion (day 21) with respect to the last administration of immunotoxin (day 4) since intravenously administered immunotoxins were cleared from the vascular system with half-lives <9 hours (Rostain-Capaillon and Casellas (1990) Cancer Research 50:2909- 2916), the effect outlasting circulating immunotoxin. This is in contrast to T cell depletion induced by unconjugated anti-CD3 antibodies (Nooij and Jonker (1987) Eur. J. Immunol. 17:1089-1093).
In monkey IWS the second dose of conjugate only appeared to result in a diminished rate of CD4+ cell recovery. However, CD4+ cells were still fewer than normal at day 21. The blunted response of monkey IWS to the second dose of immunotoxin was found to be due to a preexisting immunization of this animal to the toxin. Monkey IWS had a significant pre-treatment anti-diphtheria toxin titer as revealed by a Western blot assay. This titer was markedly increased at day 5, indicative of a classic secondary response. In contrast, monkey 8629 had no detectable pre-treatment titer and only a trace titer by day 5 and a moderate titer by day 28.
The specificity of FN18-CRM9 toward T cells can be seen by comparing the total white blood cell (WBC) count in the same two monkeys. WBCs fell, but only to 45% of baseline value on day 2 compared to 6% of baseline values for the CD4+ T cell subset. Most of the fall in WBC values can be accounted for by the T cell component of the WBC population («40%). However, B cells are initially depleted after FN18-CRM9 although these cells recover more quickly. FNl 8 is an IgG, isotype and as such is known to bind to Fc11 receptors present on B cells and macrophages with low affinity. The FN18-CRM9 depletion of B cells indicates that significant interactions between the Fc portion of the FNl 8 antibody and B cells is taking place.
The peripheral T cell depletion induced by unconjugated FNl 8 at a dose known to produce immunosuppression 0.2mg/kg/day (Nooij and Jonker (1987) Eur. J. Immunol. 17:1089-1093) was compared to the immunotoxin FN18-CRM9 administered at l/9th the FN 18 dose. Peripheral CD4+ T cell depletion is more pronounced and more long-lasting with the conjugate. The demonstration that FN18-CRM9 reduces the peripheral helper T cell subset (CD4+) to levels less than or equal to 200 cell/mm3 for a period as long as 21 days demonstrates that this immunotoxin and its anti-human analogs are effective immunosuppressive reagents.
The demonstration that FN18-CRM9 is a potent agent for inducing T cell depletion in non-human primates demonstrates that an anti-human homolog of FN18-CRM9, UCHT1-CRM9 (Oxoid USA, Charlotte, NC) for example, is a potent agent for inducing T cell depletion in humans.
The Fc binding region of anti-TCR/CD3 monoclonals may or may not be needed to induce T cell depletion when the anti-TCR/CD3 monoclonals are conjugated to CRM9. The Fen binding regions can be removed, for example, by forming the conjugates with F(ab')2 derivatives as is indicated in the literature (Thorpe et al. (1985) J. Nat'l. Cancer Inst. 75:151-159). hi addition, anti-TCR/CD3 IgA switch variants such as monoclonal antibody T3.A may be used (Ponticelli et al. (1990) Transplantation 50:889-892). These avoid rapid vascular clearance characteristic of F(ab')2 immunotoxins. F(ab')2 and IgA switch variants of anti-TCR/CD3-CRM9 immunotoxins are therefore derivative anti-TCR/CD3 immunotoxins. These derivatives will avoid the B cell interaction noted and can increase specificity. However, IgG23 switch variants will maximize T cell activation through the Fci, receptor and may be useful in certain situations where T cell activation aids immunotoxin induced toxicity.
General methods to make antibodies lacking the Fc region or to make antibodies which are humanized are set forth in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1988. Thus, as used in the claims, antibody can mean the entire antibody or any portion of the antibody sufficient for specific antigen or receptor binding.
EXAMPLE 2
Treatment of Autoimmune Diseases Using Other Antibody-CRM9 Conjugates which Route by the Anti-CD3 Pathway
Since receptor recycling is a requirement for effective CRM9 based immunotoxins and since TCR/CD3 recycles as a unit, antibodies directed at other epitopes on TCR/CD3 will constitute effective derivatives, in particular antibodies directed at the approximately 50 VjS subset families or the approximately equal number of Va subsets can be used to conjugate CRM9 and ablate specific V/3 or Va subsets in vivo. In addition, in some cases it will be desireable to develop specific monoclonal antibodies reacting with unique rearrangements of either the Va or VjS subset families.
The advantage of targeting the specific Wβ or Va subset(s) as opposed to the entire T cell population is twofold: (1) Elimination of a VjS subset does not create a generalized immunodeficiency, only a hole in the immune repertoire is generated. Therefore, the ability to ward off most infections and maintain immune surveillance of most malignant transformations would remain intact. (2) Immuno toxin log kill increases linearly as the target cell burden decreases, assuming dose is unchanged. A 50-fold increase in log kill can be obtained as the target is changed from the entire set of T cells to a single VjS subset. However, due to (1) the high affinity of binding of these immunotoxins, (2) the very low total dose given which is below target cell receptor saturation and (3) the irreversible nature of the endocytotic process, the target cells deplete the effective dose and this depletion decreases as target burden decreases. Since the log kill is exponential in effective dose, much higher increases in log kill than 50-fold on changing the target from T cells to a VjS subset can occur. The expected increase in log kill will only occur if the immunotoxin is specific for the defined target. Extraneous interactions with other cell types via the antibody Fc piece is preferably eliminated.
Because HIV has been shown to preferentially infect one (V βn) or a few of the 20 V/3 subset families providing a small T cell reservoir of HIV replication, and because HIV infection apparently involves an unknown superantigen, CRM9 based immunotoxins directed at these specific Vj3 subsets such as anti-VjSi2-CRM9 can reduce the HIV virus load. In addition, total ablation of a VjS subset in the presence of an endogenous superantigen can lead to long-term ablation of the subset since maturing T cells are negatively selected in the presence of endogenous superantigens. Since the specific VjS subset responding to the superantigen is eliminated, infection cannot take place.
The two strategies that can be utilized for using anti-V/3i2-CRM9 immunotoxins to treat HIV infections are (1) treatment depleting the susceptible VjS subset to an extent where continued infection cannot be maintained and (2) treatment to the extent that all or nearly all of the VjS12 subset is eradicated.
Anti-human VjS monoclonal antibodies such as S5-11 (anti-V/Si2) are available (T Cell Sciences, Cambridge, MA) and can be conjugated to CRM9 by standard methodologies. Briefly, as in Example 5, conjugation of anti-V/3 and anti-VαlgG monoclonal antibodies to CRM9 is performed by the same methods used to conjugate anti-CD3 to CRM9 using a non-cleavable linker such as bismaleimidohexase and previously described in detail (Neville et al. (1988) J. of Biol. Chem. 264:14653-61).
Conjugates can be administered as an LV. bolus in a carrier consisting of 0.1M Na2SO4 + 0.01M phosphate buffer, pH 7.4 plus 1 part in 50 of serum previously obtained from the patient. The dose schedule is every other or third day for 3 to 6 days. The total dose is preferably from 25 to 200 micrograms of toxin per kg of body weight, but may be increased if anti-diphtheria toxin antibodies are present in the patient's sera in significant amounts.
Other Vβ or Va subsets which may be found to be associated with HIV infection can be treated in the same manner described herein by conjugating the CRM9 to the antibody specifically reactive with the appropriate V/3 or Va subset.
EXAMPLE 3
T Cell Depletion and Immunosuppression in Monkeys Using the Immunotoxin Anti- CD3-CRM9.
CRM9 is a diphtheria toxin (DT) binding site mutant and forms the basis of the anti- T cell immunotoxin anti-CD3-CRM9. This immunotoxin has been constructed against human and rhesus T cells and has shown above to kill 3 logs of human T cells in a nude mouse xenograft system. The present example demonstrates a 2 log kill of T cells in rhesus monkey lymph nodes that is also shown to produce prolongation of skin allograft rejection in monkeys.
Humans are immunized against diphtheria toxin by exposure to DPT vaccines in childhood. This long lasting immunity may interfere with the efficacy of DT based immunotoxins. Many monkeys are immunized against DT by natural exposure to toxin producing Corynebacterium. The present method addresses any potential interference of pre-existing DT antibodies with the activity of the present immunotoxins.
ELISA ELISA assays were performed in order to determine the levels of anti-DT titers existing in 9 individuals in a population ages 27 to 55. There were 3 individuals with titers of 1 : 100 (low) and 6 with titers of 1 : 1000 (moderate).
Rhesus monkeys were screened by the same assay and a 1 : 1000 titered monkey was selected.
Administration of Non-Toxic Diphtheria Toxin Mutant
Monkeys were treated by LV. route 5 min prior to the immunotoxin dose with a 100 fold excess of CRM 197 over the CRM9 content of the immunotoxin to be administered. Just prior to administering CRMl 97, a Hl histamine blocking agent such as Benadryl or Tagevil was given LV. to minimize any possibility of an anaphylactic reaction (for Benadryl 4 mg/kg). No histaminic reaction was detected.
Anti-CD3-CRM9 was given at a total dose between 0.1 and 0.2 mg/kg (toxin weight) in 3 equally divided doses (approximately 0.033 mg/kg) on 3 consecutive days. In these monkeys, the total dose of immunotoxin was 0.1 mg/kg.
A comparison of the efficacy of anti-CD3-CRM9 in monkeys was conducted by comparing the decrease in the lymph node T/B cell ratio (a measure of lymph node T cell depletion) and the immunosuppressive effect of the immunotoxin as judged by prolongation of mismatched skin graft survival. Effects on the survival of skin grafts is a clear indicator of the general effect a given treatment has on the subject's immune system.
The monkey with the preexisting anti-DT titer that was pretreated with CRM 197 shows the same level of T/B cell inversion as in the negative titered monkey. Skin graft survival was significantly prolonged over the titered monkey treated without CRMl 97. The failure to achieve a prolongation of graft survival equal to the negatively titered monkey is likely due to the lower weight of this monkey which causes T cells to repopulate faster, in this case 3-4 days faster, due to the larger thymic T cell precursor pool in younger animals. Age related effects such as these can be compensated for by modification of dosage levels and timing of administration.
EXAMPLE 4
Immunotoxin UCHT1-CRM9 for the Treatment of Steroid Resistant Graft- Versus- Host Disease Treatment protocols for this type of disease can be expected to last a year, with Patients being followed for at least 5 years.
Characterization of UCHT1-CRM9 and CRM197
UCHT1-CRM9 is a covalent 1 :1 conjugate of anti-human CD3 IgGl monoclonal antibody and CRM9. The conjugate is synthesized, purified, sterile filtered and assayed for concentration, biological efficacy toward target cells and non-target cell toxicity by standardized culture assays. The method of synthesis, purification assay are identical to that used for FNI8-CRM9 which was used in the pre-clinical monkey studies described in Examples 5 - 7.
CRM9 and CRM 197 are produced by the Biotechnology Unit, NIH and purified by the Cooperating Facility. UCHTl is produced in mouse ascites fluid and is purified by affinity chromatography over Protein A Sepharose. The synthesis, purification and storage of UCHTl -CRM9 is performed in a dedicated secure area. UCHT1-CRM9 is purified in 2 mg lots which are pooled and stored at 4°C. Shelf life is documented to be five months at full biological potency but does not exceed 4 months for this study. Preferably, most of the immunotoxin is used within 3 months of synthesis.
Patient Population
The patient population consists of individuals suffering from steroid resistant GVHD whose prognosis is poor. Patients are assayed for anti-CRM9 (anti-DT) titers and antibodies to murine immunoglobulin. Patients having anti-CRM9 titers of 1 : 1000 and below are treated according to the present protocol. Patients who have a history of receiving murine immunoglobulins or who exhibit positive anti-Ig titers may require special consideration.
Dosage of CRM9 Immunotoxin and Non-Toxic Mutant
UCHT1-CRM9 is administered at a dose which is 1/10 or less of the estimated minimum lethal dose (MLD) in a T lymphopenic patient. The MLD is expected to be at least 0.15 mg/kg (CRM9 content) based on the MLD of 0.15 mg/kg of IgGl-CRM9 in guinea pigs which lack a target cell population for the IgGl. (The presence of target cells in humans raises the MLD by providing a sink for the immunotoxin.) The optimal dose schedule has been found in monkeys to be administration on 3 consecutive days in 3 equally divided doses, and this schedule can be used throughout the treatment period. This permits administration of the total dose before any rise in pre-existing antitoxin titers due to a secondary response. In addition, the initial repopulation from the thymus is also eliminated, thus, further lowering the total T lymphocyte pool. Therefore, a total of 0.0125 mg/kg in three equally divided doses is given to the patient. This dose does induces T cell depletion in monkeys so that monitoring of T cell subsets and signs and symptoms of GVHD is relevant at the lowest dose. For the administration of this dose patients with anti-CRM9 titers of 1:100 or less will be treated. This permits pretreatment doses of CRM197 at 0.33 mg/kg or 1/10 the dose easily tolerated in monkeys. A second dosage group can include patients selected for antitoxin titers of 1 :330 or less to whom CRM197 will be given at 1.0 mg/kg. A third dosage group can include patients with 1:1000 antitoxin titers or less will be given CRM197 at 3.3 mg/kg, a dose expected to be tolerable in humans, because it is easily tolerated by monkeys (see Example 7). The monkey MLD data should be very similar to humans on a per weight basis. However, GVHD patients are expected to be more like guinea pigs, because they have a smaller target cell population compared to non-GVHD patients.
Dose escalation can be tested by increasing the dose by a factor of 1.5. Table 1 exemplifies such a dose escalation test. For example three patients are used in each dosage group. There is a 3 to 4 week delay between each patient so that any late toxicity is detected before a dosage group is completed:
Table 1
CRM9 Dose each day Total Dose
Patient # mg/kg Mg/kg Week ending
1,2,3 0.00417 0.0125 12
4,5,6 0.00636 0.019 24
7,8,9 0.0083 0.028 36
10,11,12 0.0125 0.042 48
Assuming each patient weighs on the average 70 kg, the first dosage group will consume 2.6 mg of the CRM9 immunotoxin, and will be supplied as a pool of two 2 mg batches. The second group will consume 3.9 mg and will also be supplied as 2 pooled batches. The third group will require 5.9 mg and will be supplied as three pooled batches. The fourth group will require 8.9 mg and will be supplied as three pooled batches and an additional two pooled batches. Administration
Prior to administering CRM 197 a Hl histamine blocking agent such as Benadryl or Tagevil is given LV. to minimize any possibility of an anaphylactic reaction (for Benadryl 4 mg/kg). The CRMl 97 is administered LV. in a 5 mg/ml sterile filtered solution in phosphate buffered saline pH 7.4 (PBS) over a 5 min time period. The immunotoxin is then given LV. at 0.2 mg/ml over 2 min time period in a sterile filtered solution of 0.9OmM sodium sulfate and 1OmM sodium phosphate pH 7.4.
Measurements of Biological Parameters
The following parameters can be measured at various intervals during treatment (as exemplified by the schedule below):
A Cytokines, TNF alpha, gamma IFN, IL-6
B Routine clinical chemistries
C WBC, Hct,diff; lymphocyte subsets CD3, CD4, CD8, CD2, CD16, CD20
D Body Weight
E Immune function assays. ELIS A assays of serum to monitor antibody responses to UCHTl (primary response) and CRM9 (secondary response). ELISA assays to monitor antibody responses to polio and DPT reimmunizations done at 1 year following bone marrow transplantation.
(before IT)Day 0 A,B,C,D,E Also A 2 hrs post
Day 1 A,C,D
Day 2 A,C,D
Day 3 A,B,C,D
Day 4 C,D
Day 7 A,C,D
Day 10 B,C
Day 14 A,C,D
Day 21 C5D
Day 28 A,B,C,D,E
Day 45 C5D
Day 60, B,C,D,E EXAMPLE 5
An anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood
The present Example examines the effect of human serum with pre-existing anti-DT antibodies on the toxicity of UCHTl -CRM9, an immunotoxin directed against CD3 molecules on T-lymphocytes. Sera with detectable anti-DT antibodies at 1 : 100 or greater dilutions inhibited the immunotoxin toxicity. Experiments with radiolabeled-UCHTl-CRM9 indicate that anti-DT antibodies partially block its binding to the cell surface as well as inhibit the translocation from the endosome to the cytosol. The inhibitory effect could be adsorbed using a full-length DT mutant or B-subfragment. A C-terminal truncation mutant could not adsorb the inhibitory effect, suggesting that the last 150 amino acids contain the epitope(s) recognized by the inhibitory antibodies.
Therefore, an anti-CD3 single-chain immunotoxin, sFv-DT390, was made with a truncated DT. The IC50 of sFv-DT390 was 4.8 X 10"n M, 1/16 the potency of the divalent UCHTl -CRM9. More importantly, sFv-DT390 toxicity was only slightly affected by the anti-DT antibodies in human sera. "sFv" and "scUCHTl" both are singe chain antibodies containing the variable region.
Mutated full-length and truncated diphtheria toxin (DT) molecules are used for making immunotoxins. These immunotoxins show strong cytotoxic effects to their target cells, and some of them have already been used in clinical trials (1-7).] Previously, an immunotoxin directed against the CD3e molecule of the T-cell receptor complex, a pan T-cell marker was constructed. This construct is made with a monoclonal antibody of mouse-origin, UCHTl, and a binding site mutant of diphtheria toxin (DT), CRM9 (8). The immunotoxin, UCHT1-CRM9, is capable of regressing established xenografted human T-cell (Jurkat) tumors in nude mice (9). A rhesus monkey analog of UCHTl -CRM9, FN18-CRM9 was capable of not only depleting circulating T-cells but also depleting resident T-cells in the lymph nodes 1. This immunotoxin also delayed skin allograft rejection as compared to antibody treatment and non-treatment controls. FN18-CRM9 has also been used as an adjunct in inducing tolerance to mismatched kidney transplants (24).
In contrast with ricin and Pseudomonas exotoxin (PE) based immunotoxins, there is a potential problem using UCHTl -CRM9, or other DT-based immunotoxins, in the treatment of human diseases. Most people have been immunized against DT. Therefore these people have a pre-existing anti-DT antibody titer which could potentially inhibit or alter the efficacy of these immunotoxins. This limitation also occurred in rhesus monkey studies. FNl 8-CRM9 could deplete T cells in the blood, but to a much lesser extent in animals with anti-DT antibodies, and the T cells repopulated several days earlier compared to those monkeys without anti-DT titers. In order to overcome this antibody mediated inhibition, the first examination of the effect and the mechanism of human sera containing anti-DT antibodies on UCHT1-CRM9 toxicity was done.
A DT point-mutant, a truncation mutant and DT-subfragments were used in an attempt to neutralize the anti-DT effect in human sera. Based on the neutralization data, a single-chain immunotoxin was constructed with a C-terminal deletion mutant of DT which is expected to bypass the inhibitory effect of the pre-existing anti-DT antibodies.
Cells.
Jurkat cells (ATCC) were maintained in RPMI 1640 supplemented with 10% fetal calf serum, 25 mM sodium bicarbonate and 50 μg/ml of gentamycin sulfate.
Serum and adsorbing molecules.
Goat anti-DT serum was provided by Dr Randall K. Holmes (USUHS, Bethesda, MD). Human serum samples were provided by Dr. Henry McFarland (NESfDS, NIH, Bethesda MD). CRM197, an A-subfragment mutant (GIy 52 to GIu) of DT (see Figure IA), with no enzymatic activity (10) is available from Biocine-IRIS (Siena, Italy). MSPΔ5, a truncation mutant (amino acid 385) of DT with an additional 5 amino acids at the C- terminus was provided by Dr. Richard Youle (NINDS, NIH, Bethesda MD). Purification of the DT B-subfragment has been described (11). Immunotoxins- UCHT1-CRM9 synthesis has been described (12).
The recombinant immunotoxin, sFv-DT390, was generated in two phases. First the coding sequences for the variable light (VL) and variable heavy (VH) chain regions of the UCHTl antibody were amplified by a two step protocol of RT-PCR using primers based on the published sequence (13). The 5' VL primer added a unique Ncol restriction enzyme site while the 3' VH primer added a termination codon at the J to constant region junction and an EcoRI site. The VL region was joined to the VH region by single-stranded overlap extension and the two regions are separated by a (Gly3Ser)4 linker that should allow for proper folding of the individual variable domains to form a function antibody binding site (14). Second, genomic DNA was isolated from a strain of C. diphtheriae producing the DT mutant CRM9 (07[JS*'0*-20"*-911']) as described (15). This DNA was used for PCR. The 5' primer was specific for the toxin gene beginning at the signal sequence and added a unique Ndel restriction site. The 3' primer was specific for the DT sequence terminating at amino acid 390 and added an Ncol site in frame with the coding sequence. The PCR products were digested with the appropriate restriction enzymes and cloned into the E. coli expression plasmid pET-17b (Novagen, Inc., Madison, WI, USA) which had been linearized with Ndel and EcoRI. The resulting plasmid was used to transformed E. coli BL21/DE3 cells. Cells were grown to an OD590 of 0.5, induced with 0.5 M IPTG (Invitrogen, San Diego, CA, USA) and incubated for an additional 3 hours. The sFv-DT390 protein was isolated in the soluble fraction after cells were broken with a French Press and the lysate subjected to centrifugation at 35,000 X g.
Protein synthesis inhibition assay.
Inhibition assays were performed as described (12) with the following modifications.
Immunotoxins were incubated for 30 minutes with the indicated serum sample or leucine1 free medium at room temperature prior to addition to cells. In some experiments the serum was pre-incubated for 30 minutes with an adsorbing molecule at the given concentrations to bind the antibodies. The immunotoxin/serum mixture was incubated with Jurkat cells (5 x 104 cells/well in 96 well plate) for 20 hours. A 1 hour pulse of [3H]-leucine (4.5 μCi/ml) was given before cells were collected onto filters with a Skatron harvester. Samples were counted in a Beckman scintillation counter. Each experiment was performed in 4 replicates.
Results were calculated into a mean value, and recorded as a percentage of control cells.
Serum antibody detection.
Anti-DT antibodies were detected in human serum by ELISA. CRM9 (10 μg/ml) was adsorbed to Costar 96-well EIA/RIA flat bottom plates (Costar, Cambridge, MA, USA) for 2 hours and then washed in phosphate buffered saline (PBS) containing 0.1% Tween 20. Each well was then incubated with PBS containing 3% gelatin to prevent non-specific binding of antibodies to the plastic. Serum samples were diluted in PBS containing 0.1% Tween 20 and 0.3% gelatin prior to addition to the plate. After 1 hour incubation, the wells were washed as above, and incubated for an additional hour with protein A/G-alkaline phosphatase (1 :5,000; Pierce, Rockford, IL, USA). Wells were washed, and phosphatase substrate (Pierce) was added following the manufacturer's directions. After 30 minutes color development was stopped with NaOH and the optical density (OD) was measured with a kinetic microplate reader (Molecular Devices Corporation, Palo Alto, CA, USA). Each sample was performed in triplicate. Results are presented as O.D. values and antibody titers.
Endocytosis assay.
UCHT1-CRM9 was iodinated using the Bolton-Hunter reagent (NEN Dupont, Wilmington, DE, USA) as described (16). Jurkat cells were washed twice with binding medium (RPMI 1640 supplemented with 0.2% bovine serum albumin, 10 mM Hepes (pH 7.4) and without sodium bicarbonate). Cells (1.5 x 106) were incubated for 2 hours on ice with 125I-UCHTl -CRM9 (1 x 10"9 M) that had been pre-incubated with serum or binding medium. Unbound antibody was removed by washing the cells twice in PBS (pH 7.4) with centrifugation and resuspension. Duplicate samples were incubated for 30 minutes on ice or at 37°C. One sample from each temperature point was centrifuged at 800 x g to separate the total cell associated (pellet) from the exocytosed or dissociated counts (supernatant). Both fractions were counted in a Beckman a γ-counter. To determine the amount of internalized immunotoxin, cells from the second sample at each temperature were incubated in low pH medium (binding medium containing 10 mM morpholinoethanesulfonic acid, all of which was titrated to pH 2.0 with HCl) for 5 minutes to dissociate the surface bound 125I-immunotoxin (17). Samples were centrifuged at 800 x g to separate the internalized (pellet) from the membrane bound (supernatant). Both fractions were counted in a Beckman γ-counter (Beckman, FuUerton, CA, USA).
Serum with anti-DT antibodies inhibits UCHT1-CRM9 toxicity.
Since humans are immunized against DT, the presence of anti-DT antibodies in the serum was determined by ELISA (Table 2). In a limited sample population, 80% of the serum samples had an anti-DT antibody titer of 1 : 100 or above. The vaccination status of the donors was not available. To determine the effect of these antibodies on UCHT1-CRM9 toxicity, the immunotoxin was pre-incubated with different concentrations of serum and the toxicity of the mixture was assayed (Table 2). Serum samples without a significant ELISA O.D. (2 fold above background) were incapable of affecting UCHT1-CRM9 toxicity at high concentrations of serum (1:10). However, serum samples with a positive ELISA result could neutralize the cytotoxic effect at 1:10 dilution, and those with a high ELISA O.D. (7-11 fold above background) inhibited toxicity even at a 1 : 100 dilution. Similar results were seen in assays conducted with monkey serum samples.
Table 2. Human serum with anti-DT antibodies inhibits the toxicity of UCHTl -CRM9 and the inhibition correlates with the anti-DT titer
Figure imgf000042_0001
aELISA was performed in triplicate for each serum sample as described under "Materials and Methods." The O.D. values were derived from 1:100 dilutions and presented as a mean value ± SD. The background value was 0.060 ± 0.02. titers are recorded as the highest serum dilution that showed a positive reaction in ELISA. bUCHTl-CRM9 (2 x 10'10) was incubated with different dilutions of serum for 30 min. The mixture was then added to cells as described under "Materials and Methods." Four replicates were performed for each sample. Data are presented as a mean value ± S. C. in percentage of the control counts. UCHTl -CRM9 inhibited protein synthesis to 2.0% of controls. The goat anti-DT serum could be diluted to 1 : 10,000 and still completely inhibited the toxicity of UCHTl -CRM9. 0ND, not done
Sera do not inhibit endocytosis of UCHT1-CRM9.
The inhibitory effect of serum on UCHT1-CRM9 toxicity could be due to prevention of the immunotoxin binding to the cell surface or the endocytosis of UCHTl -CRM9 into the cell. Endocytosis assays were conducted using ' 25I-UCHT 1-CRM9 to determine if either of these processes were affected by anti-DT antibodies present in sera. The results indicate that the presence of serum (goat anti-DT or human) reduces as much as 80% of the immunotoxin counts binding to the cell surface (Table 3). While this is a significant reduction in binding, limiting 90% of input immunotoxin (one log less UCHT1-CRM9) in toxicity assays reduces protein synthesis to <25% of controls (see Figure 1). In contrast, the inhibitory effect of serum containing anti-DT antibodies is 100%. Therefore the effect of the anti-DT antibodies is not all at the level of inhibition of binding to the cell surface. The pre-incubation of ' 25I-UCHT 1-CRM9 for 2 hours on ice and subsequent washing at room temperature resulted in 18 to 25% of the total cell associated counts internalized (Table 3). After incubation for 30 minutes at 37°C, there is a doubling of internalized counts both with and without serum, indicating that the same percentage of labeled immunotoxin is endocytosed. The identical dilutions of serum were incubated with non-labeled UCHTl -CRM9 and used in protein synthesis inhibition assays. The results demonstrate that the ratio of immunotoxin to serum used was capable of completely inhibiting the toxicity (Table 3), although the endocytosis of UCHTl -CRM9 was not affected.
Table 3. Inhibition of UCHT1-CRM9 toxicity by serum does not correlate with inhibition of endocytosis.
Figure imgf000044_0001
[12 1]-UCHTl -CRM9 (2 x 10-9M) was incubated with medium or anti-DT serum (1 :4 dilution of human sample 10010 or a 1 : 1 ,000 dilution of goat serum; Table 2) for 30 minutes at room temperature. This mixture was added to Jurkat cells (1.5 X 106) for 2 hours on ice (final concentration of [125I]-UCHT1-CRM9 was 1 x 10-10). The cells were then washed and endocytosis assays performed as described in Materials and Methods. The % Bound value represents the cell associated counts divided by the cell associated counts divided by the cell associated counts without serum. Non- labeled UCHT1-CRM9 was incubated with the above dilutions of sera and the resulting mixture was used in protein synthesis inhibition assays. The results shown are representative of two independent assays.
The inhibitory effect of anti-DT antibodies can be removed by adsorption.
To prevent the inhibitory effect of serum as well as gain insight into the mechanism by which serum inhibits toxicity, experiments were designed to adsorb the protective anti-DT antibodies from the serum. The serum (a pool of all human sera with positive anti-DT ELISA or goat anti-DT) was pre-incubated for 30 minutes with increasing concentrations of CRM 197 (an A-chain mutant of DT with no enzymatic activity), MSPΔ5 (a truncation mutant missing the last 150 amino acids) and the purified A- and B-subfragments of DT (Figure IA). The adsorbed serum was then incubated with UCHTl -CRM9 in protein synthesis inhibition assays. CRMl 97, the full length DT-like construct, was capable of completely adsorbing the protective antibodies from both goat (Figure IB) and pooled human serum (Figure 1C). The B-subfragment of DT is also capable of complete adsorption, however —100 fold more is required. The A-subfragment of DT had little or no effect on either serum, although the serum samples were demonstrated to contain antibodies reactive to both the A- and the B-subfragments by Western Blot analysis. Of interest were the results seen with MSPΔ5, the truncation mutant. Adsorption of goat serum with MSPΔ5 gave a dose dependent removal of the serum's protecting effect (Figure IB). However, this adsorption could not bring toxicity down to levels obtained when CRMl 97 or the B-subfragment was used.
In contrast to the results observed with the goat serum, MSPΔ5 had little effect on pooled human serum (Figure 1C). These results suggest that the pre-existing anti-DT antibodies important for the protecting effect in human serum are mainly directed against the last 150 amino acids of DT.
sFv-DT390 is not inhibited by anti-DT antibodies present in human sera.
Having observed that the epitope(s) recognized by the antibodies important for protection lay in the C-terminal 150 amino acids, a single-chain immunotoxin was generated with the first 390 amino acids (out of 535) of DT. Position 390 was chosen for 2 reasons: first, the 3 dimensional structure of DT suggested that this position was an external point on the molecule away from the enzymatic domain (18), and second, fusion toxins have been generated with longer DT subfragments with no reports of serum effects (19). The DNA encoding the first 390 amino acids of DT was ligated to DNA encoding the anti-CD3esFv (VL linked to VH using a (Gly3Ser)4 linker sequence). The predicted molecular weight for the fusion protein is 71,000 Daltons and has been confirmed by Western Blot analysis of both in vitro transcribed and translated protein as well as protein isolated from E. coli using goat anti-DT antibodies. The toxicity of sFv-DT390 protein, isolated from E. coli strain BL21/DΕ3, was compared to UCHTl -CRM9 in protein synthesis inhibition assays. The IC50 (concentration required to inhibit protein synthesis to 50% of controls) of sFv-DT390 was 4.8 X 10"11 M compared to 2.9 X 10~12 M for UCHT1-CRM9, a 16-fold difference (i.e., 16-fold less toxic). To demonstrate the specificity of the sFv-DT390 construct, competition experiments were performed using increasing concentrations of UCHTl antibody as competitor. The results showed that approximately 1/8 antibody is needed to compete the sFv-DT390 toxicity to 50% as compared to UCHT1-CRM9. The antibody was capable of totally competing toxicity of both constructs thereby showing their specificity. The immunotoxins were then subjected to protein synthesis assays in the presence of increasing dilutions of serum (Table 4).
UCHT1-CRM9 toxicity was completely inhibited with a 1:10 dilution of the human sera but at a 1 :100 dilution toxicity was equivalent to controls without serum. In contrast, the sFv-DT390 immunotoxin is only partially inhibited with the 1:10 dilution of the human, sera and the 1 : 100 dilution no effect on the toxicity. Both immunotoxins are completely inhibited by goat anti-DT serum (1 : 1,000 dilution). These results indicate that the sFv-DT390 immunotoxin partially evades the pre-existing anti-DT antibodies present in most human sera.
These results indicate that the pre-existing anti-DT antibodies present in human serum inhibit the toxicity of the immunotoxin UCHT1-CRM9. This inhibition of toxicity was also observed with goat anti-DT serum, however less goat serum was needed to completely inhibit toxicity. The experiments were designed in such a way to mimic the in vivo situation. The peak concentration of circulating immunotoxin currently being tested in animal models is 1 X 10"9 M. The immunotoxin concentration incubated with the 1 :10 dilution of human serum was 1 X 10"10 M, thus approximating in vivo conditions. The inhibition of toxicity correlates with the serum antibody levels as determined by ELISA (Table 3), indicating that sera with higher anti-DT titers have a stronger inhibitory effect. Similarly, the goat anti-DT serum which gave the highest ELISA value could be diluted 10,000 times and still completely inhibited UCHT1-CRM9 toxicity. Since this correlation exists, there is no indication that any other component of the serum inhibits the toxicity of UCHT1-CRM9. Furthermore, the data show that a titer of 1 : 1 OO dilution is necessary for an inhibition of the immuno toxin toxicity. A construct in which the first 486 amino acids of DT were fused to interleukin-2, DAB486IL-2, was used in lymphoid malignancy patients. A partial response to DAB486IL-2 was observed in several patients who had a anti-DT titer below 1 : 100 dilution prior to the treatment.
Intoxication of cells by immunotoxins can be subdivided into four general stages: 1) specific binding to the cell surface, 2) endocytosis into the cell, 3) translocation of enzymatic domain of the toxin out of the endosome and 4) enzymatic inactivation of the target molecule. The results presented indicate that, while the amount of immunotoxin reaching the cell surface is lower in the presence of serum, the same percentage of bound immunotoxin is endocytosed. Taking into account the reduced amount of immunotoxin bound to the cell, the amount of endocytosed immunotoxin should intoxicate the cells to below 25% of controls. However, the immunotoxin had no effect on protein synthesis in the presence of serum containing anti-DT antibodies. Since the A-subfragment of DT could not adsorb the protective effect of serum while the B-subfragment could, the effect of serum is not likely to be at the level of inhibiting enzymatic activity of the toxin. Therefore, the anti-DT antibodies probably affect the translocation of the A-subfragment into the cytosol.
CRMl 97, B-subfragment, and MSPΔ5 could adsorb the protecting anti-DT antibodies from the goat and rhesus monkey sera. However, among the 3 DT mutants, MSPΔ5 could not prevent the UCHTl -CRM9 toxicity in the presence of the human sera, showing a difference in the anti-DT antibody repertoire among humans, goat and rhesus monkeys. This difference does not seem to be due to immunization routes, because monkeys used in the present study were not immunized for DT and presumably acquire the antibodies after a natural infection with toxigenic strains of C. diphtheriae. There have been reports showing that rhesus monkeys and humans shared a similar antibody repertoire (21), but the present results suggest that the effect of antibodies from the host for whom immunotoxin treatment is intended should be useful.
To overcome the blocking effect of the pre-existing anti-DT antibodies in human sera, there are basically two pathways existing. One is to neutralize the antibodies with non-toxic DT mutants, and the other is to modify the DT structure used for making immunotoxin (3). The antibody neutralization pathway has been tested in monkey studies of FN18-CRM9 treatment as described above. The present results showed that although antibodies against both A- and B-subfragments existed in human sera, MSP5 could not neutralize the pre-existing protective anti-DT antibodies, and therefore could not prevent the inhibition of the cytotoxicity of UCHT1-CRM9. However, it did block the inhibitory effect of the goat and monkey sera. This prompted the construction of the present recombinant immunotoxin, sFv-DT390. The IC50 of sFv-DT390 is 4.8 x 10"11 M, 1/16 as potent as UCHT1-CRM9. Like many other single-chain constructs, sFv-DT390 is monovalent as compared to immunotoxins generated with full length, bivalent antibodies. The reduced toxicity in sFv-DT390 could be explained primarily on this affinity difference. Immunotoxins generated with purified F(ab)' fragments of antibodies also show an in vitro loss in toxicity (generally a 1.5 log difference) when compared to their counterparts generated with full length antibodies (22). The toxicity of sFv-DT390 is comparable to that reported for DAB486IL-2 (23). From the present data some advantages of sFv-DT390 are expected. First, sFv-DT390 is only 1/3 of the molecular weight of UCHT1-CRM9. The molar concentration of sFv-DT390 will be 3 times higher than that of UCHTl -CRM9 if the same amount is given (for example, 0.2 mg/kg). Therefore, their difference in potency could be reduced to approximately 5 times. Second, in an in vitro experiment (Table 4), the same molar concentration of sFv-DT390 and UCHT1-CRM9 was used for serum inhibition test, although the former is only 1/16 potent compared to the latter. The pre-existing anti-DT antibodies in human sera could only partially block the toxicity of sFv-DT390 while the effect of UCHTl -CRM9 was completely blocked. Thus, sFv-DT390 is expected to bypass the anti-DT antibodies in in vivo situations while UCHT1-CRM9 cannot. Third, sFv-DT390 contains only the variable region of UCHTl, and is expected to have less immunogenicity in human anti-mouse antibody (HAMA) responses than the native murine antibody UCHTl. Finally, the production cost of sFv-DT390 is much lower than that of UCHT1-CRM9. Based on these reasons, sFv-DT390, or others with similar properties, are expected to be useful in the treatment of T-cell mediated diseases in humans, especially in anti-DT positive individuals and in patients who need repeated treatments. To obtain evidence supporting this assumption, it is only necessary to construct a rhesus monkey analog of sFv-DT390, and test it in monkey models as described in previous examples. Table 4: Anti-DT antibodies present in human sera have reduced effect on sFv-DT390 toxicity.
Protein synthesis (% Contol)
Serum ELISA Sample value UchTlCRM9 sFv-DT390 (± S.D.)
1:10 1:1(T l:103 1:10 l:102 l:10J
10012 0.491 ± 119 ± 8 ± 2 NDa 47 ± 9 21 ± 8 ND
0.025 24
Pooled 0.331 ± 108 ± 7 ± 1 NDa 49 ± 7 16 ± 7 ND
0.015 37
Goat 1.450 ± ND ND 94 ± 21 ND ND 8 ± 11
0.013
aNot done
UCHT1CRM9 or sFv-DT390 (2 x 10'9M) was incubated with the indicated dilutions of serum for 30 mm. The mixture was then added to cells as descπbed under "Materials and Methods." The final concentration of lmmunotoxin on cells was 1 x 10"10M. Four replicates were performed for each sample. Data are presented as a mean value ± S.D. in percentage of the control counts. UCHT1-CRM9 inhibited protein synthesis to 5% of controls while the sFv-DT390 inhibited protein synthesis to 18% of controls. The ELISA value was determined using a 1:100 dilution of serum. The results are representative of two independent expeπments.
EXAMPLE 6
Expression and Characterization of A Divalent Chimeric Anti-human CD3 Single Chain Antibody
Murine anti-CD3 monoclonal antibodies (mAbs) are used in clinical practice for immunosuppression. However, there are two major drawbacks of this treatment: the associated cytokine release syndrome and human anti-mouse antibody response. To overcome these side effects, a chimeric anti-human CD3 single chain antibody, scUCHTl was generated. It is an IgM variant of the UCHTl described in Example 9. scUCHTl consists of the light and heavy variable chain binding domains of UCHTl and a human IgM Fc region (CH2 to CH4). The method used was reported by Shu et al. [37] and is further described below. The following data show that the engineered chimeric anti-CD3 single chain antibody (scUCHTl) will be useful in clinical immunosuppressive treatment.
Oligonucleotide primers and DNA amplification.
The procedures of cloning scUCHTl is schematically depicted in Fig. 2. mRNA isolated from UCHTl hybridoma cells (provided by Dr. P. C. Beverley, Imperial Cancer Research Fund,London was reverse transcribed into cDNA. The VL and VH regions of UCHTl were amplified with polymerase chain reaction (PCR) from the cDNA using primer pairs Pl, P2 and P3, P4 respectively. Primers P2 and P3 have a 25 bp complementary overlap and each encoded a part of a linker peptide (Gly4Ser)3. The single chain variable fragment (VL- linker- VH) was created by recombinant amplification of VL and VH using primers Pl and P4. A mouse kappa chain signal sequence was added at the VL 5'-end by PCR, first with primers SP2 and P4, and then with primers SPl and P4. The human IgM Fc region (CH2 to CH4) was amplified from the plasmid pBlue-hulgM (kindly provided by Dr. S. V. S. Kashmiri, National Cancer Institute, Bethesda. This gene fragment was about 1.8 kb. The VL-linker-vH-CH2 region which is important for antigen recognition was confirmed by sequence analysis. Finally, the single chain variable fragment and the human IgM Fc region were cloned into plasmid pBK/CMV (Stratagene, La Jolla, CA, USA). Using the generated pBK/scUCHTl plasmid as template, an in vitro transcription-translation assay yielded a product of 75 kDa, the expected size. Expression in COS-7 and SP2/0 cells.
The gene fragment encoding scUCHTl was then cloned into an expression vector pLNCX [36]. The scUCHTl gene construct was introduced into COS-7 cells with a calcium-phosphate method [32], and introduced into SP2/0 myeloma cells by electroporation [33]. Cells transfected were selected with 500 μg/ml G418 (GIBCO/BRL, Gaithersburg, MD, USA) in DMEM medium. The drug resistant transfectants were screened for scUCHTl secretion by an anti-human IgM ELISA technique. Transfectants secreting scUCHTl were cloned by limiting dilution.
Two stable clones, COS-4C10 and SP2/0-7C8, which could produce about 0.5 mg/ml scUCHTl in culture medium, were selected for further evaluation. The culture supernatant of COS-4C10 and SP2/0-7C8 cells was analyzed by immunoblotting using anti-human IgM antibody. Human IgM antibody was included as a control in the analysis. Under reducing conditions, scUCHTl produced by COS-7 and SP2/0 cells had a similar electrophoretic mobility to that of the control human IgM heavy chain (75 kDa). Under non-reducing conditions, scUCHTl from COS-7 cells appeared as a single band of approximately 150 kDa, which was thought to be a homodimer of the single chain antibody. SP2/0 cells mainly produced a protein of similar size with some higher molecular weight products.
In constructing scUCHTl, the domain orientation of sFv, VH-VL, which Shu et al. used to VL-VH orientation, was changed so that the heavy chain constant domains were linked to the VH domain. In mammalian cells, secretion of immunoglobulin molecules is mediated by light chain, and free light chain is readily secreted [38]. However, free heavy chain is generally not secreted [39]. In a bacterial expression system, the yield of secreted sFv with a VL-VH domain orientation was about 20-fold more than that obtained with a VH-VL domain orientation [40]. It was reasoned that VL at the NH2 -terminal position and VH linked to heavy chain constant region in scUCHTl construct might enhance the secretion of this immunoglobulin-like molecule in mammalian cells. In fact scUCHTl was efficiently produced by both COS-7 and SP2/0 cells. Hollow fiber culture should increase its production. Moreover, scUCHTl, the IgM-like molecule, has a secretory tailpiece with a penultimate cysteine (Cys 575) which is involved in polymerization and also provides retention and degradation of IgM monomers [41-43]. Replacing the Cys 575 with serine might also greatly improve the yield. scUCHTl secreted from COS-7 cells was shown to be a divalent form by immunoblotting, suggesting a disulfide bond linkage of two monovalent molecules. The disulfide bond is likely situated between the CH2 and CH3 regions, where the Cys 337-Cys 337 disulfide bond is thought to exist. Cys 337 is believed to be sufficient for assembly of IgM monomers, and was neither sufficient nor necessary for formation of polymers. However, Cys 575 was necessary for assembly of IgM polymers, and Cys 414 was not required for formation of IgM monomers or polymers [44]. This divalent form of the single chain antibody should increase its binding affinity. While scUCHTl produced from SP2/0 cells was mainly in the divalent form, a small fraction of the antibody had a higher molecular weight, nearly comparable to that of the human IgM pentamer, the natural form of secreted human IgM.
Western blotting analysis of scUCHTl. scUCHTl was precipitated from the culture supernatant using goat anti-human IgM-Agarose (Sigma, St. Louis, MO, USA), and separated on 4-20% SDS-PAGE gradient gel under reducing and non-reducing conditions. The separated proteins were transferred to ProBlottTM membrane (Applied Biosystems, Foster City, CA, USA) by electroblotting at 50 volts for 1 hour. The membrane was blocked and incubated with alkaline phosphatase labeled goat anti-human IgM antibody (PIERCE, Rockford, IL, USA) following the manufacturer's instruction. Color development was carried out with substrate NBT/BCIP (PIERCE).
Purification of scUCHTl.
Culture supernatant was mixed with anti-human IgM-Agarose, and incubated at 4°C with shaking overnight, and then the mixture was transferred to a column. The column was washed with washing buffer (0.01 M Na-phosphate, pH 7.2, 0.5 M NaCl) until the OD280 of flow-through was <0.01. scUCHTl was eluted with elution buffer (0.1 M glycine, pH 2.4, and 0.15 M NaCl). The fractions were neutralized with 1 M Na-phosphate (pH 8.0) immediately, and then concentrated and dialyzed against PBS.
Competitive binding assay.
The parental antibody UCHTl was iodinated using Bolton-Hunter Reagent (NEN, Wilmington, DE, USA) as described previously [34]. The 125I-labeled UCHTl was used as tracer and diluted with DMEM medium to 0.3-0.6 nM. UCHTl and the purified scUCHTl from COS-7 and SP2/0 transfectant cells were used as competitors. Human CD3 expressing Jurkat cells were suspended in DMEM medium (2 x 107/ml). 50 μl of such cell suspension (1 x 106) was incubated with 50 μl diluted tracer and 50 ml diluted competitors on ice for 2 hours. Afterwards, cells were pelleted, and counted in a gamma counter. Results were expressed as a percentage of the 125I-UCHTl bound to cells in the absence of competitors. scUCHTl from both COS-7 and SP2/0 cells could specifically inhibit the binding of 125I-UCHTl to Jurkat cells in a dose dependent way. As the concentration of the competitors (UCHTl, scUCHTl from COS-7 and SP2/0 cells) increased from 1 to 100 nM , the tracer (125I iodinated UCHTl) bound to Jurkat cells decreased from 80% to nearly 0%. No significant difference was observed among the affinity curves of UCHTl and scUCHTl from COS-7 and SP2/0 cells. This indicates that the engineered antibody scUCHTl has nearly the same affinity as UCHTl . Moreover, scUCHTl contains human IgM constant region, and is expected be less immunogenic than UCHTl. The degree of its immunogenicity might vary due to the murine variable region of scUCHTl . Humanized variable regions by CDR-grafting or human variable regions can be used to further reduce its immunogenicity [31].
T-cell proliferation assay.
T-cell proliferation in response to UCHTl and scUCHTl was tested on human PBMCs from a healthy donor. Human peripheral blood mononuclear cells (PBMCs) were isolated from blood of a healthy adult by density centrifuge over Ficoll-Hypaque gradient [34]. The PBMCs were resuspended in RPMI 1640 supplemented with 10% FCS and aliquoted to 96-well U-bottom plates at 5 x 104 cells/well. Increasing amounts of anti-CD3 antibodies (UCHTl, scUCHTl) were added. After 72 hours of culture at 37°C in a humidified atmosphere containing 5% CO2, 1 μCi [3H]thymidine (NEN) was added to each well. 16 hours later, cells were harvested and [3H]thymidine incorporation was counted in a liquid scintillation counter.
The parental antibody UCHTl started to induce proliferation at 0.1 ng/ml, and peaked at 100 ng/ml. A small drop in CPM was observed as the concentration increased to 1,000 ng/ml. However, [3H]thymidine incorporation in PBMCs incubated with scUCHTl was only slightly increased in the range of 0.1 - 10 ng/ml, and when the concentration was higher than 10 ng/ml, the incorporated counts decreased and were close to 0 counts at 1,000 ng/ml. Thus showing that scUCHTl did not induce a human T cell proliferation response.
Measurement of TNF-α and IFN-γ.
TNF-α and IFN-γ productions of human PBMCs induced by UCHTl and scUCHTl were measured with ELISA. 4 x 105 PBMCs were cultured with serial dilutions of anti-CD3 antibodies (UCHTl, scUCHTl) in 96-well flat-bottom plates in RPMI 1640 supplemented with 10% FCS. Supernatant was collected at 36 hours for TNF-α and 72 hours for IFN-γ after the start of the culture [35]. TNF-α and IFN-γ were measured with ELISA kits (Endogen Inc. Cambridge, MA, USA) following the manufacturer's instruction.
The native antibody UCHTl induced production of both TNF-α and IFN-γ in a dose dependent way. Higher concentration of UCHTl induced higher production of TNF-α and IFN-γ. On the contrary, scUCHTl did not induce secretion of TNF-α at any concentration, and inhibited IFN-γ production when its concentration was higher than 0.1 ng/ml. At the time of supernatant harvesting, the PBMCs cultured with UCHTl and scUCHTl were also checked with trypan blue exclusion test. Cells were shown to be alive in both situations. In TNF-α and IFN-γ ELISA assays, an unrelated human IgM was included and it did not affect the TNF-a and IFN-g production.
Anti-CD3 mAbs can induce T cell activation and proliferation both in in vitro and in vivo situations [45]. Crossing-linking of anti-CD3 antibody between T cells and FcR expressing cells is an essential step in this process [46]. T cell activation therefore reflects an efficient interaction of the mAb with a human FcR. Previous data of in vitro study indicated that T cell activation resulted in increased production of TNF-α, IFN-γ, and IL-2 [24]. Human IgG Fc receptors (FcγR I, FcγR π, FcγR HT) are distributed on human monocytes, T, B lymphocytes, and NK cells [47]. FcγR I and FcγR II can recognize both mouse and human IgG. In accordance with the above observation, UCHTl was potent in induction of T cell proliferation and TNF-α and IFN-γ release. Human IgM Fc receptor (FcμR) was reported to be present mainly on a small fraction of B lymphocytes, NK cells, and possibly a helper subset of T lymphocytes [47, 48]. Pentamer form of IgM and an intact CH3 domain are required for optimal binding to FcμR. Monomelic or dimeric subunits of IgM are less efficient in binding to FcμR [49, 50]. Cross-linking of IgM to FcμR on T cells inhibited the mitogen-induced T cell proliferation, and FcμR may function as a negative signal transducing molecule [51, 52]. Therefore, it can specifically bind to human CD3 molecule and FcμR. It is conceivable that scUCHTl can cross-link human B and T cells, and possibly T and T cells. In an in vitro assay, scUCHTl from both COS-7 and SP2/0 cells had little effect in the T cell proliferation assay at low concentrations (below 10 ng/ml), and became inhibitory as the concentration increased. In accordance with these results, scUCHTl did not induce TNF-α production and even inhibited the basal yield of IFN-γ.
The present chimeric anti-CD3 single chain antibody scUCHTl possesses high human CD3 binding specificity and affinity, and does not induce T cell proliferation and cytokine release. Moreover, it has a human IgM Fc fragment, which should decrease the possibility of inducing human anti-mouse antibody response. Thus, scUCHTl can be used for clinical immunosuppressive treatment.
EXAMPLE 7 Cloning the full-length of DT gene for the construction of DTM2.
Corynebacteriophage beta (C.diphtheriae) tox 228 gene sequence was from genebank. (Science 221, 885-858, 1983). The sequence is 2220 bp. There are 300 bp of 5' untranslated region (1 to 300) including the promoter sequence around (-180 to -10), 1682 of coding region (301- 1983) including signal peptide (301 to 376), A chain (377 to 955) and B chain (956 to 1983), and 3' untranslated region (1984 to 2220).
The full-length DT was amplified in two fragments. The pelB leader sequence ( ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTGCGCT GCC CAA CCA GCG ATG GCC 3') SEQ ID NO:1) was added to the 5' end of the DT coding sequenc to all the constructs during polymerase chain reaction by primer EcosignalDT-1 and EcosignalDT-2. The upstream fragment of 311 bp (from position 301 to 546 bp) was amplified by oligo EcosignalDT-2 and p546R with CRM9 DNA as a template and the downstream fragment of 1471 bp was amplified by p514S and pl983R with the DTMl DNA as template. Then, the combined PCR product of full-length DT was amplified with primer EcosignalDT-1 and pl983R. As a result, the amplified DT coding sequence (position 376 to 1983bp) acquired the pelB leader sequence added to the 5' end and contains the two mutant sites [(508 Ser to Phe ) and (525 Ser to Phe)] as DTMl does. Primers:
EcosignalDT-1 5' ATG AAA TAC CTATTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTC GCT GCC CAA 3' (SEQ ID NO:2)
EcosignalDT-2 5' GGA TTG TTA TTA CTC GCT GCC CAA CAA GCG ATG GCCGGC GCT GAT GATGTT GTT GAT TC 3' (SEQ ID NO:3) p546R: 5' CGGTACTATAAAACTCTTTCCAATCATCGTC 3' (SEQ ID NO:4) p514S: 5' GACGATGATTGGAAAGAGTTTTAT AGTACCG 3' (SEQ ID NO:5) pl983R: 5'AGATCTGTCGA/CTCATCAGCTTTTGATTTCAAAAAATAGCG 3' (SEQ ID NO:6).
A mutant residue was introduced at position 52. The glycine (GGG) at position 52 wild type DT was substituted by glutamic acid (GAG). The two primers p546R and p514S carried the mutant codon (GGG to GAG). The PCR products of these two primers contained the substituted codon (GAG) instead of codon GGG. The jointed double stranded DNA of the two fragments (1683bp) were cloned into pET 17b by restriction site Ndel and BamHI.
The data show that anti-human blocking antibodies are specifically directed at the toxin C-terminus. Although a specific sequence derived from the UCHTl VLVH regions is described, anyone skilled in the art could make sequence variations in VLVH domains which can be designed to increase the affinity of the sc-anti-CD3-antibody conferring a more favorable therapeutic ratio to fusion immunotoxins using this derivative. Such modifications are within the scope of the present teaching. The disadvantage of the monovalent antibody VLVH construct, is that it has a lower affinity for T cells compared to the chemically coupled conjugate which utilizes a divalent antibody.
These are believed to be the first instances of a sc anti-CD3 antibodies. IgM was chosen since very few B cells or macrophages contain IgM Fc receptors. (Binding of imrnuno toxin to cells other than T cells reduces the specificity of the anti-T cell immunotoxin and this situation is purposefully avoided). However, using a bacterial expression system no carbohydrate is attached to the antibody which also eliminates Fc receptor binding. Thus, substituting other human IgG constant domains would be a routine modification and should be claimed.
A variety of divalent fusion protein immunotoxins are provided. These have been expressed in E. coli, and Western blots of reduced and non-reduced SDS gels confirm that most of the immunotoxin is secreted as the dimeric (divalent) species. The position of the toxin has been varied in an attempt to minimize stearic hindrance of the divalent antibody site, yet provide the best interactions with the CD3 receptor to facilitate toxin translocation across the membrane. PCR amplification was conducted using BamHI and Ndel restriction sites and the pET17b vector. Figs. 3 and 4 show two different clones expressing divalent immunotoxin fusion proteins cartooned in Figs. 5 and 6, respectively. Another variation is shown in Fig. 7. The clone producing this consists of a clone constructed by using the single chain antibody followed by a stop codon and the single chain immunotoxin, all under one promoter (Better et al. Proc. Natl. Acad. Sci. 90:457-461, January 1993). After secretion and oxidation of the interchain disulfide, 3 species are present: sc divalent antibody, divalent fusion immunotoxin, and a divalent sc antibody containing only one toxin. This species is isolated by size separation and is the species cartooned in Fig. 7. The advantage of this species is that stearic hindrance to the divalent antibody domains is limited by the presence of only one toxin domain. Other variations are routine to construct given the methods described herin and in the art. Those diagramed are considered to be the most likely to exhibit divalent character. Numerous orientations of toxin relative to antibody domains can be made and many are expected to be effective.
In addition, the length of the toxin C-terminus has been varied to provide optimization between two competing functions. The numbers after DT refer to the number of amino acid residues counting the amino terminus of the toxin A chain as 1. The full length toxin is called DTMl and was provided by Dr. Richard Youle NINDS, NIH (Nicholls et al. J. Biol. Chem. 268(7):5302-5308, 1993). It has point mutations S to F at positions 508 and 525. This full length toxin mutant has the essential mutation of CRM9, S to F at 525 which reduces binding to the DT receptor by 3-4 logs without abolishing the translocation function. The other mutation S to F at 508 has been added because of previous restrictions on cloning mutant DT that can revert to wild type toxin with a minimum lethal dose of 0.1 microgram/kg by means of a single base pair reversion. Other mutations can be routinely made in the C terminus to perform this function (Shen et al. J. Biol. Chem. 269(46):29077- 29084, 1994). They are: F530A; K526A; N524A; V523A; K516A Y514A. A clone having a single point mutation in DT reducing toxicity by 10-100 fold can be made providing that the clone contains an antibody fragment fusion protein, because chemical conjugation of antibody to DT has been shown to reduce systemic wild type toxin toxicity by 100 fold (Neville et al. J. Biol. Chem. 264(25): 14653-14661, 1989). Therefore, the present invention provides a full length mutant DT sequence with the 525 S to F mutation alone as well as those listed above. These same mutations are also contemplated for the B chain mutant site in DTM2 and can be made similarly. Previous data with chemical conjugation has shown that the longer the C-terminus the better the translocation function (Colombatti et al. J. Biol. Chem. 261(7):3030-3035, 1986). However, the shorter the C-terminus has the less effect of circulating anti-toxin blocking antibodies. Since patients have different levels of blocking antibodies which can be measured, the optimal immunotoxin can be selected for individual patients. scUCHTl fusion proteins with DTMl and DT483 (see Fig. 8), DT390 (Fig. 8) and DT370 (Fig. 10) have been cloned and expressed in E. coli. Each of these variations as well as the divalent scUCHTl fusion proteins using each of these toxin domains are provided.
The present invention provides an improvement on CRM 197 (a non- toxic toxin mutant described in U.S. Serial No. 08/034,509, filed September 19, 1994) referred to herein as DTM2. DTM2 has the same mutation as CRM 197 plus two mutations in the C- terminus which block binding (see sheet). This is expected to reduce the likelihood of immune complex disease which could result when CRMl 97 becomes bound to cells and then is further bound by circulating antitoxin. Kidneys are particularly susceptible. DTM2 can not bind to cells thereby lessening the possibility of tissue damage. In addition DTM2 is made for high level production by including the pelB secretory signal for production in E. coli or a iron independent mutated promoter DT sequence cloned from CRM9 DNA for production in C. diptheriae. The essential feature of DTM2 is the S to F mutation at 525 and the G to E mutation at 52, and a construct containing these two mutations is provided.
All of the constructs reported here can be expressed in E. coli using pelB signal sequences or other appropriate signal sequences. Expression can also be carried out in C. diphtheriae using appropriate shuttle vectors (Serwold-Davis et al. FEMS Microbiol. Letters 66:119-14, 1990) or in protease deficient strains of B. subtilis and using appropriate shuttle vectors (Wu et al. Bio. Technol. 11:71, January 1993).
Throughout this application various publications are referenced by numbers within parentheses. Full citations for these publications may be found at the end of the specification immediately preceding the claims. Also, some publications mentioned hereinabove are hereby incorporated in their entirety by reference. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains. While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be appreciated by one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention and appended claims.
EXAMPLE 8
A fold-back single-chain diabody format enhances the bioactivity of an anti-CD3 recombinant diphtheria toxin based immunotoxin.
Anti-CD3 immunotoxins induce profound but transient T cell depletion in vivo by inhibiting eukaryotic protein synthesis, and they have utility in non-human primate models of transplantation tolerance and autoimmune disease therapy (Neville et al, 1992; Hu et al, 1997; Fechner et al, 1997, Thomas et al, 1997 and Contreras et al, 2003). The conjugated immunotoxins were formed by chemically cross-linking the antibody or antibody fragment to a diphtheria toxin binding site mutant, CRM9. In this way the binding site of the immunotoxin was dictated by the antibody moiety (Neville et al, 1996). The disadvantages of these chemically conjugated immunotoxins are linkage heterogeneity, Fc receptor interactions and a mutated toxin-binding domain in which binding to DT receptors is reduced but not eliminated. These disadvantages were overcome by developing recombinant immunotoxins based on diphtheria toxin truncated at residue 390 which provided optimal translocation of the toxin A chain into the cytosol while eliminating the toxin binding domain (Williams et al, 1990 and Thompson et al, 2001). These DT based immunotoxins were restricted to having the antibody moiety placed C-terminal to the truncated toxin because antibody domains fused to the N- terminal of the toxin interfered with translocation of biologically active A chain (Madshus et al, 1992 and Hexam et al, 2001). Although the affinity of anti-CD3 scFv was reduced to 3% of its initial value when tethered to the C-terminus of DT390, this loss was partially compensated by forming a biscFv construct by adding second scFv through a (G4S)3 linker (Thompson et al, 2001). The beneficial effect of the second scFv was ascribed to the divalent character of the biscFv binding, which in the case of the anti-human CD3 antibody UCHTl was increased 5 -fold for the biscFv binding over the scFv binding toward human T cells.
The construction of an anti-monkey CD3 immunotoxin utilizing a biscFv format of an affinity-matured mutant of antibody FNl 8 known as C207 was recently reported (Wang et al, 2007). Anti-monkey CD3 immunotoxins are important tools in organ transplantation research where the primary goal is to achieve tolerance to allografted organ transplants. Rodents are easily tolerized and are not a good model for human transplantation tolerance protocols compared to monkeys (Fechner et al., 1997, Thomas et al., 1997 and Contreras et ah, 2003). The FN18 scFv appeared more sensitive than anti-human UCHTl to positional loss of affinity when placed distal to the DT390 toxin domains compared to the UCHTl scFv. The divalent character of the C207 biscFv was judged to be suboptimal as determined by the relatively low increase in binding to monkey T cells of the biscFv relative to the scFv which was only 1.7±0.4 fold, compared to 5-fold for the UCHTl biscFv/scFv binding ratio.
The weaker binding of C207 biscFv could occur through suboptimal associations between the 2 sets of VL/VH domains within the biscFv. Thus, a more rigid structure that forced optimal VL/VH pairing would produce a higher affinity immunotoxin. The current work explores the use of diabody formats to increase the binding of anti-monkey immuno toxins based on the C207 mutant. Diabodies are recombinant non-covalent dimeric molecules with cross-over pairing of the VL and VH domains achieved by linking the VL and VH domains with a peptide linker that is too short to allow the interchain assembly of a functional Fv fragment (Holliger et al., 1993). If the linked VL and VH domains are derived from the same Fv the diabody will be bivalent. If the linked VL and VH domains are derived from two different Fv structures the diabody will be bispecific (Le Gall et al., 2004).
These structures spontaneously form non-covalent dimers and are stabilized by the presence of 4 simultaneous variable domain interactions. Single-chain monomelic diabodies have also been generated by linking two diabodies through a longer linker that allows the diabody subunits to fold back head to tail (Kontermann and Muller, 1999).
The initial exploration of anti-monkey CD3 immunotoxin efficacy was done using the continuous cultured monkey T line HSC-F (Akari et al., 1996). Specific cytotoxicity was assayed by the inhibition of protein synthesis. Equilibrium binding studies were also performed in order to determine the correlation between cytotoxicity and immunotoxin T cell binding. Previous studies on the equilibrium binding of anti-CD3 antibodies to T cells and the kinetics of dissociation had revealed a multicomponent binding process consisting of a combination of monovalent and bivalent binding and two equilibrium constants for both monovalent and bivalent binding differing by 10- fold. These were associated with two different dissociation rates also differing by 10-fold (Marano et al., 1989). In order to simplify binding comparisons between antibody fragments and immunotoxins in different formats, equilibrium binding competition studies were performed competing the same labeled tracer, FITC-FNl 8, and monitor relative binding by the ratios of concentrations at equal tracer displacement. Also cytotoxicity was assayed in resting monkey T cells between different formats. These positive in vivo tests showed that serum clearance was not a limiting factor for in vivo T cell depletion for these new recombinant immunotoxins.
Plasmids, bacterial and yeast strains, antibodies, cell lines.
Plasmid pPICZα was purchased from Invitrogen. The hybridoma secreting FN 18 was kindly provided by Dr. Margreet Jonker, Biomedical Primate Research Center Rijswijk, and was produced and purified by the National Cell Culture Center, Minneapolis, MN. Chemically conjugated anti-monkey CD3 immunotoxin, FN18-CRM9, was prepared as previously described (Neville et al., 1989). The Herpes Saimiri virus transformed cynomolgous cell T cell line HSC-F (Akari et al., 1996) was supplied by the Centralized Facility for ADDS Reagents supported by EU Programme EVA and the UK Medical Research Council. This cell line exhibits the moderate binding FNl 8 phenotype (Liu et al., 2007).
Protein synthesis inhibition assay.
This was performed by measuring the incorporation of 3H-labeled leucine into HSC- F cells after a 20 h exposure to immunotoxins at different concentrations. Means and standard deviations of 6 replicates were calculated and divided by the means of non- immunotoxin treated controls x 100 to give % control protein synthesis as previously described (Thompson et al, 2001).
T cell binding assay of recombinant scFv antibodies and immunotoxins.
FN18-FITC conjugate was purchased from Biosource and added to 250,000 HSC-F cells at 5 x 10"9 M in the presence of varying concentrations of scFv and immunotoxin binding competitors at 40C for 30 min. The displacement of FN18-FITC was measured by FACS on a Beckman-Coulter Cytomics FC 500 instrument after washing the cells two times at 400 x g at 40C and resuspending in 0.5 mL of 1 X PBS containing 2.5 μg of propidium iodide to exclude dead cells from further analysis. Mean channel fluorescent values, MCI, were corrected (MCF') by subtracting an appropriate FITC-isotope control from both the FN18-FITC tracer, and FN18-FITC tracer plus competitor MCF values. The % inhibition was determined as [(MCF'FNIS-FΓΓC - MCF^18-F1TC + COMPETITOR) / MCF'FNIS-FΓΓC] X 100. Relative binding affinity between any two competitors was determined by dividing their respective concentrations at equal % inhibition obtained from plots of % inhibition versus concentration as previously described (Thompson et al., 2001).
Immunotoxin induced loss of CD3+CD4+ resting monkey T cells.
T cells from normal monkeys were isolated from blood by two centrifugations through Lymphocyte Separation Medium from BioWhittaker following the manufacturer's directions. About 400,000 cells were washed and incubated in RPMI 1640 medium containing 25 mM HEPES (Gibco) with 10% fetal calf serum + 2 g/L NaHCO3, adjusted to pH 7.4, + 0.1 mM nonessential amino acids + 1.0 mM sodium pyruvate + 50 μg/L of gentamicin sulfate with and without varying concentrations of immunotoxins for 72 h at 5% CO2, 370C. Cells were washed and then stained for 30 min at 40C with anti-CD3 (SP34-2- PE BD Pharmingen), anti-CD4-FITC (BD Pharmingen), anti-CD20-PE Cy7 (BD Biosciences), and the vital dye 7- ADD (BD Pharmingen) and analyzed on a Beckman- Coulter Cytomics FC 500 instrument counting 104 events. Cells were analyzed for uptake of the vital dye, the per cent of cells within the lymphocyte forward scatter/ side scatter gate, and the per cent of cells within the lymphocyte gate within the quadrant displaying the CD3+ and CD4+ epitopes by 2-color FACS. The % of cells within the lymphocyte gate at each immunotoxin concentration was divided by % of cells within the lymphocyte gate for the 72 h no-treatment control (Gl). The % of cells within the CD3+CD4+ quadrant at each immunotoxin concentration was divided by % of cells within the CD3+CD4+ quadrant for the 72 h no-treatment control (Ql). The % loss of CD3+CD4+ cells was calculated as Gl x Ql x 100.
Expression and purification of biscFv(C207) and DT390-biscFv(C207).
C207 is an affinity matured anti-rhesus CD3 mutant antibody selected from a library of FN 18 sFvs randomly mutagenized with nucleotide analogs, displayed on yeast and selected by sorting flow cytometry using dye-labeled monkey CD3εγ ectodomain heterodimer (Wang et al., 2007). Construction of biscFv(C207) and its production in P. pastoris has been described as has the construction of the diphtheria toxin based immunotoxin utilizing biscFv(C207) (Wang et al., 2007) shown in Table 5 schematic E. In brief, the VL and VH domains of C207 were linked by a (G4S)3 linker to form the scFv and two scFvs were linked by third (G4S)3 linker to form the biscFv (Table 5, D). Table 5 Schematic of fusion proteins
(G4S)3
(A) scFv(C207) VLC207 | VHC2O7
G4S
(B) Db(C207) VLc207 I VHc207
G4S (G4S)3 G4S
(C) scfbDb(C207) VLc207 I VHc207 I VLc207 I VHC207
(G4S)3 (G4S)3 (G4S)3
(D) biscFv(C207) VLc207 I VHc2O? ! VLC207 I VHC207
(G4S)3 (G4S)3 (G4S)3
(E) A-dmDT390- biscFv(C207)
Figure imgf000063_0001
G4S
(F) A- dmDT390- Db(C207)
Figure imgf000063_0002
G4S G4S (G4S)3 G4S
(G) A-dmDT390- scfbDb(C207)
Figure imgf000063_0003
Expression and purification of diabody (C207) and fold-back diabody (C207) in P. pastoris.
For the construction of diabody form of C207, (Table 5, B) the (G4S)3 linker existing between VL and VH scFv(C207) (Table 5, A) was replaced with a G4S linker. The ScFv(FN 18-C207) gene was amplified by PCR using C207 yeast display plasmid as a template DNA and primers GP-095 and WP-052. The primers GP-94, GP-95 and GP-96 are listed in Table 6. (All of the remaining GP and WP primers are listed in Table 1 of Wang et al., 2007.) Sequencing of this vector, pGK1903, was performed using two universal primers, T4 and SP6 located on the TA cloning vector, pDrive (Qiagen). Then, this plasmid was used as a template for the PCR in order to construct Db(C207) (Table 5, B) and scfbDB(C207) (Table 5, C). As described in the previous paper (Wang et al., 2007), the original α-factor signal sequence in the vector system was replaced with a killer toxin (kt) signal peptide in order to have a complete cleavage between the signal peptide sequence and the inserted protein sequences of interest. To obtain diabody (C207), the Db(C207) gene was PCR-amplified from the plasmid pGK1903 using the primers GP-102 and WP-052. These vectors were sequenced using two primers located in the pPICZα, 5'-AOXl primer and 3'-AOXl primer (Invitrogen). Expression and purification of diabody (C207) and fold- back diabody (C207) was performed using a protein L affinity resin as described previously (Wang et al., 2007).
Expression and purification of the diabody and fold-back diabody immunotoxins in P. pastoris.
To make A-dmDT390-scfbDb(C207), fold-back diabody bivalent immunotoxin, (Table 5, G) the Db(C207) gene was PCR amplified from plasmid pGK1903 using two primer sets; the first amplification used primers GP-94 & WP-053 and second used primers GP-90 & WP-052.
The first PCR product was digested with Ncol and BamHl and the second PCR product was digested with BamHl and EcoRI. Then the two scFv parts in the vector pGK2006 (A-dmDT390-biscFv(C207) in pwPICZα) were sequentially replaced with C207- Db counterparts using Ncol and BamHl for the first scFv and BamHl and EcoRI for the second scFv (see Table 5, G). The resulting plasmid (pGK2019) was transformed into Pichia pastoris JW 107 and the transformants were selected on YPD plates containing zeocin (100 μg/ml). Because A-dmDT390-scfbDb(C207) expression in strain JW107 was too low to be purified from the induction medium, the expression cassette was moved from pGK2019 to the vector pPIC9K (Invitrogen) by Sad and EcoRI digestion , and then introduced into a new Pichia pastoris stain (Liu & Neville, unpublished data) that had a much higher expression level. This new strain, alleviates some of the negative effects of the unfolded protein response that is induced by the expression of certain heterologous proteins in P. pastoris (Liu et al., 2005).
To make A-dmDT390-Db(C207) diabody bivalent immunotoxin, Table 5, F the Db(C207) gene from pGK1903 was cut out with Ncol and EcoRI digestion and the 753 bp fragment was purified by gel electrophoresis followed by elution from the gel and then ligated into pGK2019 which was treated with the same restriction enzymes. The resulting plasmid (pGK2017) was transformed into Pichia pastoris JW107 and transformants were selected as described above. The vectors for constructing the diabody and fold-back diabody immunotoxins were sequenced using 5'-AOXl primer, V-AOXl primer (Invitrogen) and two internal primers Reverse 1 and Forward 1 (Table 6). Expression and purification of DT390-Db(C207) was performed as described previously for A-dmDT390-biscFv(C207) (Wang et al, 2007).
Table 6. Primer sequence for the construction and sequencing of diabody and diabody-immunotoxin fusion proteins'*
Primers Sequence (5 '-» 3')
GP-094 CTAGC CATGG GGTGG AGGTG GTTCT GACTT TGTTATGTCT CAATC TCC (SEO ID NO:7)
GP-095 GAGCA TGCTA GCCAT GGGGT GGAGG TGGCT CTGAC TTTGT TATGT CTCAA TC (SEQ
ID NO:8) GP-096 CGATG CAATT GGACT TGGGA ACCTC CGCCA CCCTT GATTT CCAAC TTGGT ACC (SEQ
ID NO:9)
Reverse 1 TCCAC CCCAT GGCAA GAATG (SEQ ID NO: 10)
Forward 1 CCACA ACTCC TACAA CCGTC (SEQ ID NO: 1 1 )
a Restriction sites are underlined. Boldface indicates the DNA sequences used to integrate a G4S linker.
DT390-scfbDb(C207) induced T cell depletion in monkeys
A-dmDT390-scfbDb(C207) (Table 5, G) was administered as an intravenous bolus in two dosing schedules;(A) doses given on day 0 and 2 doses at a total dose of 0.15 mg/kg (monkey CX3X) and (B) 8 divided doses given over 4 days, 6 hours apart for a total dose of 0.2 mg/kg (monkey 32972). Lymphocyte phenotype levels were monitored in blood and also in lymph nodes following maceration by flow cytometry on a Beckman-Coulter Cytomics FC 500 instrument counting 104 events. Staining reagents were: CD3+(CD3 sp34 FITC, Pharmingen, Catalog # 556611, clone SP34), CD4+ (CD4 PerCP-Cy5.5, Pharmingen, Catalog # 552838, clone L200), CD8b+ (CD8beta ECD, Coulter, Catalog # 6607123, clone 2st8.5h7), CD20+ (CD20 PeCy7, BD/Pharmingen, Catalog # 335793). Appropriate IgG isotype controls (isotype for sp34: IgG3 FITC, Southern Biotech, Catalog # 0105-02, clone BlO and isotype for fhl8: IgGl FITC, Coulter, Catalog # IM0639U, clone 679.1Mc7) were subtracted from mean fluorescent values. Blood T and B cell values were calculated by multiplying the total lymphocyte count per mm3 by the % of T cells or B cells enumerated by flow cytometry. When the total lymphocyte count was not performed on a cytometry day, the count obtained on the previous day was used.
Purity of fusion protein constructs.
Purified diabody immunotoxin A-dmDT390-Db(C207) (Table 5, F) ran as a single band by SDS-PAGE coincident with A-dmDT390-biscFv(C207) (Table 5, E) (Fig. 12) and gave a major peak on Superdex-200 10/300 GL (Amersham Biosciences) corresponding to the dimeric protein and a small trailing shoulder corresponding to the monomer representing 8.3% of the applied protein in 276 nm absorbance area units . On HPLC size exclusion chromatography on a calibrated Superdex-200 10/300 GL (Amersham Biosciences) 85.7% of the applied purified fold-back immunotoxin A-dmDT390scfbDb(C207) (Table 5, G) eluted coincident with DT390-biscFv (96,500 Da) while 9.7% of the protein eluted corresponding to a molecular weight of 210,000. An additional band, 4.6% eluted at the column front. Since these higher molecular weight species were not seen on the SDS gel it is likely that they correspond to head to tail non-covalent dimers and higher oligomers. The purified diabody Db(C207) (Table 5, B) and the fold-back diabody scfbDb(C207) Table 5, C) both ran as single bands on SDS gels. Their molecular sizes on HPLC are described below.
The molecular sizes of diabody and fold-back diabody fusion proteins.
The size of the diabody (Table 5, B) and the diabody immunotoxin (Table 5, F) corresponds to a dimeric protein mediated through molecular associations between the VH and VL domains on neighboring molecules since intermolecular self-associations were prevented by the short G4S linker separating these domains. This is shown to be the case in Fig. 11 where the Superdex 200 size exclusion column elution times of these constructs are plotted versus log MW. The column was calibrated using BSA monomers and oligomers (solid line) and with scFv(M20) and A-dmDT390bisFv(M20), dashed line. The point for Db(C207) (Table 5,B), solid triangle, falls on the dashed line when given the calculated MW of the dimer, 53.7 kDa. The point for the diabody immunotoxin (Table 5, F), inverted solid triangle, falls on a linear extension of the dashed line when given the calculated MW of the dimer, 141.1 kDa. In contrast, the fold-back diabody (Table 5, C) and the corresponding fold-back diabody immunotoxin with the longer inter-domain (G4S)3 linkers (Table 5, G) fall on or near the dashed line when given their respective monomer molecular weight values
Relative binding of scFv, diabody and single-chain fold-back diabody constructs.
The relative binding of these constructs to the monkey T cell line HSC-F is estimated from the inhibition of the anti-monkey anti-T cell antibody FNl 8 labeled with FITC by the constructs in a competition assay. The ratio of the construct concentrations at equal levels of inhibition reflects the relative avidity of the constructs and is shown in Fig. 13. The rank order of competitor binding from highest to lowest is scfbDb(C207) (Table 5, C), Db(C207) (Table 5, B), biscFv(C207) (Table 5, D) and scFv(C207) (Table 5, A). FNl 8 competition for FITC-labeled FNl 8 is shown for a comparative standard. In replicate assays the ratio of concentrations at equal displacement for Db(C207)/ scFv(C207) is 7±2 while the ratio for biscFv(C207)/ scFv(C207) is 2.5±0.1 (errors are SD).
Relative binding of immunotoxin constructs made with scFv, diabody and a single- chain fold-back diabody.
Although the diabody of C207 (Table 5, B) has high T cell binding, the immunotoxin made in the diabody format (Table 5, F) fails to show demonstrable binding judged by lack of inhibition FN18-FITC binding (solid squares, Fig. 14). In contrast the immunotoxin made in the fold-back diabody format (Table 5, G) exhibits robust binding, solid circles, 10-fold greater than that of the immunotoxin made in the biscFv format, (Table 5, E), empty circles.
Anti-T cell activity of immunotoxin made in the fold-back diabody format.
The anti-T cell activity of immunotoxin made in the fold-back diabody format was judged by two in vitro assays and by its effects in vivo. In Fig. 15 the % control inhibition of protein synthesis for three immunotoxins on the transformed HSC-F monkey T line is shown. The single-chain fold-back diabody recombinant immunotoxin, A- dmDT390scft>Db(C207) (Table 5, G), solid diamonds, is the most potent immunotoxin, exceeding the immunotoxin constructed with the biscFv antibody moiety, A-dmDT390- biscFv(C207) (Table 5, E) by 5-fold (empty squares). Similar results are shown in Fig. 16 after a 72-hour exposure of immunotoxins to cultured resting monkey T cells isolated from blood. In Fig. 17 the loss of lymph node T cells over time enumerated by flow cytometry following bolus intravenous administration of the fold-back diabody immunotoxin is shown for two monkeys. Monkey 32972 received the immunotoxin twice daily, 6 h apart, over 4 days, for a total dose of 0.2 mg/kg. Monkey CX3X received two intravenous bolus doses of immunotoxin, one on day 0 and one on day 2 for a total dose of 0.15 mg/kg. For a comparison, a third monkey AH44 received another biscFv immunotoxin, A- dmDT390biscFv(M20) in the same dose and schedule as monkey CX3X. This immunotoxin was described previously (Wang et al., 2007) and is 13.5-fold less active against resting T cells compared to A-dmDT390-biscFv(C207). Lymph nodes were not noticeably deleted of T cells 4 days after the initial immunotoxin dose. The profound loss of T cells in the blood for monkey 32972 is shown in Fig. 18. B cells are only moderately affected. T cells were present in the blood one month later but the per cent of SP34+ T cells in the lymphocyte gate was reduced from the pre-treatment value of 66% to 18.7% while the % of CD20+ B cells rose from 19.2 to 35.3 as did the percentage of CD2+ SP34' cells (probable NK cells).
Discussion
This work shows that a fold-back diabody format for an anti-monkey CD3ε immunotoxin (Table 5, G) offers improvements in binding and bioactivity towards resting T cells and transformed T cell lines ranging from 4 to 10-fold compared to the biscFv format for the affinity matured mutant C207 (Table 5, E). This is a substantial improvement for a therapeutic agent and is consistent with the fact that the fold-back diabody format achieves profound in vivo depletion of T cells in the blood and lymph node compartments when the fold-back immunotoxin is administered twice daily over 4 days (Figs. 17-18). This is the first report of using a fold-back divalent diabody format in an immunotoxin. Krauss et al. (2005) used a diabody format in an RNAase based immunotoxin targeted at B cells using the CD22 epitope. However, the results showed that the dimeric diabody format was inactive using the larger DT390 based toxin moiety, probably due to steric hindrance. Therefore a fold-back diabody format was tried. In this format two identical diabodies are linked through a longer linker that allows the diabody subunits to fold back head to tail.
There are a number of papers that compare the increase in functional affinity (avidity) on going from a scFv format to a divalent diabody format. In general, the increased functional affinity in the diabody format is the result of a decrease in the equilibrium dissociation constant (KD) and is due to bivalent binding as demonstrated by using methods that independently can measure monovalent and bivalent KD values. Under most conditions of diabody binding to a protein antigen there exist two measurable KDs, one for monovalent and one for bivalent binding and the overall avidity is determined by the fraction of bivalent binding (Huang et al., 2006). Because of steric constraints in diabody- protein bivalent binding, the fraction of multivalent binding never approaches the high values seen in some low molecular weight systems such as tris-vancomycin binding a trivalent D- AIa-D- Ala ligand (Rao et al., 1998). In this case the trivalent KD (4 x 10~17 M) was approximately equal to the third power of the monovalent KD (1.6 x 10"6 M).
The fold-back divalent diabody shares the divalent diabody features of enhanced rigidity and a close to 180 degree angle between the two antigen sites and these features contribute to enhanced improvements over the biscFv format. The simultaneous and concerted interaction of all 4 domains undoubtedly stabilizes the structure and provides extra thermal stability compared to the biscFv format where only 2 concerted domain interactions occur for each part of the biscFv. The rigid 180 degree angle between the two antigen sites permits divalent interactions between monovalently bound diabody- immunotoxin on neighboring cells in closely packed tissue such as lymph nodes, thus expanding the fraction of divalent binding sites beyond that limited on a single cell surface. This decreases the overall kinetic off rate and enhances signaling facilitating endocytosis of immunotoxin.
EXAMPLE 9 Cytotoxicity data of recombinant anti-PSMA immunotoxins
Prostate cancer is the most common non-skin neoplasm in men in the United States with 250,000 cases per year and is the second leading cause of cancer mortality in men with 30,000 deaths per year. One in six men will develop prostate cancer at some point in their lives. The disease is more common in older men and those of African- American ancestry and those with first-degree relatives with prostate cancer. Environmental factors including a high animal fat diet and low selenium and vitamin D may contribute to the high rate of disease in the United States.
Because of the location of the prostate gland and the propensity for cancer to originate in the peripheral zone of the organ, symptoms are often limited until late in disease progression. The symptoms are often nonspecific for cancer and include urinary hesitancy, nocturia, urgency, diminished urinary stream and incomplete bladder emptying. These symptoms may occur with local benign prostate hyperplasia (BPH) as well. Once pelvic or bone pain occurs, prostate cancer has spread and treatments are only palliative.
The molecular mechanisms leading to prostate carcinogenesis appear to be multiple and diverse. Disorders in cell renewal (sonic hedgehog, Notch and Wnt pathways), cell survival (PTEN and Ras signaling) and cell proliferation (MAPK pathways) may all been shown to contribute to prostate cancer formation and progression. Thus, there are multiple targets for new therapeutics, but the role of particular molecules in individual prostate cancer patients is unknown and unlikely to be solitary.
New therapeutics agents for prostate cancer may nevertheless take advantage of the persistence of several prostate differentiation antigens in most metastatic tumor deposits. The cell surface membrane 100 kilodalton glycoprotein prostate specific membrane antigen (PSMA) is expressed on epithelial prostate cells on both the prostate and all stages of androgen-insensitive or metastatic disease. The antigen is an enzyme and forms a homodimer on the cell surface and undergoes rapid endocytosis on antibody binding. The protein is absent from non-prostate tissues.
Using single chain Fv fragment of murine J591 anti-PSMA monoclonal antibody, recombinant fold-back format and bisFv format anti-PSMA immunotoxins were prepared in Pichia pastoris (see Table 7). Biological potency of fold-back format and bisFv format anti-PSMA immunotoxins was assayed with LNCaPs prostate carcinoma cells obtained from ATCC. Cells were maintained in RPMI 1640, 10% Fetal Bovine Serum at 37°C/5% CO2. Duplicate 96-well flat bottomed plates containing 104 LNCaP cells/well were incubated in 100 μL medium and 50 μL serial dilutions of fold-back or bisFv format immunotoxin yielding 0-10,000 pmols final concentration were added. After 48 hours at 37°C/5% CO2, 3H-thymidine (Perkin Elmer) in 50 μL of media was added for an additional 18 hours. The cells were then harvested with a Skatron Cell Harvester (Molecular Devices), transferred to a glass fiber mat, and radioactivity gated for 3H measured using an LKB liquid scintillation counter (Perkin Elmer). The IC50 of the recombinant immunotoxin was calculated with GraphPhad Prism software. As shown in Figure 19, the fold-back format anti-PSMA immunotoxin was 18-30 fold more potent than the bisFv format immunotoxin. Table 7 Schematic of fusion proteins
(G4S)3 (G4S)3 (G4S)3
(E) A-dmDT390- biscFv(J591)
Figure imgf000071_0001
G4S G4S (G4S)3 G4S
(G) A-dmDT390- scfbDb(J591)
Figure imgf000071_0002
Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this pertains. The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon. For example, the following United States Patents and Patent Applications are herein incorporated by reference in their entirety: U.S. Patent No. 6, 103,235; U.S. Patent No. 6, 632,928; U.S. Patent No. 5,916,773; U.S. Patent No. 08,843,409; U.S. Patent No. 6, 319,691; U.S. Patent No. 7, 045,605; U.S. Application No. 11/219,563, U.S. Application No. 10/296,085; U.S. Application No. 09/389,565; and U.S. Application No. 09/959,006.
REFERENCES
1. Nicholls, P. J., et al. (1993) J Biol Chem 268, 5302-5308.
2. Neville, D. J. (1987) Ann N Y Acad Sci 507, 155-1643.
3. Williams, D. P., Parker, K., Bacha, P., Bishai, W., Borowski, M.,Genbauffe, F., Strom, T. B. and Murphy, J. R. (1987) Protein Eng 1,493-498
4. Johnson, V. G. and Youle, R. J. (1989) J Biol Chem 264, 17739-17744
5. Kreitman, R. J., Chaudhary, V. K., Waldmann, T. A., Hanchard, B., Cranston, B., FitzGerald, D. J. and Pastan, I. (1993) Leukemia 7, 553-562
6. Murphy, J. R. (1988) Cancer Treat Res 37, 123-124
7. Laske, D. W., Ilercil, O., Akbasak, A., Youle, R. J. and Oldfield, E. H. (1994) J Neurosurg 80, 520-526
8. Neville, D. J., Scharff, J. and Srinivasachar, K. (1992) J of Controlled Release 24, 133-141 9. Neville, D. J., Scharff, J. and Srinivasachar, K. (1992) Proc Natl Acad Sci U S A 89, 2585-2589
10. Giannini, G., Rappuoli, R. and Ratti, G. (1984) Nucleic Acids Res 12, 4063-4069
11. Chang, T. M. and Neville, D. M. J. (1977) J Biol Chem 252, 1505-1514
12. Neville, D. J., Srinivasachar, K., Stone, R. and Scharff, J. (1989) J Biol Chem 264, 14653-14661
13. Shalaby, M. R., Shepard, H. M., Presta, L., Rodrigues, M. L., Beberley, P. C. L., Feldman, M. and Carter, P. (1992) J Exp Med 175, 217-225
14. Johnson, S. and Bird, R. E. (1991) in Methods in Enzymol, pp.88-98, Academic Press, Inc., San Diego, California
15. Grimont, F. and Grimont, P. A. D. (1991) in Nucleic acid techniques in bacterial systematics, pp. 252, E. A. G. Stackebrandt M. John Wiley and Sons, LTD, West Sussex, England
16. Esworthy, R. S. and Neville, D. M. J. (1984) J Biol Chem 258, 11496-11504
17. Pelchen-Matthews, A., Armes, J. E., Griffiths, G. and Marsh, M. (1991) J Exp Med
173, 575-578
18. Choe, S., Bennett, M. J., Fujii, G., Curmi, P. M., Kantardjieff, K. A., Collier, R. J. and Eisenberg, D. (1992) Nature 357, 216-222
19. LeMaistre, C. F., Meneghetti, C, Rosenblum, M., Reuben, J., Parker, K., Shaw, J., Deisseroth, A., Woodworth, T. and Parkinson, D. R. (1992) Blood 79, 2547-2554
20. Platanias, L. C, et al. (1994) Leuk Lymphoma 14, 257-262
21. Higashi, K., Asada, H., Kurata, T., Ishikawa, K., Hayami, M., Spriatna, Y., Sutarman, Y. and Yamanishi, K. (1989) J Gen Virol 70,3171-3176
22. Youle, R. J. and Neville, D. M. J. (1982) J Biol Chem 257, 1598-1601
23. Williams, D. P., Snider, C. E., Strom, T. B. and Murphy, J. R.(1990) J Biol Chem 265, 11885-11889
24 Parlevliet et al. (1992) Transplant Int; 5 :234-246.
25 Cosimi et al. (1981) Transplantation;32:535-9.
26 Jaffers et al. (1986) Transplantation;41 :572-8.
27 Abramowicz et al. (1989) Transplantation; 47:606-8.
28 Burns et al. (1982) J Immunol;129:1451-7.
29 Parren et al. (1991) Res Immunol; 142:749-63. Waid et al. (1991) Transplant Proc; 23:1062-5. Khazaeli et al. (1994) J Immunotherapy; 15:42-52. Chen C and Okayama H. (1987); MoI Cell Biol 7:2745-52. Slavin-Chiorini et al. (1993) Int J Cancer ; 53:97-103. Rigaut KD, Scharff JE, Neville DM Jr. (1995) Eur J Immunol;25:2077-82. Woodle ES, Thistlethwaite JR, Jolliffe LK, et al. (1992) J Immunol; 148:2756-63. Miller AD, Rosman GJ. (1989) BioTechniques 7:980-90. Shu LM, Qi CF, Schlom J, Kashmiri SVS (1993) Proc Natl Acad Sci USA;90:7995-9. Mosmann TR, Williamson AR (1980) Cell; 20:283-92. Capon DJ, Chamow SM, Mordenti J, et al. (1989) Nature 337:525-31. Anand NN, Mandal S, MacKenzie CR, et al. (1991) J Bio Chem 266:21874-9. Sitia R, Neuberger M, Alberini CM, et al. (1990) Cell;60:781-90. Alberini CM, Bet P, Milstein C, Sitia R. (1990) Nature 347:485-7. Fra AM, Fragioli C, Finazzi D, Sitia R, Alberini CM (1993) The EMBO Journal; 12:4755-61. Wiersma EJ, Shulman MJ (1995); 154:5265-72. Smith KG, Austyn JM, Hariri G, Beverley PC, Morris PJ ( 1986) Eur J Immunol; 16:478-86. Tax WJ, Hermes FF, Willems RW, Capel PJ, Koene RA (1984) J Immunol;133:l 185-9. Lynch, RG, Sandor M., Metzger H, ed. Washington DC: American Society for Microbiology 1990:305-34. Moretta I, Webb SR, Grossi CE, Lydyard M, Cooper MD. (1977) J Exp Med; 146: 184-200. Ferrarini M, Moretta L, Mingari MC, Tonda P, Pernis B. (1976) Eur J Immunol;6: 520-1. Mathur A, Lynch RG, Kohler G (1988);J Immunol; 140:143-7. Pricop L, Rabinowich H, Morel PA, Sulica A, Whiteside TL, Herberman RB (1993) J Immunol; 151:3018-29. Emara M, Sanfilippo F (1992) Cell Immunol; 144:143-54. Akari, H., Mori, K., Terao, K., Otani, L, Fukasawa, M., Mukai, R., and Yoshikawa, Y., (1996) In vitro immortalization of Old World monkey T lymphocytes with Herpesvirus saimiri: its susceptibility to infection with simian immunodeficiency viruses. Virology 218, 382-388. Contreras, J. L., et al. (2003) Stable α- and β- islet cell function after tolerance induction to pancreatic islet allografts in diabetic primates. Am. J. Transplant. 3, 128-138. Fechner, J. H. et al. (1997) Split tolerance induced by immunotoxin in a rhesus kidney allograft model. Transplantation 63, 1339-1345. Hexham, J. M., Dudas, D., Hugo, R., Thompson, J., King, V., Dowling, C. Neville, D. M. Jr., Digan, M. E., and Lake, P. (2001) Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins. MoI. Immunol. 38, 397-408. Holliger, P., Prospero, T., and Winter, G. (1993) "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sd. U. S. A. 90, 6444-6448. Hu, H., Stavrou, S., Baker, B. C, Tornatore, C, Scharff, J., Okunieff, P., and Neville, D. M. Jr. (1997) Depletion of T lymphocytes with immunotoxin retards the progress of experimental allergic encephalomyelitis in rhesus monkeys. Cell. Immunol. 177, 26-34. Huang, B. C, Davern, S., Kennel, S. J. (2006) Mono and bivalent binding of a scFv and covalent diabody to murine laminin-1 using radioiodinated proteins and SPR measurements: effects on tissue retention in vivo. J. Immunol. Methods 313, 149- 160. Kontermann, R. E., and Muller, R. (1999) Intracellular and cell surface displayed single-chain diabodies. J. Immunol. Methods 226, 179-188. Krauss, J., Arndt, M. A. E., Vu, B. K., Newton, D. L., Seeber, S., and Rybak, S. M. (2005) Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein. Biochem. Biophys. Res. Commun. 331, 595-602. Le Gall, F., Reusch, U., Little, M., and Kipriyanov, S. M. (2004) Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng. Des. SeI. 17, 357- 366. Liu Y. Y., Woo J. H. and Neville D. M. Jr. (2005) Over expression of an anti-CD3 immunotoxin increases the expression and secretion of the molecular chaperone Bip/Kar2p from Pichia pas toris. Applied and Experimental Microbiology 71, 5332- 5340 Liu Y. Y., Wang, Z., Thomas, J., Goodwin, K. J., Stavrou, S., Neville, D. M. Jr. (2007)
Polymorphisms of CD3e in cynomolgus and rhesus monkeys and their relevance to anti-CD3 antibodies and immunotoxins. Immunol. Cell Biol. Feb 27; [Epub ahead of print] Madshus, I. H., Olsnes, S., and Stenmark, H. (1992) Membrane translocation of diphtheria toxin carrying passenger protein domains. Infect. Immun. 60, 3296-3302.
66 Marano, N., Holowka, D. and Baird, B. (1989) Bivalent binding of an antibody to Jurkat cells induces association of the T cell receptor complex with the cytoskeleton. J Immunol. 143, 931-938.
67 Neville, D. M. Jr., Scharff, J., Rigaut, K., Hu, H., Shiloach, J., Slingerland, W., and Jonker, M. (1996) A new reagent for the induction of T cell depletion, anti-CD3- CRM9. J. Immunother. Emphasis. Tumor Immunol. 19, 85-92.
68 Nielsen, U. B., Adams, G. P., Weiner, L. M., and Marks, J. D. (2000) Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res. 60, 6434-6440.
69 Perisic, O., Webb, P. A., Holliger, P., Winter, G., and Williams, R. L. (1994) Crystal structure of a diabody, a bivalent antibody fragment. Structure 2, 1217-1226.
70 Rao, J., Lahiri, J., Isaacs, L., Weis, R. M., Whitesides, G. M. (1998) A trivalent system from vancomycin.D-ala-D-Ala with higher affinity than avidin.biotin. Science 280, 708-711.
71 Thomas, J. M., et al. (1997) Preclinical studies of allograft tolerance in rhesus monkeys. Transplantation 64, 124-135;
72 Thompson, J., et al. (2001) Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion. Protein Eng. 14, 1035-1041.
73 Wang, Z., et al. (2007) Improvement of a recombinant anti-monkey CD3 diphtheria toxin based immunotoxin by yeast display affinity maturation of the scFv. Bioconjug. Chem. 18, 947-955.
SEQUENCES
(1) Amino acid sequence of A-dmDT390-foldback-bisFv(J591) (SEO ID NO:12)
1-391 : A-dmDT390
392-393: amino acid residues corresponding to Ncol restriction site
394-500: first VL of J591 antibody
501-505: GGGGS linker
506-620: first VH of J591 antibody
621-635: (G4S)3 linker
636-742: second VL of J591 antibody
743-747: GGGGS linker
748-862: second VH of J591 antibody
394-862: fold-back-bisFv(J591)
1 AGADDWDSS KSFVMENFAS YHGTKPGYVD SIQKGIQKPK SGTQGNYDDD WKGFYSTDNK 60
61 YDAAGYSVDN ENPLSGKAGG WKVTYPGLT KVLALKVDNA ETIKKELGLS LTEPLMEQVG 120
121 TEEFIKRFGD GASRWLSLP FAEGSSSVEY INNWEQAKAL SVELEINFET RGKRGQDAMY 180 181 EYMAQACAGN RVRRSVGSSL SCINLDWDVI RDKTKTKIES LKEHGPIKNK MSESPAKTVS 240 241 EEKAKQYLEE FHQTALEHPE LSELKTVTGT NPVFAGANYA AWAVNVAQVI DSETADNLEK 300 301 TTAALSILPG IGSVMGIADG AVHHNTEEIV AQSIALSSLM VAQAIPLVGE LVDIGFAAYN 360 361 FVESIINLFQ WHNSYNRPA YSPGHKTQPF LPWDIVMTQS HKFMSTSVGD RVSIICKASQ 420 421 DVGTAVDWYQ QKPGQSPKLL IYWASTRHTG VPDRFTGSGS GTDFTLTITN VQSEDLADYF 480 481 CQQYNSYPLT FGAGTMLDLK GGGGSEVQLQ QSGPELKKPG TSVRISCKTS GYTFTEYTIH 540 541 WVKQSHGKSL EWIGNINPNN GGTTYNQKFE DKATLTVDKS SSTAYMELRS LTSEDSAVYY 600 601 CAAGWNFDYW GQGTTLTVSS GGGGSGGGGS GGGGSDIVMT QSHKFMSTSV GDRVSIICKA 660 661 SQDVGTAVDW YQQKPGQSPK LLIYWASTRH TGVPDRFTGS GSGTDFTLTI TNVQSEDLAD 720 721 YFCQQYNSYP LTFGAGTMLD LKGGGGSEVQ LQQSGPELKK PGTSVRISCK TSGYTFTEYT 780 781 IHWVKQSHGK SLEWIGNINP NNGGTTYNQK FEDKATLTVD KSSSTAYMEL RSLTSEDSAV 840 841 YYCAAGWNFD YWGQGTTLTV SS
(2) DNA sequences of A-dmDT390-foldback-bisFv(J59n (SEQ K) NO: 13)
1-1173: DNA sequence coding for A-dmDT390
1174-1179: Ncol restriction enzyme site
1180-2592: DNA sequence coding for fold-back-bisFv(J591)
2593-2595: Stop codon i GCTGGTGCTG ACGACGTCGT CGACTCCTCC AAGTCCTTCG TCATGGAGAA
51 CTTCGCTTCC TACCACGGGA CCAAGCCAGG TTACGTCGAC TCCATCCAGA
101 AGGGTATCCA GAAGCCAAAG TCCGGCACCC AAGGTAACTA CGACGACGAC
151 TGGAAGGGGT TCTACTCCAC CGACAACAAG TACGACGCTG CGGGATACTC
201 TGTAGATAAT GAAAACCCGC TCTCTGGAAA AGCTGGAGGC GTGGTCAAGG
251 TCACCTACCC AGGTCTGACT AAGGTCTTGG CTTTGAAGGT CGACAACGCT
301 GAGACCATCA AGAAGGAGTT GGGTTTGTCC TTGACTGAGC CATTGATGGA
351 GCAAGTCGGT ACCGAAGAGT TCATCAAGAG ATTCGGTGAC GGTGCTTCCA
401 GAGTCGTCTT GTCCTTGCCA TTCGCTGAGG GTTCTTCTAG CGTTGAATAT
451 ATTAATAACT GGGAACAGGC TAAGGCTTTG TCTGTTGAAT TGGAGATTAA
501 CTTCGAAACC AGAGGTAAGA GAGGTCAAGA TGCGATGTAT GAGTATATGG
551 CTCAAGCCTG TGCTGGTAAC AGAGTCAGAC GTTCTGTTGG TTCCTCTTTG
601 TCCTGTATCA ACCTAGACTG GGACGTCATC AGAGACAAGA CTAAGACCAA
651 GATCGAGTCT TTGAAAGAGC ATGGCCCAAT CAAGAACAAG ATGTCCGAAT
701 CCCCCGCTAA GACCGTCTCC GAGGAAAAGG CCAAGCAATA CCTAGAAGAG
751 TTCCACCAAA CCGCCTTGGA GCATCCTGAA TTGTCAGAAC TTAAAACCGT
801 TACTGGGACC AATCCTGTAT TCGCTGGGGC TAACTATGCG GCGTGGGCAG
851 TAAACGTTGC GCAAGTTATC GATAGCGAAA CAGCTGATAA TTTGGAAAAG
901 ACAACTGCTG CTCTTTCGAT ACTTCCTGGT ATCGGTAGCG TAATGGGCAT
951 TGCAGACGGT GCCGTTCACC ACAATACAGA AGAGATAGTG GCACAATCCA
1001 TCGCTTTGTC CTCTTTGATG GTTGCTCAAG CTATCCCATT GGTCGGTGAG
1051 TTGGTTGACA TCGGTTTCGC TGCCTACAAC TTCGTCGAGT CCATCATCAA
1101 CTTGTTCCAA GTCGTCCACA ACTCCTACAA CCGTCCGGCT TACTCCCCAG
1151 GTCACAAGAC CCAACCATTC TTGCCATGGC CATGGGATAT TGTTATGACT
1201 CAATCTCATA AGTTCATGTC CACTTCCGTC GGTGATAGAG TCTCTATTAT
1251 TTGTAAGGCT TCTCAGGACG TCGGTACTGC TGTTGATTGG TATCAACAAA
1301 AGCCAGGTCA ATCTCCAAAG TTGTTGATTT ACTGGGCTTC TACTAGACAT
1351 ACTGGTGTTC CAGATAGATT CACTGGTTCT GGTTCTGGTA CTGATTTCAC
1401 CTTGACTATC ACTAACGTCC AGTCTGAGGA CTTGGCTGAC TACTTCTGCC
1451 AGCAGTACAA CTCTTACCCA TTGACTTTCG GTGCTGGAAC CATGTTGGAT
1501 TTGAAGGGTG GAGGTGGATC TGAGGTCCAG TTGCAGCAAT CTGGACCAGA
1551 GTTGAAGAAG CCAGGTACTT CTGTCAGAAT TTCTTGTAAG ACTTCTGGTT
1601 ACACTTTCAC TGAGTACACT ATTCATTGGG TTAAGCAATC TCATGGTAAG
1651 TCTTTGGAGT GGATTGGAAA CATCAACCCA AACAACGGTG GAACTACCTA
1701 CAACCAAAAG TTCGAGGATA AGGCTACTTT GACTGTTGAT AAGTCTTCTT
1751 CCACTGCTTA CATGGAATTG AGATCCTTGA CCTCTGAGGA TTCCGCTGTC
1801 TACTACTGTG CTGCTGGTTG GAACTTCGAT TACTGGGGAC AAGGAACCAC
1851 TTTGACTGTT TCCTCTGGAG GTGGCGGGTC TGGTGGAGGC GGATCCGGAG
1901 GTGGCGGATC TGATATTGTT ATGACTCAAT CTCATAAGTT CATGTCCACT
1951 TCCGTCGGTG ATAGAGTCTC TATTATTTGT AAGGCTTCTC AGGACGTCGG
2001 TACTGCTGTT GATTGGTATC AACAAAAGCC AGGTCAATCT CCAAAGTTGT 2051 TGATTTACTG GGCTTCTACT AGACATACTG GTGTTCCAGA TAGATTCACT 2101 GGTTCTGGTT CTGGTACTGA TTTCACCTTG ACTATCACTA ACGTCCAGTC 2151 TGAGGACTTG GCTGACTACT TCTGCCAGCA GTACAACTCT TACCCATTGA
2201 CTTTCGGTGC TGGAACCATG TTGGATTTGA AGGGTGGAGG TGGATCTGAG 2251 GTCCAGTTGC AGCAATCTGG ACCAGAGTTG AAGAAGCCAG GTACTTCTGT
2301 CAGAATTTCT TGTAAGACTT CTGGTTACAC TTTCACTGAG TACACTATTC
2351 ATTGGGTTAA GCAATCTCAT GGTAAGTCTT TGGAGTGGAT TGGAAACATC
2401 AACCCAAACA ACGGTGGAAC TACCTACAAC CAAAAGTTCG AGGATAAGGC 2451 TACTTTGACT GTTGATAAGT CTTCTTCCAC TGCTTACATG GAATTGAGAT 2501 CCTTGACCTC TGAGGATTCC GCTGTCTACT ACTGTGCTGC TGGTTGGAAC 2551 TTCGATTACT GGGGACAAGG AACCACTTTG ACTGTTTCCT CTTAA
C207 scFv Diabody DNA sequence [G4S-VL-G4S-VH-(G4S)3-VL-G4S-VH] (SEQ ID NO:14)
GGTGGAGGTGGCTCTGACTTTGTTATGTCTCAATCTCCATCCTCCTTGGCTGTTTCTGTTGGTGAG AGGGTTACTATGTCTTGTAAGTCCTCT1CAATCITTGTTGTACTTTTCTAACCGAAAGAACTACTTG GCTTGGTACCAACAAAAGCCAGGTCAATCTCCTAAGTTGTTGATTAACTGGGCTTCCACCAGAGA ATCTGGTGTCCCTGACAGATTCACTGGTTCTGGTTCTAGAACTGACTTCACTTTGACCATCTCTTC TGTTAAGGCTGAAGACTTGGCT1GTTTACTTCTGTCAACAATTCTACTCTTACCCTCCAACTTTCGG
TGGTGGTACCAAGTTGGAAATCAAGGGTGGCGGAGGTTCCCAAGTCCAATTGCAACAATCTGAA GCTGAATTGGCTAGACCTGGTGCTTCTGTTAAGATGTCCTGTAAGGCTTCTGGTTACACCTTCACT GACTACACTATCCACTGGTTGAGGCAAAAACCTGGTCAAGGTTTGGACTGGATTGGTTACTTCAA CCCTTCTTCTGGATCTACTGAATACAACAGAAAGTTCAAGGACAGAACCATTTTGACTGCTGACA
GATCCT1CTACCACTGTTTACATGCAA1TTGTCTTCTTTGACTTCTGAGGACTCTGCTGTCTACTACT
GTGCTAGAAAGGGTGAGAAGTTGTTGGGTAACAGATACTGGTACTTCGACGTCTGGGGTGCTGGT
ACCTCTGTCACCGTCTCCTCTGGAGGCGGAGGCAGCGGAGGCGGTGGATCCGGAGGGGGAGGCT
CGGACTTTGTTATGTCTCAATCTCCATCCTCCTTGGCTGTTTCTGTTGGTGAGAGGGTTACTATGT
CTTGTAAGTCCTCTCAATCTTTGTTGTACTTTTCTAACCGAAAGAACTACTTGGCTTGGTACCAAC
AAAAGCCAGGTCAATCTCCTAAGTTGTTGATTAACTGGGCTTCCACCAGAGAATCTGGTGTCCCT
GACAGATTCACTGGTTCTGGTTCTAGAACTGACTTCACTTTGACCATCTCTTCTGTTAAGGCTGAA
GACTTGGCTGTTTACTTCTGTCAACAATTCTACTCTTACCCTCCAACTTTCGGTGGTGGTACCAAG
TTGGAAATCAAGGGTGGCGGAGGTTCCCAAGTCCAATTGCAACAATCTGAAGCTGAATTGGCTAG
ACCTGGTGCTTCTGTTAAGATGTCCTGTAAGGCTTCTGGTTACACCTTCACTGACTACACTATCCA
CTGGTTGAGGCAAAAACCTGGTCAAGGTTTGGACTGGATTGGTTACTTCAACCCTTCTTCTGGAT
CTACTGAATACAACAGAAAGTTCAAGGACAGAACCATTTTGACTGCTGACAGATCCTCTACCACT
GTTTACATGCAATTGTCTTCTTTGACTTCTGAGGACTCTGCTGTCTACTACTGTGCTAGAAAGGGT
GAGAAGTTGTTGGGTAACAGATACTGGTACTTCGACGTCTGGGGTGCTGGTACCTCTGTCACCGT
CTCCTCT
C207 scFv Diabody AA sequence [G4S-VL-G4S-VH-(G4S)3-VL-G4S-VH] (SEQ ID
NO: 15)
GGGGSDFVMSQSPSSLAVSVGERVTMSCKSSQSLLYFSNRKJ^TVTAWYQQKPGQSPKLLINWASTRES GVPDRFTGSGSRTDFTLTISSVKAEDLAVYFCQQFYSYPPTFGGGTKLEIKGGGGSQVQLQQSEAELA RPGASVKMSCKASGYTFTD YTIHWLRQKPGQGLD WIGYFNPSSGSTEYNRKFKDRTILTADRSSTTV YMQLSSLTSEDSAVYYCARKGEKLLGNRYWYFD VWGAGTSVTVSSGGGGSGGGGSGGGGSDFVMS QSPSSLAVSVGERVTMSCKSSQSLLYFSNRKNYLAWYQQKPGQSPKLLINWASTRESGVPDRFTGSGS RTDFTLTISSVKAEDLAVYFCQQFYSYPPTFGGGT1KLEKGGGGSQVQLQQSEAELARPGASVKMSCK ASGYTFTDYTIHWLRQKPGQGLDWIGYFNPSSGSTEYNRKFKDRTILTADRSSTTVYMQLSSLTSEDS AVYYCARKGEKLLGNRYWYFDVWGAGTSVTVSS

Claims

What is claimed is:
1. An immunotoxin, comprising a mutant diphtheria toxin moiety linked to a targeting moiety, wherein the targeting moiety is a single chain variable region diabody.
2. The immunotoxin of claim 1, wherein the diabody is a fold-back diabody.
3. The immunotoxin of claim 1 , wherein the diabody is bivalent.
4. The immunotoxin of claim 1 , wherein the diabody is bispecific.
5. The immunotoxin of claim 1, wherein the immunotoxin is a fusion protein.
6. The immunotoxin of claim 1, wherein the diabody comprises the anti-CD3 VLVH region.
7. The immunotoxin of claim 6, wherein the diabody anti-CD3 comprise the UCHTl VLVH region.
8. The immunotoxin of claim 6, wherein the diabody anti-CD3 comprise the FNl 8 clone C207 VLVH region.
9. The immunotoxin of claim 1, wherein the diabody comprises the anti-PSMA VLVH region.
10. The immunotoxin of claim 9, wherein the diabody anti-PSMA comprise the J591 VLVH region.
11. The immunotoxin of claim 1, wherein the toxin moiety is a truncation mutant.
12. The immunotoxin of claim 11, wherein the truncation mutant comprises a deletion of 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, or 150 C-terminal amino acids of the full length diphtheria toxin.
13. The immunotoxin of claim 11 , wherein the immunotoxin is A- dmDT390scfbDb(J591).
14. The immunotoxin of claim 13, wherein the immunotoxin is A- dmDT390scfbDb(J591) where the furin site amino acid sequence cleavage site RVRRSV has been replaced with the MMP cleavage site GPLGMLSQ.
15. The immunotoxin of claim 13, wherein the immunotoxin is A- dmDT390scfbDb(J591) where the furin cleavage site amino acid sequence RVRRSV has been replaced with the PSA cleavage site HSSKLQ.
16. The immunotoxin of claim 11, wherein the immunotoxin is A- dmDT390scfbDb(UCHTl).
17. The immunotoxin of claim 11, wherein the immunotoxin is A- dmDT390scfbDb(C207).
18. An immunotoxin fusion protein comprising a diphtheria toxin moiety and a targeting moiety, wherein the targeting moiety is a diabody, wherein the sequence from the amino terminus from left to right is toxin moiety, L1, VL1, L2, VHI, L3, VL2, L4, VH2, wherein the toxin moiety comprises a truncation mutation, Li, L2, and L4 are (G4S) linkers, and VL and VH are the variable light and heavy domains.
19. The immunotoxin of claim 18, wherein the diabody is a fold-back diabody.
20. The immunotoxin of claim 18, wherein L3 is a (G4S)3 linker.
21. The immunotoxin of claim 18, wherein the VLI and VHI comprise the VLVH region of an anti-CD3 antibody.
22. The immunotoxin of claim 21 , wherein the anti-CD3 antibody is UCHTl .
23. The immunotoxin of claim 21, wherein the anti-CD3 antibody is C207.
24. The immunotoxin of claim 18, wherein the Vn and VHI comprise the VLVH region of an anti-PSMA antibody.
25. The immunotoxin of claim 24, wherein the anti-PSMA antibody is J591.
26. The immunotoxin of claim 18, wherein VLI and VH I are the same as VL2 and VH2.
27. The immunotoxin of claim 18, wherein the toxin moiety is a truncation mutant.
28. The immunotoxin of claim 27, wherein the truncation mutant comprises a deletion of 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, or 150, C-terminal amino acids of the full length diphtheria toxin.
29. The immunotoxin of claim 18, wherein the immunotoxin is A- dmDT390scfbDb(C207).
30. The immunotoxin of claim 18, wherein the immunotoxin is A- dmDT390scfbDb(UCHT 1 ).
31. The immunotoxin of claim 18, wherein the immunotoxin is A- dmDT390scfbDb(J591).
32. A method of treating a cancer in a subject comprising administering to the subject the immunotoxin of claim 1, or a derivative thereof, under conditions such that the cancer is treated.
33. The method of claim 32, wherein the diabody is an anti-PSMA diabody.
34. The method of claim 33, wherein the diabody comprises the VLVH regions of J591.
35. The method of claim 32, wherein the toxin moiety of the immunotoxin is a truncation mutant.
36. The method of claim 35, wherein the truncation mutant comprises a deletion of 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, or 150 C-terminal amino acids of the full length diphtheria toxin.
37. The method of claim 32, wherein the immunotoxin is A-dmDT390scfbDb(J591).
38. The method of claim 32, wherein the cancer is prostate cancer.
39. The method of claim 32, wherein the cancer is breast cancer.
40. A method of treating an autoimmune disease in an animal comprising administering to the animal the immunotoxin of claim 1, or derivatives thereof, under conditions such that the autoimmune disease is treated.
41. A method of treating T cell leukemias or lymphomas in an animal comprising administering to the animal the immunotoxin of claim 1, or derivatives thereof, under conditions such that the T cell leukemias or lymphomas are treated.
42. The method of claim 41, wherein the diabody is an anti-CD3 diabody.
43. The method of claim 42, wherein the diabody comprises the VLVH regions of UCHTl.
44. The method of claim 41 , wherein the toxin moiety of the immunotoxin is a truncation mutant.
45. The method of claim 44, wherein the truncation mutant comprises a deletion of 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, or 150 C-terminal amino acids of the full length diphtheria toxin.
46. The method of claim 41, wherein the immunotoxin is A-dmDT390scfbDb(UCHTl).
47. A method of treating acquired immunodeficiency syndrome in an animal, comprising administering to the animal the immunotoxin of claim 1, or derivatives thereof under conditions such that the acquired immunodeficiency syndrome is treated.
48. A method of treating graft- versus-host disease in an animal, comprising administering to the animal the immunotoxin of claim 1, or derivatives thereof under conditions such that the graft-versus-host disease is treated.
49. A method of inducing immune tolerance to a graft in a recipient, comprising:
(a) administering to the recipient the immunotoxin of claim 1, thereby reducing the recipient's T-cell population; and
(b) administering to the recipient an agent that inhibits dendritic cell maturation.
50. A method of inhibiting a rejection response in a primate recipient to foreign mammalian graft comprising the steps of: a) administering to the recipient an anti- CD3-DT immunotoxin, wherein the immunotoxin comprises scfbDb-DT, so as to reduce the recipient's T-cell lymphocyte population by at least 80%, as compared to the recipient's T-cell lymphocyte population prior to administration of the immuno toxin; and b) transplanting the graft into the recipient, such that a rejection response by the recipient to the graft is inhibited.
51. The method of any one of claim 48-50, further comprising administering an immunosuppressive agent.
52. The method of claim 51, wherein the immunosuppressive agent is cyclosporin.
53. The method of claim 51, wherein the immunosuppressive agent is mycophenolate mofetil.
54. The method of claim 51 , wherein the immunosuppressive agent is rituximab.
55. The method of claim 51, wherein the immunosuppressive agent is rapamycin.
56. The method of claim 51, wherein the immunosuppressive agent inhibits dendritic cell maturation.
57. The method of claim 51, wherein the agent that inhibits dendritic cell maturation is an inhibitor of nuclear translocation of NFKB.
58. The method of claim 57, wherein the inhibitor of nuclear translocation of NFKB is deoxyspergualin.
59. The method of claim 57, wherein the inhibitor of nuclear translocation of NFKB is bortezomib.
60. The method of claim 57, wherein the agent that inhibits dendritic cell maturation activates one or more NF-AT dependent Th2 cytokines.
61. The method of claim 57, wherein the agent that inhibits dendritic cell maturation inhibits one or more NFKB dependent ThI cytokines.
62. The method of claim 57, wherein the inhibitor of dendritic cell maturation is a soluble IL- 17 receptor Fc fusion protein.
63. The method of claim 57, wherein the inhibitor of dendritic cell maturation is a glucocorticoid.
64. The method of claim 57, wherein the inhibitor of dendritic cell maturation is a blocker of tumor necrosis factor alpha binding.
65. The method of claim 57, wherein the inhibitor of dendritic cell maturation is a blocker of granulocyte macrophage colony stimulating factor binding.
66. The method of claim 57, wherein the inhibitor of dendritic cell maturation is a blocker of EL-12p70 binding.
67. The method of claim 57, wherein the inhibitor of dendritic cell maturation is a blocker of EL- 1/3 binding.
68. The method of claim 57, wherein the inhibitor of dendritic cell maturation is anti- CD 154 ligand.
69. The method of claim 51, wherein the immunosuppressant is administered beginning from about 0 to 6 hours before the transplanting step.
70. The method of claim 56, wherein the agent that inhibits dendritic cell maturation is administered to the recipient at least once.
71. The method of claim 51, further comprising administering to a transplant donor, prior to harvesting the transplant, an agent that inhibits dendritic cell maturation.
72. The method of any one of claims 48-50, wherein the graft comprises donor cells, tissue or organ,
73. The method of claim 72, wherein the donor cells, tissue, or organ is selected from the group consisting of kidney, liver, heart, pancreas, lung, skin, and isolated cell transplants of pancreatic islets, hepatocytes, stem cell, and differentiated precursors cells.
74. The method of any one of claims 48-50, wherein the graft is from a cadaver.
75. The method of any one of claims 48-50, wherein the graft is allogeneic.
76. The method of any one of claims 48-50, wherein the graft is xenogeneic.
PCT/US2008/009321 2007-08-01 2008-08-01 A fold-back diabody diphtheria toxin immunotoxin and methods of use WO2009017823A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP08794978A EP2187971A2 (en) 2007-08-01 2008-08-01 A fold-back diabody diphtheria toxin immunotoxin and methods of use
CA2695382A CA2695382A1 (en) 2007-08-01 2008-08-01 A fold-back diabody diphtheria toxin immunotoxin and methods of use
US12/671,629 US9364557B2 (en) 2007-08-01 2008-08-01 Fold-back diabody diphtheria toxin immunotoxin and methods of use
AU2008282729A AU2008282729B2 (en) 2007-08-01 2008-08-01 A fold-back diabody diphtheria toxin immunotoxin and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95341607P 2007-08-01 2007-08-01
US60/953,416 2007-08-01

Publications (2)

Publication Number Publication Date
WO2009017823A2 true WO2009017823A2 (en) 2009-02-05
WO2009017823A3 WO2009017823A3 (en) 2009-03-19

Family

ID=40193537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/009321 WO2009017823A2 (en) 2007-08-01 2008-08-01 A fold-back diabody diphtheria toxin immunotoxin and methods of use

Country Status (5)

Country Link
US (1) US9364557B2 (en)
EP (1) EP2187971A2 (en)
AU (1) AU2008282729B2 (en)
CA (1) CA2695382A1 (en)
WO (1) WO2009017823A2 (en)

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011020783A3 (en) * 2009-08-17 2011-04-28 Roche Glycart Ag Targeted immunoconjugates
WO2011069019A3 (en) * 2009-12-02 2012-07-05 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
CN103025759A (en) * 2010-04-01 2013-04-03 安进研发（慕尼黑）股份有限公司 Cross-species-specific psmaxcd3 bispecific single chain antibody
WO2013059885A3 (en) * 2011-10-28 2014-07-17 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
US8951737B2 (en) 1996-05-06 2015-02-10 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US9605061B2 (en) 2010-07-29 2017-03-28 Xencor, Inc. Antibodies with modified isoelectric points
US9636334B2 (en) 2014-05-01 2017-05-02 Teva Pharmaceuticals Australia Pty Ltd Combination of lenalidomide and polypeptide construct, and uses thereof
US9650446B2 (en) 2013-01-14 2017-05-16 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US9745381B2 (en) 2012-05-18 2017-08-29 Scott & White Healthcare (Swh) Bispecific scFv immunofusion (BIf)
US9822186B2 (en) 2014-03-28 2017-11-21 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
US9850320B2 (en) 2014-11-26 2017-12-26 Xencor, Inc. Heterodimeric antibodies to CD3 X CD20
US9856327B2 (en) 2014-11-26 2018-01-02 Xencor, Inc. Heterodimeric antibodies to CD3 X CD123
WO2018033749A1 (en) * 2016-08-18 2018-02-22 Polytherics Limited Anti-psma antibodies, uses thereof and conjugates thereof
US9963515B2 (en) 2013-04-29 2018-05-08 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
US10316088B2 (en) 2016-06-28 2019-06-11 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US10392425B2 (en) 2015-02-05 2019-08-27 Molecular Templates, Inc. Multivalent CD20-binding molecules comprising Shiga toxin A subunit effector regions and enriched compositions thereof
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10501543B2 (en) 2016-10-14 2019-12-10 Xencor, Inc. IL15/IL15Rα heterodimeric Fc-fusion proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10517969B2 (en) 2009-02-17 2019-12-31 Cornell University Methods and kits for diagnosis of cancer and prediction of therapeutic value
EP3587454A1 (en) * 2018-06-27 2020-01-01 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
US10526417B2 (en) 2014-11-26 2020-01-07 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US10544199B2 (en) 2014-10-29 2020-01-28 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha 2B variants
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10787518B2 (en) 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10815469B2 (en) 2014-06-11 2020-10-27 Molecular Templates, Inc. Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
EP3842461A1 (en) 2019-12-23 2021-06-30 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
US11225509B2 (en) 2018-04-17 2022-01-18 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A subunit scaffolds
US11242400B2 (en) 2016-09-21 2022-02-08 Aptevo Research And Development Llc CD123 binding proteins and related compositions and methods
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
US11312751B2 (en) 2014-01-27 2022-04-26 Molecular Templates, Inc. MHC class I epitope delivering polypeptides
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
US11358999B2 (en) 2018-10-03 2022-06-14 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
US11365223B2 (en) 2015-05-30 2022-06-21 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
US11389542B1 (en) 2016-12-07 2022-07-19 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
US11406692B2 (en) 2017-01-25 2022-08-09 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, Shiga toxin a subunit effectors and CD8+ t-cell epitopes
US11472890B2 (en) 2019-03-01 2022-10-18 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
US11591401B2 (en) 2020-08-19 2023-02-28 Xencor, Inc. Anti-CD28 compositions
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
WO2012145714A2 (en) 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
US20160145348A1 (en) * 2013-03-14 2016-05-26 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
BR112017021536A2 (en) * 2015-04-06 2018-07-03 Harvard College compositions and methods for nonmyeloablative conditioning
SG10202002577XA (en) 2015-09-21 2020-04-29 Aptevo Res & Development Llc Cd3 binding polypeptides
EA039364B1 (en) * 2015-10-09 2022-01-18 Президент Энд Феллоус Оф Гарвард Колледж Compositions and methods for non-myeloablative conditioning
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP3565535A4 (en) 2017-01-05 2020-12-30 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
WO2019191752A1 (en) * 2018-03-30 2019-10-03 Ohio State Innovation Foundation Methods for pre-conditioning patients for t-cell therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103235A (en) * 1995-10-30 2000-08-15 The United States Of America As Represented By The Department Of Health And Human Services Methods of inducing immune tolerance using immunotoxins
WO2001087982A2 (en) * 2000-05-18 2001-11-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US20040213791A1 (en) * 2001-06-01 2004-10-28 Neil Bander Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2005012495A2 (en) * 2003-08-01 2005-02-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Methods for expression and purification of immunotoxins
US20060020258A1 (en) * 2004-07-20 2006-01-26 Medtronic, Inc. Surgical apparatus with a manually actuatable assembly and a method of operating same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517527B2 (en) 1995-10-30 2009-04-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
CA2452288A1 (en) * 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
AU2004263538B2 (en) * 2003-08-08 2009-09-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
WO2005070456A2 (en) * 2004-01-09 2005-08-04 Millennium Pharmaceuticals, Inc. Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103235A (en) * 1995-10-30 2000-08-15 The United States Of America As Represented By The Department Of Health And Human Services Methods of inducing immune tolerance using immunotoxins
WO2001087982A2 (en) * 2000-05-18 2001-11-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US20040213791A1 (en) * 2001-06-01 2004-10-28 Neil Bander Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2005012495A2 (en) * 2003-08-01 2005-02-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Methods for expression and purification of immunotoxins
US20060020258A1 (en) * 2004-07-20 2006-01-26 Medtronic, Inc. Surgical apparatus with a manually actuatable assembly and a method of operating same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM GEUN-BAE ET AL: "A fold-back single-chain diabody format enhances the bioactivity of an anti-monkey CD3 recombinant diphtheria toxin-based immunotoxin." PROTEIN ENGINEERING, DESIGN & SELECTION : PEDS SEP 2007, vol. 20, no. 9, September 2007 (2007-09), pages 425-432, XP002512188 ISSN: 1741-0126 *
TAKEMURA SHIN-ICHI ET AL: "A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma." CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII MAR 2002, vol. 51, no. 1, March 2002 (2002-03), pages 33-44, XP002512189 ISSN: 0340-7004 *

Cited By (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8951737B2 (en) 1996-05-06 2015-02-10 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US10517969B2 (en) 2009-02-17 2019-12-31 Cornell University Methods and kits for diagnosis of cancer and prediction of therapeutic value
WO2011020783A3 (en) * 2009-08-17 2011-04-28 Roche Glycart Ag Targeted immunoconjugates
US8945571B2 (en) 2009-08-17 2015-02-03 Roche GlyeArt AG Targeted immunoconjugates
JP2013502209A (en) * 2009-08-17 2013-01-24 ロシュ グリクアート アーゲー Targeted immunoconjugate
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN105085681A (en) * 2009-12-02 2015-11-25 伊麦吉纳博公司 J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
EP3511023A1 (en) * 2009-12-02 2019-07-17 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
WO2011069019A3 (en) * 2009-12-02 2012-07-05 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
EP2506876A2 (en) * 2009-12-02 2012-10-10 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
AU2010325969B2 (en) * 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
EP2506876A4 (en) * 2009-12-02 2013-07-31 Imaginab Inc J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
EP3135302A1 (en) * 2009-12-02 2017-03-01 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
CN105085681B (en) * 2009-12-02 2018-12-28 伊麦吉纳博公司 Target the J591 miniantibody and double antibody of human prostate-specific membrane antigen
US11180570B2 (en) 2009-12-02 2021-11-23 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use
CN107090044A (en) * 2010-04-01 2017-08-25 安进研发（慕尼黑）股份有限公司 Cross-species-specific PSMAxCD3 bispecific single-chain antibodies
CN103025759A (en) * 2010-04-01 2013-04-03 安进研发（慕尼黑）股份有限公司 Cross-species-specific psmaxcd3 bispecific single chain antibody
US9605061B2 (en) 2010-07-29 2017-03-28 Xencor, Inc. Antibodies with modified isoelectric points
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EA034989B1 (en) * 2011-10-28 2020-04-15 Тева Фармасьютикал Австралия Пти Лтд Polypeptide construct for use in treating cancer comprising attenuated alpha interferon
JP2015500796A (en) * 2011-10-28 2015-01-08 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド Polypeptide constructs and uses thereof
WO2013059885A3 (en) * 2011-10-28 2014-07-17 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
CN104203982A (en) * 2011-10-28 2014-12-10 特瓦制药澳大利亚私人有限公司 Polypeptide constructs and uses thereof
AU2012327877B2 (en) * 2011-10-28 2017-10-12 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
JP7111669B2 (en) 2011-10-28 2022-08-02 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド Polypeptide constructs and uses thereof
US9611322B2 (en) 2011-10-28 2017-04-04 Teva Pharmaceuticals Australia Pty Ltd Fusions of antibodies to CD38 and attenuated interferon alpha
AU2018200221B2 (en) * 2011-10-28 2020-01-16 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
US10981986B2 (en) 2011-10-28 2021-04-20 Teva Pharmaceuticals Australia Pty Ltd Fusions of antibodies to CD38 and attenuated interferon alpha
JP2020010697A (en) * 2011-10-28 2020-01-23 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド Polypeptide construct and use thereof
US9745381B2 (en) 2012-05-18 2017-08-29 Scott & White Healthcare (Swh) Bispecific scFv immunofusion (BIf)
US10472427B2 (en) 2013-01-14 2019-11-12 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US11718667B2 (en) 2013-01-14 2023-08-08 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10738133B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
US10738132B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9650446B2 (en) 2013-01-14 2017-05-16 Xencor, Inc. Heterodimeric proteins
US11634506B2 (en) 2013-01-14 2023-04-25 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US11814423B2 (en) 2013-03-15 2023-11-14 Xencor, Inc. Heterodimeric proteins
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10287364B2 (en) 2013-03-15 2019-05-14 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11299554B2 (en) 2013-03-15 2022-04-12 Xencor, Inc. Heterodimeric proteins
US9963515B2 (en) 2013-04-29 2018-05-08 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
US11312751B2 (en) 2014-01-27 2022-04-26 Molecular Templates, Inc. MHC class I epitope delivering polypeptides
US12037367B2 (en) 2014-01-27 2024-07-16 Molecular Templates, Inc. MHC class I epitope delivering polypeptides
US12065469B2 (en) 2014-01-27 2024-08-20 Molecular Templates, Inc. De-immunized Shiga toxin a subunit effector polypeptides for applications in mammals
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
US10858451B2 (en) 2014-03-28 2020-12-08 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
US11840579B2 (en) 2014-03-28 2023-12-12 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
US9822186B2 (en) 2014-03-28 2017-11-21 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
US11253591B2 (en) 2014-05-01 2022-02-22 Teva Pharmaceuticals Australia Pty Ltd. Combination of lenalidomide and polypeptide construct, and uses thereof
US10232041B2 (en) 2014-05-01 2019-03-19 Teva Pharmaceuticals Pty Ltd Combination of lenalidomide and polypeptide construct, and uses thereof
US9636334B2 (en) 2014-05-01 2017-05-02 Teva Pharmaceuticals Australia Pty Ltd Combination of lenalidomide and polypeptide construct, and uses thereof
US10815469B2 (en) 2014-06-11 2020-10-27 Molecular Templates, Inc. Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties
US11319356B2 (en) 2014-10-29 2022-05-03 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha 2B variants
US10544199B2 (en) 2014-10-29 2020-01-28 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha 2B variants
US10913803B2 (en) 2014-11-26 2021-02-09 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10889653B2 (en) 2014-11-26 2021-01-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10526417B2 (en) 2014-11-26 2020-01-07 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US9850320B2 (en) 2014-11-26 2017-12-26 Xencor, Inc. Heterodimeric antibodies to CD3 X CD20
US11225528B2 (en) 2014-11-26 2022-01-18 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US11945880B2 (en) 2014-11-26 2024-04-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US11352442B2 (en) 2014-11-26 2022-06-07 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US11673972B2 (en) 2014-11-26 2023-06-13 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US9856327B2 (en) 2014-11-26 2018-01-02 Xencor, Inc. Heterodimeric antibodies to CD3 X CD123
US11859011B2 (en) 2014-11-26 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US11111315B2 (en) 2014-11-26 2021-09-07 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
US11104707B2 (en) 2015-02-05 2021-08-31 Molecular Templates, Inc. Multivalent CD20-binding molecules comprising Shiga toxin a subunit effector regions and enriched compositions thereof
US10392425B2 (en) 2015-02-05 2019-08-27 Molecular Templates, Inc. Multivalent CD20-binding molecules comprising Shiga toxin A subunit effector regions and enriched compositions thereof
US11248061B2 (en) 2015-02-05 2022-02-15 Molecular Templates, Inc. Multivalent CD20-binding molecule comprising Shiga toxin A subunit effector polypeptides and enriched compositions thereof
US11091548B2 (en) 2015-03-05 2021-08-17 Xencor, Inc. Modulation of T cells with bispecific antibodies and Fc fusions
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
US11365223B2 (en) 2015-05-30 2022-06-21 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
US11623957B2 (en) 2015-12-07 2023-04-11 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
US11236170B2 (en) 2016-06-14 2022-02-01 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US11492407B2 (en) 2016-06-14 2022-11-08 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US10787518B2 (en) 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US10316088B2 (en) 2016-06-28 2019-06-11 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US11225521B2 (en) 2016-06-28 2022-01-18 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US12054545B2 (en) 2016-06-28 2024-08-06 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
JP7039554B2 (en) 2016-08-18 2022-03-22 ポリセリックス・リミテッド Anti-PSMA antibody, its use and its conjugate
US11059903B2 (en) 2016-08-18 2021-07-13 Polytherics Limited Anti-PSMA antibodies, uses thereof and conjugates thereof
JP2019535232A (en) * 2016-08-18 2019-12-12 ポリセリックス・リミテッド Anti-PSMA antibodies, uses thereof and conjugates thereof
CN110049999B (en) * 2016-08-18 2023-12-19 阿布泽纳(英国)有限公司 anti-PSMA antibodies, uses thereof, and conjugates thereof
EP4403226A3 (en) * 2016-08-18 2024-10-16 Abzena (UK) Limited Anti-psma antibodies, uses thereof and conjugates thereof
JP2022084715A (en) * 2016-08-18 2022-06-07 ポリセリックス・リミテッド Anti-psma antibodies, uses thereof and conjugates thereof
WO2018033749A1 (en) * 2016-08-18 2018-02-22 Polytherics Limited Anti-psma antibodies, uses thereof and conjugates thereof
JP7486538B2 (en) 2016-08-18 2024-05-17 ポリセリックス・リミテッド Anti-PSMA antibodies, uses thereof and conjugates thereof
CN110049999A (en) * 2016-08-18 2019-07-23 宝力泰锐克斯有限公司 Anti- PSMA antibody, its purposes and its conjugate
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11242400B2 (en) 2016-09-21 2022-02-08 Aptevo Research And Development Llc CD123 binding proteins and related compositions and methods
US11939392B2 (en) 2016-09-21 2024-03-26 Aptevo Research And Development Llc CD123 binding proteins and related compositions and methods
US10550185B2 (en) 2016-10-14 2020-02-04 Xencor, Inc. Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments
US10501543B2 (en) 2016-10-14 2019-12-10 Xencor, Inc. IL15/IL15Rα heterodimeric Fc-fusion proteins
US11389542B1 (en) 2016-12-07 2022-07-19 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
US11857628B2 (en) 2016-12-07 2024-01-02 Molecular Templates, Inc. Shiga toxin A subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
US11406692B2 (en) 2017-01-25 2022-08-09 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, Shiga toxin a subunit effectors and CD8+ t-cell epitopes
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US11225509B2 (en) 2018-04-17 2022-01-18 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A subunit scaffolds
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
WO2020002015A1 (en) 2018-06-27 2020-01-02 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
EP3587454A1 (en) * 2018-06-27 2020-01-01 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
US11358999B2 (en) 2018-10-03 2022-06-14 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
US11472890B2 (en) 2019-03-01 2022-10-18 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
EP3842461A1 (en) 2019-12-23 2021-06-30 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
WO2021130042A1 (en) 2019-12-23 2021-07-01 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
US11591401B2 (en) 2020-08-19 2023-02-28 Xencor, Inc. Anti-CD28 compositions
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3

Also Published As

Publication number Publication date
CA2695382A1 (en) 2009-02-05
US20110189209A1 (en) 2011-08-04
WO2009017823A3 (en) 2009-03-19
US9364557B2 (en) 2016-06-14
AU2008282729A1 (en) 2009-02-05
AU2008282729B2 (en) 2015-07-16
EP2187971A2 (en) 2010-05-26

Similar Documents

Publication Publication Date Title
US9364557B2 (en) Fold-back diabody diphtheria toxin immunotoxin and methods of use
US7696338B2 (en) Immunotoxin fusion proteins and means for expression thereof
Hertler et al. Immunotoxins: a clinical review of their use in the treatment of malignancies.
Carter et al. Antibody-drug conjugates for cancer therapy
EP1015496B1 (en) Divalent anti-t cells immunotoxins and use thereof
Dosio et al. Advances in anticancer antibody-drug conjugates and immunotoxins
US6103235A (en) Methods of inducing immune tolerance using immunotoxins
CN112189020A (en) Use of antibody drug conjugates comprising tubulin disruptors for the treatment of solid tumors
EP1287147B1 (en) Immunotoxin fusion proteins and means for expression thereof
AU2001261760A1 (en) Immunotoxin fusion proteins and means for expression thereof
EP0830146B1 (en) Methods of inducing immune tolerance using immunotoxins
US20240209080A1 (en) Folr1 binding agents, conjugates thereof and methods of using the same
EP1073463B1 (en) Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US7517527B2 (en) Immunotoxin with in vivo T cell suppressant activity and methods of use
US20050142117A9 (en) Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US7125553B1 (en) Methods of inducing immune tolerance using immunotoxins
Zaman Topics in Anti-Cancer Research
WO2022064191A1 (en) Anti-cd45 antibodies and related therapeutics
JP2024521667A (en) Combination medicine comprising an anti-CD205 antibody and an immune checkpoint inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08794978

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008282729

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2695382

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008282729

Country of ref document: AU

Date of ref document: 20080801

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2008794978

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008794978

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12671629

Country of ref document: US